WO2005077897A1 - Substituted azetidine compounds, their preparation and use as medicaments - Google Patents

Substituted azetidine compounds, their preparation and use as medicaments Download PDF

Info

Publication number
WO2005077897A1
WO2005077897A1 PCT/EP2005/001658 EP2005001658W WO2005077897A1 WO 2005077897 A1 WO2005077897 A1 WO 2005077897A1 EP 2005001658 W EP2005001658 W EP 2005001658W WO 2005077897 A1 WO2005077897 A1 WO 2005077897A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
optionally
substituted
mono
linear
Prior art date
Application number
PCT/EP2005/001658
Other languages
French (fr)
Inventor
Rosa Cuberes Altisen
Jordi Frigola Constansa
Bonifacio Gutierrez Silva
Original Assignee
Laboratorios Del Dr. Esteve S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from ES200400379A external-priority patent/ES2244314B1/en
Application filed by Laboratorios Del Dr. Esteve S.A. filed Critical Laboratorios Del Dr. Esteve S.A.
Priority to RU2006133258/04A priority Critical patent/RU2006133258A/en
Priority to AU2005212835A priority patent/AU2005212835A1/en
Priority to BRPI0507801-6A priority patent/BRPI0507801A/en
Priority to CA002556565A priority patent/CA2556565A1/en
Priority to JP2006553539A priority patent/JP2007522255A/en
Priority to EP05715383A priority patent/EP1718609A1/en
Publication of WO2005077897A1 publication Critical patent/WO2005077897A1/en
Priority to IL177456A priority patent/IL177456A0/en
Priority to US11/505,463 priority patent/US20070066587A1/en
Priority to NO20064078A priority patent/NO20064078L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Definitions

  • the present invention relates to substituted Azetidine compounds of general formula (I), methods for their preparation, medicaments comprising these compounds as well as their use for the preparation of a medicament for the treatment of humans and animals.
  • Cannabinoids are compounds, which are derived from the cannabis sativa plant which is commonly known as marijuana.
  • the most active chemical compound of the naturally occurring cannabinoids is tetrahydrocannabinol (THC), particularly ⁇ 9 -THC.
  • cannabinoids as well as their synthetic analogues promote their physiological effects via binding to specific G-coupled receptors, the so-called cannabinoid-receptors.
  • CB ⁇ and CB 2 are involved in a variety of physiological or pathophysiological processes in humans and animals, e.g. processes related to the central nervous system, immune system, cardiovascular system, endocrinous system, respiratory system, the gastrointestinal tract or to reproduction, as described for example, in Hollister, Pharm. Rev. 38, 1986, 1-20; Reny and Singha, Prog. Drug. Res., 36, 71-114, 1991; Consroe and Sandyk, in Marijuana/Cannabinoids, Neurobiology and Neurophysiology, 459, Murphy L and Barthe A. Eds., CRC Press, 1992.
  • medicaments preferably in medicaments for the modulation of Cannabinoid receptors, particularly Cannabinoid 1 (CB-i) receptors.
  • said medicaments should be suitable for the prophylaxis and/or treatment of disorders related to the central nervous system, the immune system, the cardiovascular system, the endocrinous system, the respiratory system, the gastrointestinal tract or reproduction in humans and/or animals.
  • the present invention relates to substituted Azetidine compounds of general formula I,
  • R 1 represents an optionally at least mono-substituted phenyl group
  • R 2 represents a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic group, which may be condensed with an optionally at least mono-substituted mono- or polycyclic ring system, or an optionally at least mono-substituted aryl or heteroaryl group, which may be condensed with an optionally at least mono-substituted mono- or polycyclic ring system
  • R 3 represents a linear or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic group, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic group, which may be condensed with a mono- or polycyclic ring- system and/or which may be bonded via a linear or branched alkylene group, or an optionally at least mono-substituted
  • R 4 represents a hydrogen atom, a cyano group, a carboxy group, a linear or branched alkyl group, or an optionally at least mono-substituted aryl group,
  • R 5 represents an -O-SO 2 -R 6 -moiety, an -NH-CO-R 7 -moiety, an -Nh -moiety, an - NH-SO 2 -R 8 moiety, an -NR 9 -SO 2 -R 10 -moiety or an -O-CO-R 11 -moiety,
  • R 6 represents a linear or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic group, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic group, which may be condensed with a mono- or polycyclic ring- system and/or which may be bonded via a linear or branched alkylene group, or an optionally at least mono-substituted aryl or heteroaryl group, which may be condensed with a mono- or polycyclic ring system and/or which may be bonded via a linear or branched alkylene group,
  • R 7 represents a linear or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic group, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic group, which may be condensed with a mono- or polycyclic ring- system and/or which may be bonded via a linear or branched alkylene group, or an optionally at least mono-substituted aryl or heteroaryl group, which may be condensed with a mono- or polycyclic ring system and/or which may be bonded via a linear or branched alkylene group
  • R 8 represents a linear or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic group, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic group, which may
  • R 9 represents an -S0 2 -R 12 -moiety, a -CO-R 13 -moiety, a linear or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic group, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic group, which may be condensed with a mono- or polycyclic ring-system and/or which may be bonded via a linear or branched alkylene group and/or bridged by a linear or branched alkylene group, or an optionally at least mono-substituted aryl or heteroaryl group, which may be condensed with a mono- or polycyclic ring system and/or which may be bonded via an alkylene group,
  • R 10 represents a linear or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic group, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic group, which may be condensed with a mono- or polycyclic ring- system and/or which may be bonded via a linear or bridged alkylene group, and/or which may be bridged by a linear or branched alkylene group, or an optionally at least mono-substituted aryl or heteroaryl group, which may be condensed with a mono- or polycyclic ring system and/or which may be bonded via a linear or branched alkylene group
  • R 11 represents a linear or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic group, a saturated or unsaturated, optionally at least mono-substituted, optionally at
  • R 12 represents a linear or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic group, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic group, which may be condensed with a mono- or polycyclic ring- system and/or which may be bonded via a linear or bridged alkylene group, and/or which may be bridged by a linear or branched alkylene group, or an optionally at least mono-substituted aryl or heteroaryl group, which may be condensed with a mono- or polycyclic ring system and/or which may be bonded via a linear or branched alkylene group,
  • R 13 represents a linear or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic group, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic group, which may be condensed with a mono- or polycyclic ring- system and/or which may be bonded via a linear or bridged alkylene group, and/or which may be bridged by a linear or branched alkylene group, or an optionally at least mono-substituted aryl or heteroaryl group, which may be condensed with a mono- or polycyclic ring system and/or which may be bonded via a linear or branched alkylene group, optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/
  • a mono- or polycyclic ring-system means a mono- or polycyclic hydrocarbon ring-system that may be saturated, unsaturated or aromatic. If the ring system is polycyclic, each of its different rings may show a different degree of saturation, i.e. it may be saturated, unsaturated or aromatic. Optionally each of the rings of the mono- or polycyclic ring system may contain one or more, e.g. 1 , 2 or 3, heteroatoms as ring members, which may be identical or different and which can preferably be selected from the group consisting of N, O, S and P, more preferably be selected from the group consisting of N, O and S. Preferably the polycyclic ring-system may comprise two rings that are condensed.
  • the rings of the mono- or polycyclic ring-sytem are preferably 5- or 6-membered.
  • condensed means that a ring or ring- system is attached to another ring or ring-system, whereby the terms “annulated” or “annelated” are also used by those skilled in the art to designate this kind of attachment.
  • each of the substituents may be independently selected from the group consisting of hydroxy, fluorine, chlorine, bromine, branched or unbranched C ⁇ .
  • residues R 2 , R 3 and R 6 -R 13 represents or comprises a cycloaliphatic group, which contains one or more heteroatoms as ring members, unless defined otherwise, each of these heteroatoms may preferably be selected from the group consisting of N, O and S.
  • a cycloaliphatic group may contain 1 , 2 or 3 heteroatoms independently selected from the group consisting of N, O and S.
  • Suitable saturated or unsaturated, optionally at least heteroatom as ring member containing, optionally at least mono-substituted cycloaliphatic groups may preferably be selected from the group consisting of Cyclopropyl, Cyclobutyl, Cyclopentyl, Cyclohexyl, Cycloheptyl, Cyclooctyl, Cyclopentenyl, Cyclohexenyl, Cycloheptenyl, Cyclooctenyl, Pyrrolidinyl, Piperidinyl, Piperazinyl, Homo-Piperazinyl and Morpholinyl.
  • each of the substituents may be independently selected from the group consisting of hydroxy, fluorine, chlorine, bromine, branched or unbranched C-i- 4 -alkoxy, branched or unbranched C ⁇ -alkyl, branched or unbranched C 1 - 4 - perfluoroalkoxy, branched or unbranched C ⁇ - 4 -perfluoroalkyl, amino, carboxy, oxo, amido, cyano, nitro, -SO 2 NH 2 , -CO-C- M -alkyl, -SO-C ⁇ -alkyl, -SO 2 -d ⁇ -alkyl, -NH- SO 2 -C ⁇ - 4 -alkyl , wherein the C
  • each of the substituents may be independently selected from the group consisting of a halogen atom, a linear or branched C ⁇ _ 6 -alkyl group, a linear or branched C ⁇ . 6 alkoxy group, a formyl group, a hydroxy group, a trifluoromethyl group, a trifluoromethoxy group, a -CO-C-
  • 6 -alkyl group a cyano group, a carboxy group, a - CO-O-C- ⁇ - 6 -alkyl group, a -CO-NR A R B - moiety, a -CO-NH-NR c R D -moiety, an -S-d-e- alkyl group, an -SO-d. 6 -alkyl group, an -S0 2 -C ⁇ . 6 -alkyl group, a -C ⁇ . 6 -alkylene-S-C ⁇ . 6 - alkyl group, a -C ⁇ . 6 -alkylene-SO-C ⁇ .
  • R A , R B identical or different, represent hydrogen or a C ⁇ . 6 -alkyl group, or R A and R B together with the bridging nitrogen atom form a saturated, mono- or bicyclic, 3-10 membered heterocyclic ring system, which may be at least mono-substituted by one or more, identical or different, C-i-e alkyl groups and/or which may contain at least one further heteroatom selected from the group consisting of nitrogen, oxygen and sulphur as a ring member,
  • R c , R D identical or different, represent a hydrogen atom, a C ⁇ - 6 -alkyl group, a -CO-O-C ⁇ - 6 -alkyl group, a C 3 - 8 -cycloalkyl group, a C ⁇ - 6 -alkylene-C 3 .
  • R E , R F identical or different, represent hydrogen or a C ⁇ . 6 -alkyl group, or R E and R F together with the bridging nitrogen atom form a saturated, mono- or bicyclic, 3-10 membered heterocyclic ring system, which may be at least mono-substituted by one or more, identical or different Ci- ⁇ alkyl groups and/or which may contain at least one further heteroatom selected from the group consisting of nitrogen, oxygen and sulphur as a ring member.
  • Preferred aryl groups which may optionally be at least mono-substituted, are phenyl and naphthyl. If one or more of the residues R 2 , R 3 and R 6 -R 13 represents or comprises a heteroaryl group, which is substituted by one or more, e.g.
  • each of the substituents may be independently selected from the group consisting of a halogen atom, a linear or branched Ci- 6 -alkyl group, a linear or branched C-i- 6 alcoxy group, a formyl group, a hydroxy group, a trifluoromethyl group, a trifluoromethoxy group, a -CO-C ⁇ . 6 -alkyl group, a cyano group, a carboxy group, a - CO-O-d.
  • 6 -alkyl group a -CO-NR A R B - moiety, a -CO-NH-NR c R D -moiety, an -S-d_ 6 - alkyl group, an -SO-d-6-alkyl group, an -SO 2 -C ⁇ . ⁇ -alkyl group, a -C ⁇ . 6 -alkylene-S-C ⁇ . 6 - alkyl group, a -C ⁇ . 6 -alkylene-SO-C ⁇ . 6 -alkyl group, a -C ⁇ - 6 -alkylene-SO 2 -C ⁇ . 6 -alkyl group, a d- 6 -alkyl group substituted by one or more hydroxy groups and a -d- ⁇ - alkylene-NR E R F group,
  • R A , R B identical or different, represent hydrogen or a C ⁇ . 6 -alkyl group, or R A and R B together with the bridging nitrogen atom form a saturated, mono- or bicyclic, 3-10 membered heterocyclic ring system, which may be at least mono-substituted by one or more, identical or different, C ⁇ _ 6 alkyl groups and/or which may contain at least one further heteroatom selected from the group consisting of nitrogen, oxygen and sulphur as a ring member,
  • R c , R D identical or different, represent a hydrogen atom, a C ⁇ . 6 -alkyl group, a -CO-O-d- 6 -alkyl group, a C 3 . 8 -cycloalkyl group, a C ⁇ . 6 -alkylene-C 3 . 8 -cycloalkyl group, C ⁇ - 6 -alkylene-0-C ⁇ - 6 -alkyl group or a C ⁇ .
  • 6 -alkyl group substituted with one or more hydroxy groups, or R c , R D together with the bridging nitrogen atom form a saturated, mono- or bicyclic, 3-10 membered heterocyclic ring system, which may be at least mono-substituted by one or more substituents independently selected from the group consisting of d- 6 alkyl group, a -CO-Ci- 6 -alkyl group, a -CO-O- Ci- ⁇ -alkyl group, a - CO-NH- C ⁇ _ 6 -alkyl group, a -CS-NH- C ⁇ . 6 -alkyl group, an oxo group, a C ⁇ .
  • 6 -alkyl group substituted with one or more hydroxy groups, a C ⁇ . 6 -alkylene-O-C ⁇ . 6 -alkyl group and a -CO-NH 2 group and/or which may contain at least one further heteroatom selected from the group consisting of nitrogen, oxygen and sulphur as a ring member, and
  • R E , R F identical or different, represent hydrogen or a C ⁇ . 6 -alkyl group, or R E and R F together with the bridging nitrogen atom form a saturated, mono- or bicyclic, 3-10 membered heterocyclic ring system, which may be at least mono-substituted by one or more, identical or different C ⁇ _ 6 alkyl groups and/or which may contain at least one further heteroatom selected from the group consisting of nitrogen, oxygen and sulphur as a ring member,
  • heteroatoms which are present as ring members in the heteroaryl radical, may, unless defined otherwise, independently be selected from the group consisting of nitrogen, oxygen and sulphur.
  • a heteroaryl radical may contain 1, 2 or 3 heteroatoms independently selected from the group consisting of nitrogen, oxygen and sulphur.
  • Suitable heteroaryl groups may preferably be selected from the group consisting of thienyl, furyl, pyrrolyl, pyridinyl, imidazolyl, pyrimidinyl, pyrazinyl, indolyl, chinolinyl, isochinolinyl, benzo[1 ,2,5]- thiodiazolyl, benzo[b]thiophenyl, benzo[b]furanyl, imidazo[2,1-b]thiazolyl and pyrazolyl, more preferably be selected from the group consisting of thienyl-, benzo[1,2,5]-thiodiazolyl, benzo[b]thiophenyl, imidazo[2,1-b]thiazolyl and pyrazolyl.
  • each of the substituents may be independently selected from the group consisting of hydroxy, fluorine, chlorine, bromine, branched or unbranched C ⁇ - 4 -alkoxy, branched or unbranched Ci- 4 -perfluoroalkoxy, branched or unbranched d- 4 -perfluoroalkyl, amino, carboxy, amido, cyano, nitro, -SO 2 NH 2 , -CO-d- 4 -alkyl, -SO-C ⁇ .
  • d. 4 -alkyl may in each case be branched or unbranched, and a phenyl group, more preferably be selected from the group consisting of hydroxy, F, Cl, Br, methoxy, ethoxy, CF 3 and a phenyl group.
  • Preferred linear or branched, saturated or unsaturated aliphatic groups which may be substituted by one or more substituents, may preferably be selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, iso-butyl, sec-butyl, tert- butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, n-nonyl, n-decyl, vinyl, ethinyl, propenyl, propinyl, butenyl and butinyl.
  • any of the residues R 3 and R 6 -R 13 comprises a linear or branched alkylene group
  • said alkylene group may preferably be selected from the group consisting of methylene (-(CH 2 )-), ethylene (-(CH 2 ) 2 -), n-propylene (-(CH 2 ) -), isopropylene (-(C(CH )2-), n-butylene (-(CH 2 ) 4 -), n-pentylene (-(CH 2 ) 5 -), n-hexylene ( -(CH 2 ) 6 -), n-heptylene (-(CH 2 ) 7 -), n-octylene (-(CH 2 ) 8 -), n-nonylene( -(CH 2 ) 9 -) and n-decylene (-(CH 2 ) ⁇ 0 -), more preferably from the group consisting of (-(CH 2 )-), ethylene (-(
  • R 1 represents a phenyl group, which is optionally substituted by one or more substituents independently selected from the group consisting of a halogen atom, a linear or branched Ci- 6 -alkyl group, a linear or branched C- ⁇ - 6 alkoxy group, a formyl group, a hydroxy group, a trifluoromethyl group, a trifluoromethoxy group, a -CO-C ⁇ .
  • 6 -alkyl group a cyano group, a carboxy group, a -CO-O-C ⁇ - 6 -alkyl group, a -CO-NR A R B - moiety, a -CO-NH-NR c R D -moiety, an -S-C ⁇ . 6 -alkyl group, an -SO-C ⁇ . 6 -alkyl group, an -S ⁇ 2 -C ⁇ - 6 -alkyl group, a -C ⁇ _6-alkylene-S-C ⁇ -6-alkyl group, a -C ⁇ . 6 -alkylene-SO-C ⁇ - 6 - alkyl group, a -C ⁇ . 6 -alkylene-SO 2 -C ⁇ - 6 -alkyl group, a Ci- ⁇ -alkyl group substituted by one or more hydroxy groups and a -C ⁇ . 6 -alkylene-NR E R F group,
  • R A , R B identical or different, represent hydrogen or a C ⁇ . 6 -alkyl group, or R A and R B together with the bridging nitrogen atom form a saturated, mono- or bicyclic, 3-10 membered heterocyclic ring system, which may be at least mono-substituted by one or more, identical or different, C 1 - 6 alkyl groups and/or which may contain at least one further heteroatom selected from the group consisting of nitrogen, oxygen and sulphur as a ring member,
  • R c , R D identical or different, represent a hydrogen atom, a C ⁇ . 6 -alkyl group, a -CO-O-Ci- 6 -alkyl group, a C 3 . 8 -cycloalkyl group, a C ⁇ - 6 -alkylene-C 3 . 8 -cycloalkyl group, C-
  • R E , R F identical or different, represent hydrogen or a C ⁇ . 6 -alkyl group, or R E and R F together with the bridging nitrogen atom form a saturated, mono- or bicyclic, 3-10 membered heterocyclic ring system, which may be at least mono-substituted by one or more, identical or different C-i-e alkyl groups and/or which may contain at least one further heteroatom selected from the group consisting of nitrogen, oxygen and sulphur as a ring member,
  • R 1 represents a phenyl group, which is optionally substituted by one or more substituents independently selected from the group consisting of a fluorine atom, a chlorine atom, a bromine atom, a linear or branched C ⁇ _ 6 -alkyl group, a linear or branched C ⁇ _ 6 alkoxy group, a formyl group, a hydroxy group, a trifluoromethyl group, a trifluoromethoxy group, a cyano group and a carboxy group,
  • R 1 represents a phenyl group, which is optionally substituted by one or more substituents independently selected from the group consisting of a fluorine atom, a chlorine atom, a bromine atom, a methyl group, a methoxy group, a trifluoromethyl group and a trifluoromethoxy group, most preferably R 1 represents a phenyl group, which is substituted by a chlorine atom in the 4-position,
  • R 2 -R 13 have the meaning given above, optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding N-oxide thereof, a corresponding salt thereof, or a corresponding solvate thereof.
  • R 2 represents a saturated or unsaturated, optionally at least mono-substituted, optionally at least heteroatom as ring member containing C 3 . 8 cycloaliphatic group, which may be condensed with an optionally at least mono-substituted mono- or polycyclic ring system, or an optionally at least mono-substituted, 5- or 6-membered aryl or heteroaryl group, which may be condensed with an optionally at least mono- substituted mono- or polycyclic ring system,
  • R 2 represents a phenyl group, which is optionally substituted by one or more substituents independently selected from the group consisting of a halogen atom, a linear or branched C ⁇ _ 6 -alkyl group, a linear or branched C ⁇ _ 6 alcoxy group, a formyl group, a hydroxy group, a trifluoromethyl group, a trifluoromethoxy group, a - CO-Ci- 6 -alkyl group, a cyano group, a carboxy group, a -CO-O-C ⁇ .6-alkyl group, a - CO-NR A R B - moiety, a -CO-NH-NR c R D -moiety, an -S-d.
  • substituents independently selected from the group consisting of a halogen atom, a linear or branched C ⁇ _ 6 -alkyl group, a linear or branched C ⁇ _ 6 alcoxy group, a formy
  • 6 -alkyl group an -SO-C 1 - 6 - alkyl group, an -SO 2 -C ⁇ . 6 -alkyl group, a -C ⁇ . 6 -alkylene-S-C ⁇ - 6 -alkyl group, a -d. 6 - alkylene-SO-C ⁇ - 6 -alkyl group, a -C ⁇ - 6 -alkylene-SO 2 -C ⁇ _ 6 -alkyl group, a C ⁇ . 6 -alkyl group substituted by one or more hydroxy groups and a -d. 6 -alkylene-NR E R F group,
  • R A , R B identical or different, represent hydrogen or a C ⁇ - 6 -alkyl group, or R A and R B together with the bridging nitrogen atom form a saturated, mono- or bicyclic, 3-10 membered heterocyclic ring system, which may be at least mono-substituted by one or more, identical or different, C ⁇ _ 6 alkyl groups and/or which may contain at least one further heteroatom selected from the group consisting of nitrogen, oxygen and sulphur as a ring member,
  • R c , R D identical or different, represent a hydrogen atom, a d- 6 -alkyl group, a -CO-O-Ci_ 6 -alkyl group, a C 3 . 8 -cycloalkyl group, a C ⁇ - 6 -alkylene-C 3 - 8 -cycloalkyl group, C ⁇ - 6 -alkylene-O-C ⁇ - 6 -alkyl group or a C ⁇ .
  • 6 -alkyl group substituted with one or more hydroxy groups, or R c , R D together with the bridging nitrogen atom form a saturated, mono- or bicyclic, 3-10 membered heterocyclic ring system, which may be at least mono-substituted by one or more substituents independently selected from the group consisting of C 1 . 6 alkyl group, a -CO-C ⁇ . 6 -alkyl group, a -CO-O- C ⁇ _ 6 -alkyl group, a - CO-NH- Ci- 6 -alkyl group, a -CS-NH- C ⁇ profession 6 -alkyl group, an oxo group, a C ⁇ .
  • R E , R F identical or different, represent hydrogen or a C ⁇ . 6 -alkyl group, or R ⁇ and R F together with the bridging nitrogen atom form a saturated, mono- or bicyclic, 3-10 membered heterocyclic ring system, which may be at least mono-substituted by one or more, identical or different C-j- ⁇ alkyl groups and/or which may contain at least one further heteroatom selected from the group consisting of nitrogen, oxygen and sulphur as a ring member,
  • R 2 represents a phenyl group, which is optionally substituted by one or more substituents independently selected from the group consisting of a fluorine atom, a chlorine atom, a bromine atom, a methyl group, a methoxy group, a trifluoromethyl group and a trifluoromethoxy group,
  • R 2 represents a phenyl group, which is substituted by a chlorine atom in the 4-position
  • R 1 and R 3 -R 13 have the meaning given above, optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding N-oxide thereof, a corresponding salt thereof, or a corresponding solvate thereof.
  • R 3 represents a linear or branched, saturated or unsaturated, optionally at least mono- substituted C ⁇ _ ⁇ o-aliphatic group, a saturated or unsaturated, optionally at least mono- substituted, optionally at least one heteroatom as ring member containing C 3 .
  • R 3 represents a linear or branched, optionally at least mono-substituted C ⁇ - 10 -alkyl group, or an optionally at least mono-substituted, 5- or 6- membered aryl or heteroaryl group, which may be condensed with a mono- or polycyclic ring system and/or which may be bonded via a linear or branched C ⁇ _ 6 -alkylene group, more preferably R 3 represents a linear or branched, unsubstituted C ⁇ - ⁇ 0 -alkyl group, most preferably R 3 represents a methyl group, and R 1 , R 2 and R 4 -R 13 have the meaning given above, optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding N-oxide thereof,
  • R 4 represents a hydrogen atom, a cyano group, a carboxy group, a linear or branched C ⁇ - ⁇ 0 -alkyl group, or an optionally at least mono-substituted, 5- or 6- membered aryl group
  • R 4 represents a hydrogen atom, a linear or branched Ci- 3 -alkyl group, or an optionally at least mono-substituted phenyl group, more preferably R 4 represents a hydrogen atom or a linear or branched C ⁇ _ 3 -alkyl group, most preferably R 4 represents a hydrogen atom
  • R 1 -R 3 and R 5 -R 13 have the meaning given above, optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers,
  • R 5 represents an -O-SO 2 -R 6 -moiety, an -NH-CO-R 7 -moiety, an -NH 2 -moiety, an -NH- SO 2 -R 8 moiety or an -NR 9 -SO 2 -R 10 -moiety
  • R 5 represents an -O-SO 2 -R 6 - moiety, an -NH-S0 2 -R 8 moiety or an -NR 9 -SO 2 -R 10 -moiety
  • R 1 -R 4 and R 6 -R 13 have the meaning given above, optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding N-oxide thereof, a corresponding salt thereof,
  • R 6 represents a linear or branched, saturated or unsaturated, optionally at least mono- substituted C 1 - 10 aliphatic group, a saturated or unsaturated, optionally at least mono- substituted, optionally at least one heteroatom as ring member containing C 3 . 8 - cycloaliphatic group, which may be condensed with a mono- or polycyclic ring- system and/or which may be bonded via a linear or branched C ⁇ .
  • R 6 represents an optionally at least mono-substituted C 3 -s-cycloaliphatic group or an optionally at least mono-substituted phenyl group, wherein the respective substituents are independently selected from the group consisting of a fluorine atom, a chlorine atom, a bromine atom, a linear or branched C ⁇ _ 6 -alkyl group, a linear or branched C ⁇ - ⁇ alcoxy group, a formyl group, a hydroxy group, a trifluoromethyl group, a trifluoromethoxy group, a cyano group and a carboxy group, more preferably R 6 represents a pheny
  • R 7 represents a linear or branched, saturated or unsaturated, optionally at least mono- substituted C ⁇ - ⁇ o-aliphatic group, a saturated or unsaturated, optionally at least mono- substituted, optionally at least one heteroatom as ring member containing C 3 . 8 - cycloaliphatic group, which may be condensed with a mono- or polycyclic ring- system and/or which may be bonded via a linear or branched C ⁇ .
  • R 7 represents a linear or branched, optionally at least mono-substituted C ⁇ - 5 -alkyl group, a saturated, optionally at least mono-substituted C 5tician 6 -cycloaliphatic group, or an optionally at least mono-substituted phenyl group, wherein in each case the substituents are independently from one another selected from the group consisting of group consisting of a fluorine atom, a chlorine atom, a bromine atom, a methyl group, a methoxy group, a trifluoromethyl group and a trifluoromethoxy group, and R 1 -R 6 and R 8 -R 13 have the meaning given above, optionally in form of one of the stereoisomers, preferably enantiomers
  • R 8 represents a linear or branched, saturated or unsaturated, optionally at least mono- substituted C ⁇ - ⁇ o-aliphatic group, a saturated or unsaturated, optionally at least mono- substituted, optionally at least one heteroatom as ring member containing C 3 .
  • R 8 represents a linear or branched C ⁇ - 10 -alkyl group, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C 5 .
  • R 8 represents a methyl group, an ethyl group, an n-propyl group, an n-butyl group, an optionally at least mono-substituted phenyl group, an optionally at least mono-substituted benzyl group, an optionally at least mono-substituted naphthyl group, which may be bonded via a
  • R 9 represents an -SO 2 -R 2 -moiety, a -CO-R 13 -moiety, a linear or branched, saturated or unsaturated, optionally at least mono-substituted d-10 aliphatic group, a saturated or unsaturated, optionally at least mono-substituted, optionally at least heteroatom as ring member containing C3-8 cycloaliphatic group, which may be condensed with a mono- or polycyclic ring-system and/or which may be bonded by a linear or branched C 1 .
  • R 9 represents an -SO 2 -R 12 -moiety, a linear or branched C 1 - 10 alkyl group, or an optionally at least mono-substituted phenyl group, which may be bonded via a C ⁇ _ 2 alkylene group, more preferably R 9 represents an - S0 2 -R 12 -moiety, a linear or branched d_ 3 alkyl group, or a phenyl group, which may be bonded via a C ⁇ _ 2 alkylene group and/or substituted with one or more substituents independently selected from the group consisting of a fluorine atom, a chlorine atom and a bromine atom, and R 1 -R 8 and R 10 -R 13 have the meaning given above optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably en
  • R 10 represents a linear or branched, saturated or unsaturated, optionally at least mono-substituted C ⁇ . 10 -aliphatic group, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C 3 _ 8 -cycloaliphatic group, which may be condensed with a mono- or polycyclic ring- system and/or which may be bonded via a linear or bridged Ci- 10 -alkylene group and/or which may be bridged by a linear or branched C ⁇ _ 5 -alkylene group, or an optionally at least mono-substituted 5- or 6-membered aryl or heteroaryl group, which may be condensed with a mono- or polycyclic ring system and/or which may be bonded via a linear or branched Ci-10-alkylene group, preferably R 10 represents a linear or branched
  • R 10 represents a methyl group, an ethyl group, an n-propyl group, an n-butyl group, an optionally at least mono-substituted phenyl group, an optionally at least mono-substituted benzyl group, an optionally at least mono-substituted naphthyl group, which may be bonded via
  • R 11 represents a linear or branched, saturated or unsaturated, optionally at least mono- substituted C ⁇ - ⁇ o-aliphatic group, a saturated or unsaturated, optionally at least mono- substituted, optionally at least one heteroatom as ring member containing C 3 - 8 - cycloaliphatic group, which may be condensed with a mono- or polycyclic ring- system and/or which may be bonded via a linear or bridged C ⁇ - ⁇ o-alkylene group and/or which may be bridged by a linear or branched C ⁇ - 5 -alkylene group, or an optionally at least mono-substituted 5- or 6-membered aryl or heteroaryl group, which may be condensed with a mono- or polycyclic ring system and/or which may be bonded via a linear or branched C ⁇ _ ⁇ o-alkylene group, preferably R 11 represents a -linear or-branched C
  • ring member containing C 5 - 6 - cycloaliphatic group which may be condensed with a mono- or polycyclic ring- system and/or which may be bonded via a linear or bridged C ⁇ .
  • R 11 represents a methyl group, an ethyl group, an n-propyl group, an n-butyl group, an optionally at least mono-substituted phenyl group, an optionally at least mono-substituted benzyl group, an optionally at least mono-substituted naphthyl group, which may be bonded via a C ⁇ - 3 -alkylene group, an optionally at least mono-substituted thienyl group, an optionally at least mono-substituted 2,1 ,3-Benzothiadiazole group, an optionally at least mono-substituted Benzo[b]thiophenyl group, an optionally at least mono- substituted lmidazo[2.1-b]thiazole group, an optionally at least mono-substituted 1 H- pyrazole group or a 7,7-Dimethyl-2-oxo-bicyclo-[2.2.1
  • R 12 represents a linear or branched, saturated or unsaturated, optionally at least mono- substituted Ci- 10 -aliphatic group, a saturated or unsaturated, optionally at least mono- substituted, optionally at least one heteroatom as ring member containing C 3 .
  • R 12 represents a linear or branched C ⁇ _ ⁇ o-alkyl group, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C 5 .
  • R 12 represents a methyl group, an ethyl group, an n-propyl group, an n-butyl group, an optionally at least mono-substituted phenyl group, an optionally at least mono-substituted benzyl group, an optionally at least mono-substituted naphthyl group, which may be bonded via a d- 3 -alkylene group, an optionally at least mono-substituted thienyl group, an optionally at least mono-substituted 2,1 ,3-Benzothiadiazole group, an optionally at least mono-substituted Benzo[b]thiophenyl group, an optionally at least mono- substituted lmidazo[2.1-b]thiazole group, an optionally at least mono-substituted 1 H- pyrazole group or a 7,7-Dimethyl-2-oxo-bicyclo-[2.2.1
  • R 13 represents a linear or branched, saturated or unsaturated, optionally at least mono-substituted C 1 - 10 - aliphatic group, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C 3 - 8 -cycloaliphatic group, which may be condensed with a mono- or polycyclic ring-system and/or which may be bonded via a linear or bridged C ⁇ _ ⁇ o-alkylene group and/or which may be bridged by a linear or branched C ⁇ - 5 -alkylene group, or an optionally at least mono- substituted 5- or 6-membered aryl or heteroaryl group, which may be condensed with a mono- or polycyclic ring system and/or which may be bonded via a linear or branched C- M o-alkylene group, preferably R 13 represents a linear or branched C-MO
  • R 13 represents a methyl group, an ethyl group, an n-propyl group, an n-butyl group, an optionally at least mono-substituted phenyl group, an optionally at least mono- substituted benzyl group, an optionally at least mono-substituted naphthyl group, which may be bonded via a C ⁇
  • R 7 represents a linear or branched C 1 - 5 alkyl group, said alkyl group being unsubstituted or substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, -OH, -SH, linear or branched C 1 .
  • -R 8 represents a linear or branched C 1 . 5 alkyl group; an aryl or heteroaryl group selected from the group consisting of phenyl, naphthyl, thienyl, furanyl (furyl), 2,1 ,3- benzothiadiazole, benzo[b]thiophenyl, benzo[b]furanyl, imidazo[2.1-b]thiazole and pyrazole, said aryl or heteroaryl group being unsubstituted or substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, linear or branched C 1 -6 alkyl. linear or branched C ⁇ .
  • phenyl optionally substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, OH, linear or branched C ⁇ _ 6 alkyl and linear or branched C 1 - 6 - alcoxy
  • phenoxy optionally substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, OH, linear or branched d- 6 alkyl and linear or branched C ⁇ .
  • R 10 represents a linear or branched C 1 - 5 alkyl group; an aryl or heteroaryl group selected from the group consisting of phenyl, naphthyl, thienyl, furanyl (furyl), 2,1 ,3- benzothiadiazole, benzo[b]thiophenyl, benzo[b]furanyl, imidazo[2.1-b]thiazole and pyrazole, said aryl or heteroaryl group being unsubstituted or substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, linear or branched C1- 6 alkyl, linear or branched d-6 alcoxy, phenyl (optionally substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, OH, linear or branched C ⁇ _ 6 alkyl and linear or branched d.
  • R 11 represents a linear or branched C 1 - 5 alkyl group; an aryl or heteroaryl group selected from the group consisting of phenyl, naphthyl, thienyl, furanyl (furyl), 2,1 ,3- benzothiadiazole, benzo[b]thiophenyl, benzo[b]furanyl, imidazo[2.1-b]thiazole and pyrazole, said aryl or heteroaryl group being unsubstituted or substituted with 1 , 2, 3,
  • substituents independently selected from the group consisting of F, Cl, Br, linear or branched C 1 - 6 alkyl, linear or branched d- 6 alcoxy, phenyl (optionally substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, OH, linear or branched C 1 - 6 alkyl and linear or branched C 1 - 6 - alcoxy), phenoxy (optionally substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, OH, linear or branched C 1 . 6 alkyl and linear or branched d.
  • R 12 represents a linear or branched C 1 - 5 alkyl group, an aryl or heteroaryl group selected from the group consisting of phenyl, naphthyl, thienyl, furanyl (furyl), 2,1 ,3- benzothiadiazole, benzo[b]thiophenyl, benzo[b]furanyl, imidazo[2.1-b]thiazole and pyrazole, said aryl or heteroaryl group being unsubstituted or substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, linear or branched C ⁇ - 6 alkyl, linear or branched C 1 - 6 alcoxy, phenyl (optionally substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, OH, linear or branched C 1 - 6 alkyl and linear or branched C 1 - 6 - alcoxy), phenoxy
  • R 13 represents a linear or branched C1. 5 alkyl group, an aryl or heteroaryl group selected from the group consisting of phenyl, naphthyl, thienyl, furanyl (furyl), 2,1 ,3- benzothiadiazole, benzo[b]thiophenyl, benzo[b]furanyl, imidazo[2.1-b]thiazole and pyrazole, said aryl or heteroaryl group being unsubstituted or substituted with 1 , 2, 3,
  • substituents independently selected from the group consisting of F, Cl, Br, linear or branched C 1 .6 alkyl, linear or branched C1-6 alcoxy, phenyl (optionally substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, OH, linear or branched C 1 - 6 alkyl and linear or branched d.
  • stereoisomers optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding N-oxide thereof, a corresponding salt thereof, or a corresponding solvate thereof, especially to compounds of the following formula lb,
  • X represents a halogen atom, preferably a chlorine atom
  • alkyl group said alkyl group being unsubstituted or substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, -OH, -SH, linear or branched C- ⁇ - 6 alcoxy, -CF 3 and -OCF 3 ; a cyclopentyl or cyclohexyl group, said cyclopentyl or cyclohexyl group being unsubstituted or substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, -OH, -SH, linear or branched C 1 - 6 alcoxy, -CF 3 and -OCF 3 ; or a phenyl group, said phenyl group being unsubstituted or substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, linear or branched C ⁇ . 6 alkyl, linear or branched C
  • R 8 represents a linear or branched C 1 -5 alkyl group; an aryl or heteroaryl group selected from the group consisting of phenyl, naphthyl, thienyl, furanyl (furyl), 2,1,3- benzothiadiazole, benzo[b]thiophenyl, benzo[b]furanyl, imidazo[2.1-b]thiazole and pyrazole, said aryl or heteroaryl group being unsubstituted or substituted with 1, 2, 3,
  • R 10 represents a linear or branched C 1 .5 alkyl group; an aryl or heteroaryl group selected from the group consisting of phenyl, naphthyl, thienyl, furanyl (furyl), 2,1,3- benzothiadiazole, benzo[b]thiophenyl, benzo[b]furanyl, imidazo[2.1-b]thiazole and pyrazole, said aryl or heteroaryl group being unsubstituted or substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, linear or branched C-i-e alkyl, linear or branched C 1 - 6 alcoxy, phenyl (optionally substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, OH, linear or branched d_ 6 alkyl and linear or branched d.
  • R 11 represents a linear or branched C 1 - 5 alkyl group; an aryl or heteroaryl group selected from the group consisting of phenyl, naphthyl, thienyl, furanyl (furyl), 2,1 ,3- benzothiadiazole, benzo[b]thiophenyl, benzo[b]furanyl, imidazo[2.1-b]thiazole and pyrazole, said aryl or heteroaryl group being unsubstituted or substituted with 1 , 2, 3,
  • substituents independently selected from the group consisting of F, Cl, Br, linear or branched C ⁇ - 6 alkyl, linear or branched C 1 - 6 alcoxy, phenyl (optionally substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, OH, linear or branched d_ 6 alkyl and linear or branched C 1 - 6 - alcoxy), phenoxy (optionally substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, OH, linear or branched C1- 6 alkyl and linear or branched d.
  • R 12 represents a linear or branched C1.
  • an aryl or heteroaryl group selected from the group consisting of phenyl, naphthyl, thienyl, furanyl (furyl), 2,1 ,3- benzothiadiazole, benzo[b]thiophenyl, benzo[b]furanyl, imidazo[2.1-b]thiazole and pyrazole, said aryl or heteroaryl group being unsubstituted or substituted with 1 , 2, 3,
  • substituents independently selected from the group consisting of F, Cl, Br, linear or branched C ⁇ . 6 alkyl, linear or branched C ⁇ . 6 alcoxy, phenyl (optionally substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, OH, linear or branched C ⁇ _ 6 alkyl and linear or branched C ⁇ - 6 - alcoxy), phenoxy (optionally substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, OH, linear or branched d- 6 alkyl and linear or branched d.
  • R 13 represents a linear or branched C1. 5 alkyl group, an aryl or heteroaryl group selected from the group consisting of phenyl, naphthyl, thienyl, furanyl (furyl), 2,1 ,3- benzothiadiazole, benzo[b]thiophenyl, benzo[b]furanyl, imidazo[2.1-b]thiazole and pyrazole, said aryl or heteroaryl group being unsubstituted or substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, linear or branched C ⁇ .
  • stereoisomers optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding N-oxide thereof, a corresponding salt thereof, or a corresponding solvate thereof.
  • R 1 represents a phenyl group, which is mono-substituted with a halogen atom, preferably a chlorine atom, in the 4-position of the phenyl ring,
  • R 2 represents a phenyl group, which is mono-substituted with a halogen atom, preferably a chlorine atom, in the 4-position of the phenyl ring,
  • R 3 represents a linear or branched, unsubstituted C ⁇ _ 6 alkyl group, preferably a methyl group,
  • R 4 represents a hydrogen atom
  • R 5 represents an -O-SO 2 -R 6 -moiety, an -NH-CO-R 7 -moiety, an -NH 2 -moiety, an NH-SO 2 -R 8 moiety, or an -NR 9 -SO 2 -R 10 -moiety
  • R 6 represents a phenyl ring, which is optionally substituted with one or more halogen atoms, preferably one or more fluorine and/or one or more chlorine atoms,
  • R 7 represents a linear or branched C 1 -5 alkyl group, a linear or branched C 1 - 5 alkyl group, which is at least partially fluorinated, a C 3 . 8 cycloalkyl group, or a phenyl group, which is optionally substituted with one or more halogen atoms, preferably one or more fluorine atoms,
  • R 8 represents a linear or branched C 1 . 5 alkyl group
  • a phenyl group which is optionally substituted with one or more substituents independently selected from the group consisting of a fluorine atom, a chlorine atom, an unsubstituted phenyl group, a formyl group, a methylsulfonyl group, a benzyl group and a phenoxy group, which is optionally mono-substituted by a bromine atom in its 4-position,
  • a naphthyl group which may be bonded via a methylene or ethylene group
  • Benzo[b]thiophene group which is optionally substituted with one or more methyl groups and/or one or more chlorine atoms,
  • a pyrazole group which is optionally substituted with one or more substituents independently selected from the group consisting of a methyl group, an ethyl group and a phenyl group,
  • thienyl group a furyl group, a.2,1,3-Benzothiadiazole group, a 7,7-Dimethyl-2-oxo- bicyclo-[2.2.1]-hept-1-yl group, or a benzyl group,
  • R 9 represents a C 1 . 5 alkyl group, preferably a methyl group, a phenyl group, which is optionally substituted with one or more fluorine atoms and/or one or more chlorine atoms, a benzyl group, wherein the ring is optionally substituted with one or more fluorine atoms and/or one or more chlorine atoms, or a -S0 2 -R 12 -moiety,
  • R 10 represents a phenyl group, which is optionally substituted with one or more fluorine atoms and/or one or more chlorine atoms,
  • R 12 represents a C 1 . 5 alkyl group, preferably a methyl group, or a phenyl group, which is optionally substituted with one or more fluorine atoms and/or one or more chlorine atoms,
  • stereoisomers optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding N-oxide thereof, a corresponding salt thereof, or a corresponding solvate thereof.
  • substituted azetidine compounds of general formula I given above selected from the group consisting of
  • the present invention provides a process for the preparation of substituted azetidine compounds of general formula I given above and corresponding stereoisomers thereof, according to which at least one compound of general formula
  • R 1 to R 4 have the meaning given above, is reacted with at least one compound of general formula X 1 -SO 2 -R 6 or X 2 -CO-R 11 , wherein R 6 and R 11 have the meaning given above and X 1 and X 2 represent suitable leaving groups, in a suitable reaction medium, optionally in the presence of at least one base, to yield at least one compound of general formula I given above, wherein R 5 represents an -O-S0 2 -R 6 - moiety or an -0-CO-R 11 -moiety, and optionally purifying and/or optionally isolating said compound(s),
  • R 5 represents an -O-SO 2 -R 6 or an -O-CO-R 11 moiety
  • ammonia is reacted with ammonia, to yield a compound of general formula I, wherein R 5 represents an -NH 2 -moiety, and optionally purifying and/or optionally isolating said compound(s),
  • R 5 represents an -NH 2 -moiety
  • R 7 , R 8 and R 10 have the meaning given above and X 3 , X 4 and X 5 are suitable leaving groups, in a reaction medium, optionally in the presence of at least one base, to yield a compound of general formula I given above, wherein R 5 represents an -NH-CO-R 7 -moiety, an -NH-SO 2 -R 8 -moiety or an - NR 9 -S ⁇ 2 -R 10 -moiety with R 9 representing a hydrogen atom, and optionally purifying and/or optionally isolating said compound(s),
  • R 5 represents an -NR 9 -SO 2 -R 10 -moiety with R 9 representing a hydrogen atom is reacted with at least one compound of general formula X 6 -R 9 , wherein R 9 has the meaning given above except for a hydrogen atom and X 6 is a leaving group, to yield at least one compound of general formula I given above, wherein R 5 represents an -NR 9 -SO 2 -R 10 -moiety, and optionally purifying and/or optionally isolating said compound(s),
  • R 4 represents a hydrogen atom and R 1 -R 3 have the meaning given above, is oxidized to yield at least one compound of general formula IV,
  • R 1 -R 3 have the meaning given above, which is optionally purified and/or optionally isolated, and reacted with at least one compound of general formula R 5a H, wherein R 5a represents an -NH 2 -moiety or an -NHR 9 -moiety, wherein R 9 has the meaning given above, the resulting compound is optionally purified and/or optionally isolated and optionally reacted with at least one compound of general formula X 3 -CO-R 7 , X 4 -SO 2 -R 8 or X 5 -SO 2 -R 10 , wherein R 7 , R 8 and R 10 have the meaning given above and X 3 , X 4 and X 5 represent a leaving group, in a reaction medium, optionally in the presence of at least one base, to yield a compound of general formula I given above, wherein R 5 represents an -NH 2 -moiety, an -NH-CO-R 7 -moiety, an -NH-SO2- R 8 -m
  • step (a) according to scheme 1 is carried out in one or more organic solvents as reaction medium.
  • Suitable solvents include but are not limited to halogenated, preferably chlorinated, organic solvents such as dichloromethane or chloroforme and linear or cyclic ethers, such as tetrahydrofurane, 1 ,4-dioxane, or 1,1- dimethoxyethane.
  • Reaction temperature as well as the duration of the reaction may vary over a broad range. The optimum reaction temperature and duration of reaction for a given reaction may be determined by conventional methods known to those skilled in the art.
  • Preferred reaction temperatures are 0-30 °C, preferably 15-25 °C. Suitable reaction times may vary from approximately 10 minutes to 3 days.
  • Suitable bases for use in step (a) include organic bases such as triethylamine or pyridine as well as inorganic bases such as sodium hydroxide or potassium hydroxide. Mixtures of one or more organic bases and/or one or more inorganic bases may also be used.
  • the leaving groups X 1 and X 2 may be of any type known to those skilled in the art for this type of reaction.
  • the leaving group is a halogen atom, more preferably a chlorine or bromine atom.
  • Suitable reaction media for the reaction with ammonia according to step (b) of scheme 1 include, for example, alcohols such as methanol, ethanol, isopropanol or mixtures of at least two of these alcohols.
  • the ammonia is preferably added as a concentrated, preferably aqueous solution.
  • Reaction temperature, pressure as well as the duration of the reaction may vary over a broad range.
  • the optimum conditions may be determined by conventional methods known to those skilled in the art.
  • Preferred reaction temperatures range from ambient temperature, i.e. approximately 15-25 °C to the boiling point of the reaction medium. Suitable reaction times may vary, for example from approximately 10 minutes to 3 days. Obviously the reaction may also be carried out in a reactor at elevated temperatures and pressure.
  • Preferably compounds of general formula I, wherein R 5 represents a -0-S0 2 -R 6 -moiety with R 6 representing a methyl group, are used in step (b).
  • the reaction steps (c) and (d) according to scheme 1 may also be carried out under conventional conditions known to those skilled in the art.
  • a suitable reaction medium used for these reaction steps is preferably comprises one or more organic solvents.
  • Suitable solvents include but are not limited to halogenated, preferably chlorinated, organic solvents such as dichloromethane or chloroforme and linear or cyclic ethers, such as tetrahydrofurane, 1,4-dioxane, or 1,1-dimethoxyethane.
  • Reaction temperature as well as the duration of the reaction may vary over a broad range. The optimum conditions for a given reaction may be determined by conventional methods known to those skilled in the art. Preferred reaction temperatures are 0-30 °C, preferably 15-25 °C. Suitable reaction times vary, e.g. from approximately 10 minutes to 3 days.
  • Suitable bases that may be present during reaction steps (c) and (d) include organic bases such as triethylamine or pyridine as well as inorganic bases such as sodium hydroxide or potassium hydroxide. Mixtures of one or more organic bases and/or one or more inorganic bases may also be used.
  • the leaving groups X 3 , X 4 , X 5 and X 6 may be of any type known to those skilled in the art for this type of reaction.
  • the leaving group is a halogen atom, more preferably a chlorine or bromine atom.
  • step (e) of scheme 1 may preferably be carried out according to the literature publications of Katritzky et al., J. Heterocycl. Chem., 1994, 271-275; P.R. Dave et al., J. Org. Chem., 1996, 61(16), 5453, Synlett. 1991, (11), 783-784 and Axenrod et al., Tetrahedron Lett., 1993, 6677-6680.
  • the respective descriptions are hereby incorporated by reference and form part of the present disclosure.
  • step (f) according to scheme 1 is carried out in one or more organic solvents as reaction medium such as chlorinated, organic solvents like dichloromethane or chloroforme and preferably in the presence of sodium triacetoxyborohydride and acetic acid, or in the presence of H 2 and an alcohol such as methanol and/or ethanol as a reaction medium.
  • organic solvents as reaction medium such as chlorinated, organic solvents like dichloromethane or chloroforme and preferably in the presence of sodium triacetoxyborohydride and acetic acid, or in the presence of H 2 and an alcohol such as methanol and/or ethanol as a reaction medium.
  • Reaction temperature as well as the duration of the reaction may vary over a broad range.
  • the optimum reaction temperature and duration of reaction for a given reaction may be determined by conventional methods known to those skilled in the art. Preferred reaction temperatures are 0-30 °C, preferably 15-25 °C.
  • the substituents R 1 -R 4 have the same meaning as definied above and X represents a halogen atom, preferably a bromine or chlorine atom.
  • X represents a halogen atom, preferably a bromine or chlorine atom.
  • the substituted hydroxy-alkenylene compounds used as a starting material for reaction steps A and A1 according to scheme 2 are commercially available and/or may be prepared according to methods well known to those skilled in the art, e.g. by reduction of the corresponding carbonyl compound with a suitable reducing agent such as aluminium lithium hydride, sodium borohydride or catalysed hydrogenation as described, for example, in Catalysis Letters, 1999, 62(2-4), 175-177; Tetrahedron, 1984, 40(7), 1195-1198; J. Org.
  • halogenenated alkenylene compounds used as starting material for reaction step B and B1 are commercially available and/or may be prepared from the corresponding hydroxy-alkenylene compounds using a suitable halogenation agent such as thionyl chloride, triphenyl phosphin/carbontetrachloride, bromine, hydrobromic acid, triphenyl phosphin/carbontetrabromide, phosphor tribromide and others described in the literature, for example, in Chem. Ber. 123(12), 2387-94, 1990; J. Am. Chem. Soc, 111(9), 3363-3368, 1989; J. Org.
  • a suitable halogenation agent such as thionyl chloride, triphenyl phosphin/carbontetrachloride, bromine, hydrobromic acid, triphenyl phosphin/carbontetrabromide, phosphor tribromide and others described in the literature, for example, in Chem. Ber. 123
  • reaction steps A, B and B1 may be carried out as described in Higgins et al., J.
  • Reaction step A is preferably carried out in an organic solvent such as dichloromethane, chlorofom, carbontetrachloride or mixtures thereof as reaction medium.
  • Reaction temperature as well as the duration of the reaction may vary over a broad range.
  • the optimum conditions for a given reaction may be determined by conventional methods known to those skilled in the art.
  • Preferred reaction temperatures are from -10°C to +30 °C, preferably from 0°C to 25 °C, more preferably from 0 °C to 10°C.
  • Suitable reaction times vary from a few minutes to several hours, preferably from 3 to 8 hours.
  • Reaction step B is preferably carried out by dissolving the educt in a suitable reaction medium, preferably a linear ether such as diethylether, or a cyclic ether, such as tetrahydrofuran, 1 ,4-dioxane or 1 ,1-dimethoxyethan, and in the presence of an aqueous solution of a base, preferably selected from the group consisting of an alkali metal such as lithium, sodium, or potassium, under vigorous stirring.
  • a suitable reaction medium preferably a linear ether such as diethylether, or a cyclic ether, such as tetrahydrofuran, 1 ,4-dioxane or 1 ,1-dimethoxyethan
  • a base preferably selected from the group consisting of an alkali metal such as lithium, sodium, or potassium, under vigorous stirring.
  • Reaction temperature as well as the duration of the reaction may vary over a broad range.
  • the optimum reaction conditions for a given reaction may be determined by conventional methods known to those skilled in the art.
  • Preferred reaction temperatures range from 10°C to the boiling point of the reaction mixture, preferably from 15°C to 25 °C.
  • Suitable reaction times vary from a few minutes to several hours, preferably from 3 to 8 hours
  • Reaction step B1 is preferably carried out in the presence of an oxidizing agent such as peracetic acid, m-chloro perbenzoic acid, N-Bromsuccinimide or the like.
  • an oxidizing agent such as peracetic acid, m-chloro perbenzoic acid, N-Bromsuccinimide or the like.
  • the 3-azetidinol compound is obtained by carrying out reaction step (c) according to the methods described in the literature publications of M.E. Jung, J. Org. Chem., 1991 , 56(24), 6729-6730; V.R. Gaertner, J. Org. Chem., 1967, 32, 2972, Katrizky et al., J. Heterocycl. Chem. 1994, 271-275, P.R. Dave et al, J. Org. Chem., 1996, 61 (16), 5453 and US 5,073,646.
  • the corresponding descriptions are incorporated by reference and form part of the present disclosure.
  • reaction steps A2, B2, C2a and C2b may be carried out according to conventional methods well known to those skilled in the art.
  • Step A2 is for example described in Hajipour et al., Synth. Commun. 1999, 29(10), 1697-1701 , A. Sasse et al., Arch. Pharm., 2001 , 334(2), 45-52.
  • Step B2 is for example described in the publication of Fernandez et al., Synthesis 2001 , (2), 239-242; Baruah et al., Synlett, 1999, (4), 409-410.
  • Steps C2a and C2b are for example disclosed in the publications of M. Grisar et al., J. Med.
  • Another aspect the present invention is a process for the preparation of substituted azetidine compounds of general formula I given above and corresponding stereoisomers thereof, according to which at least one compound of general formula
  • R and R 2 have the meaning given above and Y represents a halogen atom, preferably a chlorine atom or a bromine atom, is reacted with at least one compound of general formula VI,
  • azetidine compound(s) optionally in form of a salt, wherein R 3 , R 4 and R 5 have the meaning given above, in a suitable reaction medium, optionally in the presence of a base, and the resulting azetidine compound(s) is/are optionally purified and/or optionally isolated.
  • the compounds of general formula (Va) may, for example, be obtained according to step A3 of scheme 4 by reduction of a corresponding ketone compound with a suitable reducing agent such as sodium borohydride in a suitable reaction medium such as alcohol, preferably methanol, whereby the reaction temperature is preferably kept in the range of 0°C and the boling point of the reaction medium.
  • a suitable reducing agent such as sodium borohydride
  • a suitable reaction medium such as alcohol, preferably methanol
  • the compounds of general formula (Va) may, for example, also be obtained according to step B3 of scheme 4 by a Grignard reaction in a suitable inert reaction medium such as diethylether or tetrahydrofuran, whereby the reation temperature is preferably kept in the range of 0 °C and the boiling point of the reaction medium.
  • a suitable inert reaction medium such as diethylether or tetrahydrofuran
  • Reaction step C3 of scheme 4, in which X represents a halogen atom, preferably a chlorine or bromine atom, may be carried out using a suitable halogenating agent such as hydrobromic acid, thionyl bromide, thionyl chloride, acetyl bromide, in a suitable reaction medium such as acetic acid, benzene, toluene, dichloromethane or chloroform, whereby the reaction temperature is preferably kept in the range of 0°C to the boling point of the reaction medium.
  • a suitable halogenating agent such as hydrobromic acid, thionyl bromide, thionyl chloride, acetyl bromide
  • a suitable reaction medium such as acetic acid, benzene, toluene, dichloromethane or chloroform
  • the reaction of at least one compound of general formula V given above with at least one compound of general formula VI may preferably be carried out in an inert reaction medium, whereby acetonitrile, tetrahydrofuran or mixtures thereof are preferred.
  • Suitable bases include organic bases such as triethylamine and inorganic bases such as carbonates of alkali metals, preferably potassium carbonate, or potassium iodide.
  • the reaction temperature is preferably in the range of ambient temperature to the boling point of the reaction medium. The reaction times may vary over a broad range.
  • the compounds of general formula VI may be prepared from the corresponding substituted benzhydrylazetidine compounds of general formula VII,
  • compounds of general formula VI are preferably isolated in form of a corresponding salt such as a hydrochloride or hydrobromide salt.
  • the compounds of general formula VII may be prepared according to the methods described, for example, in US 5,073,646 and J. Frigola, J. Med. Chem., 1993, 36, 801-810.
  • the compounds of general formula VI are usually obtained in form of a mixture of diastereoisomers.
  • the respective enantiomers may be obtained by racemic resolution with HPLC using chiral columns or by crystallization with chiral derivatives obtained from the reaction of the corresponding racemate with chiral agents as described in the publication of J. Frigola, J. Med. Chem. 1994, 37, 4195- 4210 and J. Frigola, J. Med. Chem., 1995, 38, 1203-1215.
  • the corresponding enantiomers may also be obtained by asymmetric epoxidation in a corresponding reaction as described in scheme 2, which is carried out according to the method described in the publication of Sharpless et al., J. Am. Chem. Soc, 1980, 102, 5974- 5976; J. A. Marshall et al., Org. Lett., 2000 2(18), 2897-2900 using tert.-Butyl hydroperoxide in the presence of titanium isopropoxide and diethyl or diisopropyl tartrate as oxidant.
  • substituted azetidine compounds of general formula (I) themselves are obtained in form of a mixture of stereoisomers, particularly enantiomers or diastereomers, said mixtures may be separated by standard procedures known to those skilled in the art, e.g. chromatographic methods or fractunalized crystallization with chiral reagents. It is also possible to obtain pure stereoisomers via stereoselective synthesis.
  • Substituted azetidine compounds of general formula I which comprise nitrogen-atom containing saturated, unsaturated or aromatic rings may also be obtained in the form of their N-oxides by methods well known to those skilled in the art.
  • the present invention also provides a process for the preparation of salts of substituted azetidine compounds of general formula (I), stereoisomers thereof or N-oxides thereof, wherein at least one compound of general formula (I) having at least one basic group is reacted with at least one inorganic and/or organic acid, preferably in the presence of a suitable reaction medium.
  • Suitable reaction media include, for example, any of the ones given above.
  • Suitable inorganic acids include hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, nitric acid
  • suitable organic acids are e.g. citric acid, maleic acid, fumaric acid, tartaric acid, or derivatives thereof, p-toluenesulfonic acid, methanesulfonic acid or camphersulfonic acid.
  • the present invention also provides a process for the preparation of salts of substituted azetidine compounds of general formula (I), stereoisomers thereof or N-oxides thereof, wherein at least one compound of general formula (I) having at least one acidic group is reacted with one or more suitable bases, preferably in the presence of a suitable reaction medium.
  • suitable bases are e.g. hydroxides, carbonates or alkoxides, which include suitable cations, derived e.g. from alkaline metals, alkaline earth metals or organic cations, e.g.
  • Suitable reaction media are, for example, any of the ones given above.
  • Solvates, preferably hydrates, of the substituted azetidine compounds of general formula (I), of corresponding stereoisomers, corresponding N-oxides thereof, or of corresponding salts thereof may also be obtained by standard procedures known to those skilled in the art.
  • the purification and isolation of the inventive substituted azetidine compounds of general formula (I), of a corresponding stereoisomer, or salt, or solvate or any intermediate thereof may, if required, be carried out by conventional methods known to those skilled in the art, e.g. chromatographic methods or recrystallization.
  • substituted azetidine compounds of general formula (I), their N-oxides, their stereoisomers, corresponding salts thereof and corresponding solvates are toxicologically acceptable and are therefore suitable as pharmaceutical active substances for the preparation of medicaments.
  • an other aspect of the present invention is a medicament comprising at least one substituted azetidine compound of general formula I given above including the afore disclaimed compounds, optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding N-oxide thereof, a corresponding salt thereof, or a corresponding solvate thereof, and optionally one or more pharmaceutically acceptable excipients.
  • Said medicament may comprise any combination of one or more of the substituted azetidine compounds of general formula I given above, stereoisomers thereof, corresponding N-oxides thereof, physiologically acceptable salts thereof or physiologically acceptable solvates thereof.
  • said medicament is suitable for the modulation (regulation) of cannabinoid-receptors, preferably cannabinoid 1 (CB-i) receptors, for the prophylaxis and/or treatment of disorders of the central nervous system, disorders of the immune system, disorders of the cardiovascular system, disorders of the endocrinous system, disorders of the respiratory system, disorders of the gastrointestinal tract or reproductive disorders.
  • cannabinoid-receptors preferably cannabinoid 1 (CB-i) receptors
  • said medicament is suitable for the prophylaxis and/or treatment of one or more disorders selected from the group consisting of psychosis, schizophrenia, anxiety, depression, epilepsy, neurodegenerative disorders, cerebellar disorders, spinocerebellar disorders, cognitive disorders, cranial trauma, panic attacks, peripheric neuropathy, inflammation, glaucoma, migraine, Morbus Parkinson, Morbus Huntington, Morbus Alzheimer, Raynaud's disease, tremblement disorders, compulsive disorders, senile dementia, thymic disorders, tardive dyskinesia, bipolar disorders, cancer, medicament-induced movement disorders, dystonia, endotoxemic shock, hemorragic shock, hypotension, insomnia, immunologic disorders, sclerotic plaques, vomiting, diarrhea, asthma, food intake disorders, preferably bulimia, anorexia, cachexia, obesity, type II diabetus mellitus (non-insuline dependent diabetes mellitus), memory disorders, pruritus, alcoholism, drug addiction, medicament
  • the inventive medicament is suitable for the prophylaxis and/or treatment of pain, of food intake disorders, preferably bulimia, anorexia, cachexia, obesity or type II diabetus mellitus (non-insuline dependent diabetes mellitus), preferably diabetes, psychosis, alcoholism, drug addiction and/or medicament addiction, preferably drug addiction, diarrhea and/or pruritus.
  • food intake disorders preferably bulimia, anorexia, cachexia, obesity or type II diabetus mellitus (non-insuline dependent diabetes mellitus), preferably diabetes, psychosis, alcoholism, drug addiction and/or medicament addiction, preferably drug addiction, diarrhea and/or pruritus.
  • the inventive medicament is suitable for the prophylaxis and/or treatment of one or more disorders selected from the group consisting of obesity, psychosis and/or drug addiction.
  • Another aspect of the present invention is the use of at least one substituted azetidine compound of general formula I including the afore disclaimed compounds, optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding N-oxide thereof, a corresponding salt thereof, or a corresponding solvate thereof, and optionally one or more pharmaceutically acceptable excipients, for the preparation of a medicament for the modulation of cannabinoid-receptors, preferably cannabinoid 1 (CB ⁇ ) receptors, for the prophylaxis and/or treatment of disorders of the central nervous system, disorders of the immune system, disorders of
  • the medicament according to the present invention may be in any form suitable for the application to humans and/or animals, preferably humans including infants, children and adults and can be produced by standard procedures known to those skilled in the art.
  • the composition of the medicament may vary depending on the route of administration.
  • the medicament of the present invention may for example be administered parentally in combination with conventional injectable liquid carriers, such as water or suitable alcohols.
  • conventional pharmaceutical excipients for injection such as stabilizing agents, solubilizing agents, and buffers, may be included in such injectable compositions.
  • These medicaments may for example be injected intramuscularly, intraperitoneally, or intravenously.
  • Medicaments according to the present invention may also be formulated into orally administrable compositions containing one or more physiologically compatible carriers or excipients, in solid or liquid form. These compositions may contain conventional ingredients such as binding agents, fillers, lubricants, and acceptable wetting agents.
  • the compositions may take any convenient form, such as tablets, pellets, capsules, lozenges, aqueous or oily solutions, suspensions, emulsions, or dry powdered forms suitable for reconstitution with water or other suitable liquid medium before use, for immediate or retarded release.
  • liquid oral forms for administration may also contain certain additives such as sweeteners, flavoring, preservatives, and emulsifying agents.
  • Non-aqueous liquid compositions for oral administration may also be formulated, containing edible oils. Such liquid compositions may be conveniently encapsulated in e.g., gelatin capsules in a unit dosage amount.
  • the compositions of the present invention may also be administered topically or via a suppository.
  • the daily dosage for humans and animals may vary depending on factors that have their basis in the respective species or other factors, such as age, sex, weight or degree of illness and so forth.
  • the daily dosage for humans may preferably be in the range froml to 2000, preferably 1 to 1500, more preferably 1 to 1000 milligrams of active substance to be administered during one or several intakes per day.
  • Substances with affinity for cannabinoid receptors are known to produce a wide range of pharmacological effects. It is also known that intravenous administration of a substance with affinity for cannabinoid receptors in mice produces analgesia , hypothermia, sedation and catalepsy. Individually, none of these effects can be considered as proof that a tested substance has affinity for cannabinoid-receptors, since all of these effects are common for various classes of centrally active agents. However, substances, which show all of these effects, i.e. substances that are active in this so-called tetrad model are considered to have affinity for the cannabinoid receptors. It has further been shown that cannabinoid receptor antagonists are higly effective in blocking the effects of a cannabinoid agonist in the mouse tetrad model.
  • mice with a weight of 20-30 g Male NMRI mice with a weight of 20-30 g (Harlan, Barcelona, Spain) are used in all of the following experiments.
  • mice are acclimatized to the experimental setting.
  • Pre-Treatment control values are determined for analgesia hot plate latency (in seconds), rectal temperature, sedation and catalepsy.
  • the mice are injected intravenously with the substance to be tested or the vehicle alone. 15 minutes after injection, latency in hot plate analgesia is measured. Rectal temperature, sedation and catalepsy are measured 20 minutes after injection.
  • the hot plate analgesia is determined according to the method described in Woolfe D. et al. butThe evaluation of analgesic action of pethidine hydrochloride (Demerol)", J. Pharmacol. Exp. Ther. 80, 300-307,1944. The respective description is hereby incorporated by reference and forms part of the present disclosure.
  • mice are placed on a hot plate (Harvard Analgesimeter) at 55 ⁇ 0.5 °C until they show a painful sensation by licking their paws or jumping and the time for these sensations to occur is recorded. This reading is considered the basal value (B).
  • B basal value
  • PC cut-off time
  • mice Fifteen minuts after the administration of the substance to be tested, the mice are again placed on the hot plate and the afore described procedure is repeated. This period is called the post-treatment reading (PT).
  • PT post-treatment reading
  • the degree of analgesia is calculated from the formula :
  • % MPE of Analgesia ( PT- B) / (PC-B) x 100
  • Sedation and ataxia is determined according to the method described in Desmet L. K. C. et al. perennial Anticonvulsive properties of Cinarizine and Flunarizine in Rats and Mice", Arzneim. -Forsch. (Frug Res) 25, 9, 1975.
  • the respective description is hereby incorporated by reference and forms part of the present disclosure.
  • the chosen scoring system is
  • the percentage of sedation is determined according to the formula:
  • % of sedation arithmetic mean / 3 X 100
  • the base-line rectal temperatures are determined with a thermometer (Yello Springs Instruments Co., Panlabs) and a thermistor probe inserted to 25mm before the administration of the substance to be tested. Rectal temperature is again measured 20 minutes after the administration of the substances to be tested. The temperature difference is calculated for each animal, whereby differences of >-2 °C are considered to represent activity.
  • Catalepsy is determined according to the method described in Alpermann H. G. et al. -Pharmacological effets of Hoe 249: A new potential antidepressant", Drugs Dev. Res. 25, 267-282. 1992. The respective description is hereby incorporated by reference and forms part of the present disclosure.
  • the cataleptic effect of the substance to be tested is evaluated according to the duration of catalepsy, whereby the animals are placed head downwards with their kinlegs upon the top of the wooden block.
  • the chosen scoring system is:
  • the percentage of catalepsy is determined according ot the following formula:
  • % Catalepsy arithmetic mean / 6 X 100
  • the etheric layer of the first extraction was acidified with dilute 5 % (volume/volume) acetic acid, the acidic layer alkalinized with sodium hydroxide and extracted wilh dichloromethane, to yield 6.3 g of the compound giving a total of 16.3 g (70% of theory) of trans-3-amino-1-diphenylmethyl-2-methylazetidine having a melting point of 68-69° C.
  • the enantiomer (2S, 3R)-1-diphenylmethyl-2-methyl-3-methylsulphonyloxyazetidine was obtained by the same procedure as described above for the preparation of the trans-racemate but using (2S, 3R)-1-diphenylmethyl-3-hydroxy-2-methylazetidine.
  • the compound (2S, 3R)-1-diphenylmethyl-3-hydroxy-2-methylazetidine was obtained via the optical resolution of trans-1 -diphenylmethyl-3-hydroxy-2-methylazetidine with (+)-(1S)-camphersulfonic acid, as described in the literature publication of J. Frigola et al., J. Med. Chem., 1995, 38, 1203-1215.
  • the crude material is dissolved in 15 ml of ethanol, and an ethanolic solution saturated with hydrochloride gas is added to precipitate the corresponding hydrochloride salt, which is filtered off and washed with diethylether to yield 3.95 g (yield 85% of theory) of the hydrochloride salt having a melting point of 163 - 166 °C.
  • This compound was obtained via the hydrolysis of the ester prepared according to step (1c) given above, which was dissolved in ethanol comprising 10 % by weight of sodium hydroxide. The reaction mixture was kept at room temperature (approximately 25 °C) overnight. 1-[Bis-(4-chloro-phenyi)-methyl]-2-methyl-azetidin- 3-ol was obtained in a yield of 89%.
  • inventive azetidine compounds act as cannabinoid receptor antagonists, particularly for the CB-i-receptors.

Abstract

The present invention relates to substituted Azetidine compounds of general formula (I), methods for their preparation, medicaments comprising these compounds as well as their use for the preparation of a medicament for the treatment of humans and animals.

Description

Substituted Azetidine Compounds, their preparation and use as medicaments
The present invention relates to substituted Azetidine compounds of general formula (I), methods for their preparation, medicaments comprising these compounds as well as their use for the preparation of a medicament for the treatment of humans and animals.
Cannabinoids are compounds, which are derived from the cannabis sativa plant which is commonly known as marijuana. The most active chemical compound of the naturally occurring cannabinoids is tetrahydrocannabinol (THC), particularly Δ9-THC.
These naturally occuring cannabinoids as well as their synthetic analogues promote their physiological effects via binding to specific G-coupled receptors, the so-called cannabinoid-receptors.
At present, two distinct types of receptors that bind both the naturally occurring and synthetic cannabinoids have been identified and cloned. These recepors, which are designated CBι and CB2 are involved in a variety of physiological or pathophysiological processes in humans and animals, e.g. processes related to the central nervous system, immune system, cardiovascular system, endocrinous system, respiratory system, the gastrointestinal tract or to reproduction, as described for example, in Hollister, Pharm. Rev. 38, 1986, 1-20; Reny and Singha, Prog. Drug. Res., 36, 71-114, 1991; Consroe and Sandyk, in Marijuana/Cannabinoids, Neurobiology and Neurophysiology, 459, Murphy L and Barthe A. Eds., CRC Press, 1992.
Therefore, compounds, which have a high binding affinity for these cannabinoid receptors and which are suitable for modulating these receptors are useful in the prevention and/or treatment of cannabinoid-receptor related disorders.
Thus, it was an object of the present invention to provide novel compounds that are in particular suitable as active substances in medicaments, preferably in medicaments for the modulation of Cannabinoid receptors, particularly Cannabinoid 1 (CB-i) receptors. Preferably said medicaments should be suitable for the prophylaxis and/or treatment of disorders related to the central nervous system, the immune system, the cardiovascular system, the endocrinous system, the respiratory system, the gastrointestinal tract or reproduction in humans and/or animals.
Said object was achieved by providing the substituted Azetidine compounds of general formula I given below, stereoisomers, corresponding N-oxides, corresponding salts and corresponding solvates thereof. Surprisingly, it has been found that these compounds have a high affinity for cannabinoid receptors, particularly for the CB-i-receptor and are therefore suitable for the prophylaxis and/or treatment of various disorders related to the central nervous system, the immune system, the cardiovascular system, the endocrinous system, the respiratory system, the gastrointestinal tract or reproduction in humans and/or animals, preferably humans including infants, children and grown-ups.
Thus, in one of its aspects the present invention relates to substituted Azetidine compounds of general formula I,
Figure imgf000003_0001
wherein
R1 represents an optionally at least mono-substituted phenyl group,
R2 represents a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic group, which may be condensed with an optionally at least mono-substituted mono- or polycyclic ring system, or an optionally at least mono-substituted aryl or heteroaryl group, which may be condensed with an optionally at least mono-substituted mono- or polycyclic ring system R3 represents a linear or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic group, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic group, which may be condensed with a mono- or polycyclic ring- system and/or which may be bonded via a linear or branched alkylene group, or an optionally at least mono-substituted aryl or heteroaryl group, which may be condensed with a mono- or polycyclic ring system and/or which may be bonded via a linear or branched alkylene group, with the proviso that R3 is bonded to the azetidine ring via a carbon atom,
R4 represents a hydrogen atom, a cyano group, a carboxy group, a linear or branched alkyl group, or an optionally at least mono-substituted aryl group,
R5 represents an -O-SO2-R6-moiety, an -NH-CO-R7-moiety, an -Nh -moiety, an - NH-SO2-R8 moiety, an -NR9-SO2-R10-moiety or an -O-CO-R11 -moiety,
R6 represents a linear or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic group, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic group, which may be condensed with a mono- or polycyclic ring- system and/or which may be bonded via a linear or branched alkylene group, or an optionally at least mono-substituted aryl or heteroaryl group, which may be condensed with a mono- or polycyclic ring system and/or which may be bonded via a linear or branched alkylene group,
R7 represents a linear or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic group, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic group, which may be condensed with a mono- or polycyclic ring- system and/or which may be bonded via a linear or branched alkylene group, or an optionally at least mono-substituted aryl or heteroaryl group, which may be condensed with a mono- or polycyclic ring system and/or which may be bonded via a linear or branched alkylene group, R8 represents a linear or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic group, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic group, which may be condensed with a mono- or polycyclic ring- system and/or which may be bonded via a linear or bridged alkylene group, and/or which may be bridged by a linear or branched alkylene group, or an optionally at least mono-substituted aryl or heteroaryl group, which may be condensed with a mono- or polycyclic ring system and/or which may be bonded via a linear or branched alkylene group,
R9 represents an -S02-R12-moiety, a -CO-R13-moiety, a linear or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic group, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic group, which may be condensed with a mono- or polycyclic ring-system and/or which may be bonded via a linear or branched alkylene group and/or bridged by a linear or branched alkylene group, or an optionally at least mono-substituted aryl or heteroaryl group, which may be condensed with a mono- or polycyclic ring system and/or which may be bonded via an alkylene group,
R10 represents a linear or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic group, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic group, which may be condensed with a mono- or polycyclic ring- system and/or which may be bonded via a linear or bridged alkylene group, and/or which may be bridged by a linear or branched alkylene group, or an optionally at least mono-substituted aryl or heteroaryl group, which may be condensed with a mono- or polycyclic ring system and/or which may be bonded via a linear or branched alkylene group, R11 represents a linear or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic group, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic group, which may be condensed with a mono- or polycyclic ring- system and/or which may be bonded via a linear or bridged alkylene group, and/or which may be bridged by a linear or branched alkylene group, or an optionally at least mono-substituted aryl or heteroaryl group, which may be condensed with a mono- or polycyclic ring system and/or which may be bonded via a linear or branched alkylene group,
R12 represents a linear or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic group, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic group, which may be condensed with a mono- or polycyclic ring- system and/or which may be bonded via a linear or bridged alkylene group, and/or which may be bridged by a linear or branched alkylene group, or an optionally at least mono-substituted aryl or heteroaryl group, which may be condensed with a mono- or polycyclic ring system and/or which may be bonded via a linear or branched alkylene group,
R13 represents a linear or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic group, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic group, which may be condensed with a mono- or polycyclic ring- system and/or which may be bonded via a linear or bridged alkylene group, and/or which may be bridged by a linear or branched alkylene group, or an optionally at least mono-substituted aryl or heteroaryl group, which may be condensed with a mono- or polycyclic ring system and/or which may be bonded via a linear or branched alkylene group, optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding N-oxide thereof, a corresponding salt thereof, or a corresponding solvate thereof,
with the proviso that compounds of general formula I, in which R1 and R2 each represent an unsubstituted phenyl group, R5 represents an -O-SO2-R6-moiety and R6 represents a methyl group are excluded.
A mono- or polycyclic ring-system according to the present invention means a mono- or polycyclic hydrocarbon ring-system that may be saturated, unsaturated or aromatic. If the ring system is polycyclic, each of its different rings may show a different degree of saturation, i.e. it may be saturated, unsaturated or aromatic. Optionally each of the rings of the mono- or polycyclic ring system may contain one or more, e.g. 1 , 2 or 3, heteroatoms as ring members, which may be identical or different and which can preferably be selected from the group consisting of N, O, S and P, more preferably be selected from the group consisting of N, O and S. Preferably the polycyclic ring-system may comprise two rings that are condensed. The rings of the mono- or polycyclic ring-sytem are preferably 5- or 6-membered. The term "condensed" according to the present invention means that a ring or ring- system is attached to another ring or ring-system, whereby the terms "annulated" or "annelated" are also used by those skilled in the art to designate this kind of attachment.
If one or more of the residues R2, R3 and R6-R13 represents or comprises a saturated or unsaturated, optionally at least one heteroatom as ring member containing cycloaliphatic group, which is substituted by one or more, e.g. 1 , 2, 3, 4 or 5, substituents, unless defined-otherwise, each of the substituents may be independently selected from the group consisting of hydroxy, fluorine, chlorine, bromine, branched or unbranched Cι.4-alkyl, branched or unbranched Cι_4-alkoxy, branched or unbranched C- -perfluoroalkoxy, branched or unbranched C1-4- perfluoroalkyl, oxo, amino, carboxy, amido, cyano, nitro, -SO2NH2, -CO-C-M-alkyl, - SO-Cι-4-alkyl, -SO2-Cι^-alkyl, -NH-SO2-Cι-4-alkyl , wherein the C-u-alkyl may in each case be branched or unbranched, and a phenyl group, more preferably be selected from the group consisting of hydroxy, F, Cl, Br, methoxy, ethoxy, methyl, ethyl, oxo, CF3 and a phenyl group.
If one or more of the residues R2, R3 and R6-R13 represents or comprises a cycloaliphatic group, which contains one or more heteroatoms as ring members, unless defined otherwise, each of these heteroatoms may preferably be selected from the group consisting of N, O and S. Preferably a cycloaliphatic group may contain 1 , 2 or 3 heteroatoms independently selected from the group consisting of N, O and S.
Suitable saturated or unsaturated, optionally at least heteroatom as ring member containing, optionally at least mono-substituted cycloaliphatic groups may preferably be selected from the group consisting of Cyclopropyl, Cyclobutyl, Cyclopentyl, Cyclohexyl, Cycloheptyl, Cyclooctyl, Cyclopentenyl, Cyclohexenyl, Cycloheptenyl, Cyclooctenyl, Pyrrolidinyl, Piperidinyl, Piperazinyl, Homo-Piperazinyl and Morpholinyl.
If one or more of the residues R2, R3 and R6-R13 comprises a mono- or polycyclic ring system, which is substituted by one or more, e.g. 1, 2, 3, 4 or 5, substituents, unless defined otherwise, each of the substituents may be independently selected from the group consisting of hydroxy, fluorine, chlorine, bromine, branched or unbranched C-i- 4-alkoxy, branched or unbranched C^-alkyl, branched or unbranched C1-4- perfluoroalkoxy, branched or unbranched Cι-4-perfluoroalkyl, amino, carboxy, oxo, amido, cyano, nitro, -SO2NH2, -CO-C-M-alkyl, -SO-C^-alkyl, -SO2-d^-alkyl, -NH- SO2-Cι-4-alkyl , wherein the Cι-4-alkyl may in each case be branched or unbranched, and a phenyl group, more preferably be selected from the group consisting of hydroxy, F, Cl, Br, methyl, ethyl, methoxy, ethoxy, CF3, oxo and a phenyl group.
If one or more of the residues R2, R3, R4 and R6-R13 represents or comprises an aryl group, which is substituted by one or more, e.g. 1 , 2, 3, 4 or 5, substituents, unless defined otherwise, each of the substituents may be independently selected from the group consisting of a halogen atom, a linear or branched Cι_6-alkyl group, a linear or branched Cι.6 alkoxy group, a formyl group, a hydroxy group, a trifluoromethyl group, a trifluoromethoxy group, a -CO-C-|.6-alkyl group, a cyano group, a carboxy group, a - CO-O-C-ι-6-alkyl group, a -CO-NRARB- moiety, a -CO-NH-NRcRD-moiety, an -S-d-e- alkyl group, an -SO-d.6-alkyl group, an -S02-Cι.6-alkyl group, a -Cι.6-alkylene-S-Cι.6- alkyl group, a -Cι.6-alkylene-SO-Cι.6-alkyl group, a -Cι-6-alkylene-S02-d-6-alkyl group, a Cι.6-alkyl group substituted by one or more hydroxy groups and a -Cι-6- alkylene-NRERF group,
whereby RA, RB, identical or different, represent hydrogen or a Cι.6-alkyl group, or RA and RB together with the bridging nitrogen atom form a saturated, mono- or bicyclic, 3-10 membered heterocyclic ring system, which may be at least mono-substituted by one or more, identical or different, C-i-e alkyl groups and/or which may contain at least one further heteroatom selected from the group consisting of nitrogen, oxygen and sulphur as a ring member,
Rc, RD, identical or different, represent a hydrogen atom, a Cι-6-alkyl group, a -CO-O-Cι-6-alkyl group, a C3-8-cycloalkyl group, a Cι-6-alkylene-C3.8-cycloalkyl group, Ci-6-alkylene-0-Ci-6-alkyl group or a Cι_6-alkyl group substituted with one or more hydroxy groups, or Rc, RD together with the bridging nitrogen atom form a saturated, mono- or bicyclic, 3-10 membered heterocyclic ring system, which may be at least mono-substituted by one or more substituents independently selected from the group consisting of Ci-β alkyl group, a -CO-Ci-6-alkyl group, a -CO-O- C-|.6-alkyl group, a - CO-NH- Cι_6-alkyl group, a -CS-NH- C-i_6-alkyl group, an oxo group, a Ci-6-alkyl group substituted with one or more hydroxy groups, a Cι-6-alkylene~0-Cι_6-alkyl group and a -CO-NH2 group and/or which may contain at least one further heteroatom selected from the group consisting of nitrogen, oxygen and sulphur as a ring member, and
wherein RE, RF, identical or different, represent hydrogen or a Cι.6-alkyl group, or RE and RF together with the bridging nitrogen atom form a saturated, mono- or bicyclic, 3-10 membered heterocyclic ring system, which may be at least mono-substituted by one or more, identical or different Ci-β alkyl groups and/or which may contain at least one further heteroatom selected from the group consisting of nitrogen, oxygen and sulphur as a ring member.
Preferred aryl groups, which may optionally be at least mono-substituted, are phenyl and naphthyl. If one or more of the residues R2, R3 and R6-R13 represents or comprises a heteroaryl group, which is substituted by one or more, e.g. 1 , 2, 3, 4 or 5, substituents, unless defined otherwise, each of the substituents may be independently selected from the group consisting of a halogen atom, a linear or branched Ci-6-alkyl group, a linear or branched C-i-6 alcoxy group, a formyl group, a hydroxy group, a trifluoromethyl group, a trifluoromethoxy group, a -CO-Cι.6-alkyl group, a cyano group, a carboxy group, a - CO-O-d.6-alkyl group, a -CO-NRARB- moiety, a -CO-NH-NRcRD-moiety, an -S-d_6- alkyl group, an -SO-d-6-alkyl group, an -SO2-Cι.β-alkyl group, a -Cι.6-alkylene-S-Cι.6- alkyl group, a -Cι.6-alkylene-SO-Cι.6-alkyl group, a -Cι-6-alkylene-SO2-Cι.6-alkyl group, a d-6-alkyl group substituted by one or more hydroxy groups and a -d-β- alkylene-NRERF group,
whereby RA, RB, identical or different, represent hydrogen or a Cι.6-alkyl group, or RA and RB together with the bridging nitrogen atom form a saturated, mono- or bicyclic, 3-10 membered heterocyclic ring system, which may be at least mono-substituted by one or more, identical or different, Cι_6 alkyl groups and/or which may contain at least one further heteroatom selected from the group consisting of nitrogen, oxygen and sulphur as a ring member,
Rc, RD, identical or different, represent a hydrogen atom, a Cι.6-alkyl group, a -CO-O-d-6-alkyl group, a C3.8-cycloalkyl group, a Cι.6-alkylene-C3.8-cycloalkyl group, Cι-6-alkylene-0-Cι-6-alkyl group or a Cι.6-alkyl group substituted with one or more hydroxy groups, or Rc, RD together with the bridging nitrogen atom form a saturated, mono- or bicyclic, 3-10 membered heterocyclic ring system, which may be at least mono-substituted by one or more substituents independently selected from the group consisting of d-6 alkyl group, a -CO-Ci-6-alkyl group, a -CO-O- Ci-β-alkyl group, a - CO-NH- Cι_6-alkyl group, a -CS-NH- Cι.6-alkyl group, an oxo group, a Cι.6-alkyl group substituted with one or more hydroxy groups, a Cι.6-alkylene-O-Cι.6-alkyl group and a -CO-NH2 group and/or which may contain at least one further heteroatom selected from the group consisting of nitrogen, oxygen and sulphur as a ring member, and
wherein RE, RF, identical or different, represent hydrogen or a Cι.6-alkyl group, or RE and RF together with the bridging nitrogen atom form a saturated, mono- or bicyclic, 3-10 membered heterocyclic ring system, which may be at least mono-substituted by one or more, identical or different Cι_6 alkyl groups and/or which may contain at least one further heteroatom selected from the group consisting of nitrogen, oxygen and sulphur as a ring member,
The heteroatoms, which are present as ring members in the heteroaryl radical, may, unless defined otherwise, independently be selected from the group consisting of nitrogen, oxygen and sulphur. Preferably a heteroaryl radical may contain 1, 2 or 3 heteroatoms independently selected from the group consisting of nitrogen, oxygen and sulphur.
Suitable heteroaryl groups, which may optionally be at least mono-substituted, may preferably be selected from the group consisting of thienyl, furyl, pyrrolyl, pyridinyl, imidazolyl, pyrimidinyl, pyrazinyl, indolyl, chinolinyl, isochinolinyl, benzo[1 ,2,5]- thiodiazolyl, benzo[b]thiophenyl, benzo[b]furanyl, imidazo[2,1-b]thiazolyl and pyrazolyl, more preferably be selected from the group consisting of thienyl-, benzo[1,2,5]-thiodiazolyl, benzo[b]thiophenyl, imidazo[2,1-b]thiazolyl and pyrazolyl.
If one or more of the residues R3 and R6-R13 represents or comprises a linear or branched, saturated or unsaturated aliphatic group, such as an alkyl group, which is substituted by one or more, e.g. 1 , 2, 3, 4 or 5 substituents, unless defined otherwise, each of the substituents may be independently selected from the group consisting of hydroxy, fluorine, chlorine, bromine, branched or unbranched Cι-4-alkoxy, branched or unbranched Ci-4-perfluoroalkoxy, branched or unbranched d-4-perfluoroalkyl, amino, carboxy, amido, cyano, nitro, -SO2NH2, -CO-d-4-alkyl, -SO-Cι.4-alkyl, -SO2- Cι-4-alkyl, -NH-SO2-Cι-4-alkyl , wherein the d.4-alkyl may in each case be branched or unbranched, and a phenyl group, more preferably be selected from the group consisting of hydroxy, F, Cl, Br, methoxy, ethoxy, CF3 and a phenyl group.
Preferred linear or branched, saturated or unsaturated aliphatic groups, which may be substituted by one or more substituents, may preferably be selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, iso-butyl, sec-butyl, tert- butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, n-nonyl, n-decyl, vinyl, ethinyl, propenyl, propinyl, butenyl and butinyl. If any of the residues R3 and R6-R13 comprises a linear or branched alkylene group, unless defined otherwise, said alkylene group may preferably be selected from the group consisting of methylene (-(CH2)-), ethylene (-(CH2)2-), n-propylene (-(CH2) -), isopropylene (-(C(CH )2-), n-butylene (-(CH2)4-), n-pentylene (-(CH2)5-), n-hexylene ( -(CH2)6-), n-heptylene (-(CH2)7-), n-octylene (-(CH2)8-), n-nonylene( -(CH2)9-) and n-decylene (-(CH2)ι0-), more preferably from the group consisting of (-(CH2)-), ethylene (-(CH2)2-), n-propylene (-(CH2)3-), isopropylene (-(C(CH3)2-) and n-butylene (-(CH2)4-).
Preferred are compounds of general formula I given above, wherein R1 represents a phenyl group, which is optionally substituted by one or more substituents independently selected from the group consisting of a halogen atom, a linear or branched Ci-6-alkyl group, a linear or branched C-ι-6 alkoxy group, a formyl group, a hydroxy group, a trifluoromethyl group, a trifluoromethoxy group, a -CO-Cι.6-alkyl group, a cyano group, a carboxy group, a -CO-O-Cι-6-alkyl group, a -CO-NRARB- moiety, a -CO-NH-NRcRD-moiety, an -S-Cι.6-alkyl group, an -SO-Cι.6-alkyl group, an -Sθ2-Cι-6-alkyl group, a -Cι_6-alkylene-S-Cι-6-alkyl group, a -Cι.6-alkylene-SO-Cι-6- alkyl group, a -Cι.6-alkylene-SO2-Cι-6-alkyl group, a Ci-β-alkyl group substituted by one or more hydroxy groups and a -Cι.6-alkylene-NRERF group,
whereby RA, RB, identical or different, represent hydrogen or a Cι.6-alkyl group, or RA and RB together with the bridging nitrogen atom form a saturated, mono- or bicyclic, 3-10 membered heterocyclic ring system, which may be at least mono-substituted by one or more, identical or different, C1-6 alkyl groups and/or which may contain at least one further heteroatom selected from the group consisting of nitrogen, oxygen and sulphur as a ring member,
Rc, RD, identical or different, represent a hydrogen atom, a Cι.6-alkyl group, a -CO-O-Ci-6-alkyl group, a C3.8-cycloalkyl group, a Cι-6-alkylene-C3.8-cycloalkyl group, C-|.6-alkylene-0-Cι-6-alkyl group or a Ci-6-alkyl group substituted with one or more hydroxy groups, or Rc, RD together with the bridging nitrogen atom form a saturated, mono- or bicyclic, 3-10 membered heterocyclic ring system, which may be at least mono-substituted by one or more substituents independently selected from the group consisting of Ci-β alkyl group, a -CO-Cι.6-alkyl group, a -CO-O- d-6-alkyl group, a - CO-NH- d-e-alkyl group, a -CS-NH- d_6-alkyl group, an oxo group, a Ci-6-alkyl group substituted with one or more hydroxy groups, a Cι.6-alkylene-O-Cι.6-alkyl group and a -CO-NH2 group and/or which may contain at least one further heteroatom selected from the group consisting of nitrogen, oxygen and sulphur as a ring member, and
wherein RE, RF, identical or different, represent hydrogen or a Cι.6-alkyl group, or RE and RF together with the bridging nitrogen atom form a saturated, mono- or bicyclic, 3-10 membered heterocyclic ring system, which may be at least mono-substituted by one or more, identical or different C-i-e alkyl groups and/or which may contain at least one further heteroatom selected from the group consisting of nitrogen, oxygen and sulphur as a ring member,
preferably R1 represents a phenyl group, which is optionally substituted by one or more substituents independently selected from the group consisting of a fluorine atom, a chlorine atom, a bromine atom, a linear or branched Cι_6-alkyl group, a linear or branched Cι_6 alkoxy group, a formyl group, a hydroxy group, a trifluoromethyl group, a trifluoromethoxy group, a cyano group and a carboxy group,
more preferably R1 represents a phenyl group, which is optionally substituted by one or more substituents independently selected from the group consisting of a fluorine atom, a chlorine atom, a bromine atom, a methyl group, a methoxy group, a trifluoromethyl group and a trifluoromethoxy group, most preferably R1 represents a phenyl group, which is substituted by a chlorine atom in the 4-position,
and the residues R2-R13 have the meaning given above, optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding N-oxide thereof, a corresponding salt thereof, or a corresponding solvate thereof.
Also preferred are compounds of general formula I given above, wherein R2 represents a saturated or unsaturated, optionally at least mono-substituted, optionally at least heteroatom as ring member containing C3.8 cycloaliphatic group, which may be condensed with an optionally at least mono-substituted mono- or polycyclic ring system, or an optionally at least mono-substituted, 5- or 6-membered aryl or heteroaryl group, which may be condensed with an optionally at least mono- substituted mono- or polycyclic ring system,
preferably R2 represents a phenyl group, which is optionally substituted by one or more substituents independently selected from the group consisting of a halogen atom, a linear or branched Cι_6-alkyl group, a linear or branched Cι_6 alcoxy group, a formyl group, a hydroxy group, a trifluoromethyl group, a trifluoromethoxy group, a - CO-Ci-6-alkyl group, a cyano group, a carboxy group, a -CO-O-Cι.6-alkyl group, a - CO-NRARB- moiety, a -CO-NH-NRcRD-moiety, an -S-d.6-alkyl group, an -SO-C1-6- alkyl group, an -SO2-Cι.6-alkyl group, a -Cι.6-alkylene-S-Cι-6-alkyl group, a -d.6- alkylene-SO-Cι-6-alkyl group, a -Cι-6-alkylene-SO2-Cι_6-alkyl group, a Cι.6-alkyl group substituted by one or more hydroxy groups and a -d.6-alkylene-NRERF group,
whereby RA, RB, identical or different, represent hydrogen or a Cι-6-alkyl group, or RA and RB together with the bridging nitrogen atom form a saturated, mono- or bicyclic, 3-10 membered heterocyclic ring system, which may be at least mono-substituted by one or more, identical or different, Cι_6 alkyl groups and/or which may contain at least one further heteroatom selected from the group consisting of nitrogen, oxygen and sulphur as a ring member,
Rc, RD, identical or different, represent a hydrogen atom, a d-6-alkyl group, a -CO-O-Ci_6-alkyl group, a C3.8-cycloalkyl group, a Cι-6-alkylene-C3-8-cycloalkyl group, Cι-6-alkylene-O-Cι-6-alkyl group or a Cι.6-alkyl group substituted with one or more hydroxy groups, or Rc, RD together with the bridging nitrogen atom form a saturated, mono- or bicyclic, 3-10 membered heterocyclic ring system, which may be at least mono-substituted by one or more substituents independently selected from the group consisting of C1.6 alkyl group, a -CO-Cι.6-alkyl group, a -CO-O- Cι_6-alkyl group, a - CO-NH- Ci-6-alkyl group, a -CS-NH- Cι„6-alkyl group, an oxo group, a Cι.6-alkyl group substituted with one or more hydroxy groups, a Cι_6-alkylene-0-Cι_6-alkyl group and a -CO-NH2 group and/or which may contain at least one further heteroatom selected from the group consisting of nitrogen, oxygen and sulphur as a ring member, and
wherein RE, RF, identical or different, represent hydrogen or a Cι.6-alkyl group, or Rε and RF together with the bridging nitrogen atom form a saturated, mono- or bicyclic, 3-10 membered heterocyclic ring system, which may be at least mono-substituted by one or more, identical or different C-j-β alkyl groups and/or which may contain at least one further heteroatom selected from the group consisting of nitrogen, oxygen and sulphur as a ring member,
more preferably R2 represents a phenyl group, which is optionally substituted by one or more substituents independently selected from the group consisting of a fluorine atom, a chlorine atom, a bromine atom, a methyl group, a methoxy group, a trifluoromethyl group and a trifluoromethoxy group,
most preferably R2 represents a phenyl group, which is substituted by a chlorine atom in the 4-position,
and R1 and R3-R13 have the meaning given above, optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding N-oxide thereof, a corresponding salt thereof, or a corresponding solvate thereof.
Preference is also given to compounds of formula I given above, wherein R3 represents a linear or branched, saturated or unsaturated, optionally at least mono- substituted Cι_ιo-aliphatic group, a saturated or unsaturated, optionally at least mono- substituted, optionally at least one heteroatom as ring member containing C3.8- cycloaliphatic group, which may be condensed with a mono- or polycyclic ring- system and/or which may be bonded via a linear or branched Cι-6-alkylene group, or an optionally at least mono-substituted, 5- or 6- membered aryl or heteroaryl group, which may be condensed with a mono- or polycyclic ring system and/or which may be bonded via a linear or branched Ci-β-alkylene group,
preferably R3 represents a linear or branched, optionally at least mono-substituted Cι-10-alkyl group, or an optionally at least mono-substituted, 5- or 6- membered aryl or heteroaryl group, which may be condensed with a mono- or polycyclic ring system and/or which may be bonded via a linear or branched Cι_6-alkylene group, more preferably R3 represents a linear or branched, unsubstituted Cι-ι0-alkyl group, most preferably R3 represents a methyl group, and R1, R2 and R4-R13 have the meaning given above, optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding N-oxide thereof, a corresponding salt thereof, or a corresponding solvate thereof.
Further preferred compounds of general formula I given above are compounds, in which R4 represents a hydrogen atom, a cyano group, a carboxy group, a linear or branched Cι-ι0-alkyl group, or an optionally at least mono-substituted, 5- or 6- membered aryl group, preferably R4 represents a hydrogen atom, a linear or branched Ci-3-alkyl group, or an optionally at least mono-substituted phenyl group, more preferably R4 represents a hydrogen atom or a linear or branched Cι_3-alkyl group, most preferably R4 represents a hydrogen atom, and R1-R3 and R5-R13 have the meaning given above, optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding N-oxide thereof, a corresponding salt thereof, or a corresponding solvate thereof.
Also preferred are compounds of general formula I given above, in which R5 represents an -O-SO2-R6-moiety, an -NH-CO-R7-moiety, an -NH2-moiety, an -NH- SO2-R8 moiety or an -NR9-SO2-R10-moiety, preferably R5 represents an -O-SO2-R6- moiety, an -NH-S02-R8 moiety or an -NR9-SO2-R10-moiety, and R1-R4 and R6-R13 have the meaning given above, optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding N-oxide thereof, a corresponding salt thereof, or a corresponding solvate thereof.
Preference is also given to compounds of general formula I given above, wherein R6 represents a linear or branched, saturated or unsaturated, optionally at least mono- substituted C1-10 aliphatic group, a saturated or unsaturated, optionally at least mono- substituted, optionally at least one heteroatom as ring member containing C3.8- cycloaliphatic group, which may be condensed with a mono- or polycyclic ring- system and/or which may be bonded via a linear or branched Cι.6-alkylene group, or an optionally at least mono-substituted, 5- or 6-membered aryl or heteroaryl group, which may be condensed with a mono- or polycyclic ring system and/or which may be bonded via a linear or branched Cι-6-alkylene group, preferably R6 represents an optionally at least mono-substituted C3-s-cycloaliphatic group or an optionally at least mono-substituted phenyl group, wherein the respective substituents are independently selected from the group consisting of a fluorine atom, a chlorine atom, a bromine atom, a linear or branched Cι_6-alkyl group, a linear or branched Cι-β alcoxy group, a formyl group, a hydroxy group, a trifluoromethyl group, a trifluoromethoxy group, a cyano group and a carboxy group, more preferably R6 represents a phenyl group, which is optionally substituted by one or more substituents independently selected from the group consisting of a fluorine atom, a chlorine atom, a bromine atom, a methyl group, a methoxy group, a trifluoromethyl group and a trifluoromethoxy group, and R1-R5 and R7-R13 have the meaning given above, optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding N-oxide thereof, a corresponding salt thereof, or a corresponding solvate thereof.
Furthermore, compounds of general formula I given above are preferred, in which R7 represents a linear or branched, saturated or unsaturated, optionally at least mono- substituted Cι-ιo-aliphatic group, a saturated or unsaturated, optionally at least mono- substituted, optionally at least one heteroatom as ring member containing C3.8- cycloaliphatic group, which may be condensed with a mono- or polycyclic ring- system and/or which may be bonded via a linear or branched Cι.6-alkylene group, or an optionally at least mono-substituted aryl or heteroaryl group, which may be condensed with a mono- or polycyclic ring system and/or which may be bonded via a linear or branched Cι-6-alkylene group, preferably-R7 represents a linear or branched, optionally at least mono-substituted Cι.5-alkyl group, a saturated, optionally at least mono-substituted Cs-β-cycloaliphatic group, or an optionally at least mono-substituted phenyl group, more preferably R7 represents a linear or branched, optionally at least mono-substituted Cι-5-alkyl group, a saturated, optionally at least mono-substituted C5„6-cycloaliphatic group, or an optionally at least mono-substituted phenyl group, wherein in each case the substituents are independently from one another selected from the group consisting of group consisting of a fluorine atom, a chlorine atom, a bromine atom, a methyl group, a methoxy group, a trifluoromethyl group and a trifluoromethoxy group, and R1-R6 and R8-R13 have the meaning given above, optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding N-oxide thereof, a corresponding salt thereof, or a corresponding solvate thereof.
Also preferred are compound of general formula I given above, wherein R8 represents a linear or branched, saturated or unsaturated, optionally at least mono- substituted Cι-ιo-aliphatic group, a saturated or unsaturated, optionally at least mono- substituted, optionally at least one heteroatom as ring member containing C3.8- cycloaliphatic group, which may be condensed with a mono- or polycyclic ring- system and/or which may be bonded via a linear or bridged Cι.ι0-alkylene group and/or which may be bridged by a linear or branched Cι_5-alkylene group, or an optionally at least mono-substituted 5- or 6-membered aryl or heteroaryl group, which may be condensed with a mono- or polycyclic ring system and/or which may be bonded via a linear or branched Ci-10-alkylene group, preferably R8 represents a linear or branched Cι-10-alkyl group, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C5.6- cycloaliphatic group, which may be condensed with a mono- or polycyclic ring- system and/or which may be bonded via a linear or bridged Cι_3-alkylene group and/or which may be bridged by a linear or branched Cι-3-alkylene group, or an optionally at least mono-substituted 5- or 6-membered aryl or heteroaryl group, which may be condensed with a mono- or polycyclic ring system and/or which may be bonded via a linear or branched Ci-3-alkylene group, more preferably R8 represents a methyl group, an ethyl group, an n-propyl group, an n-butyl group, an optionally at least mono-substituted phenyl group, an optionally at least mono-substituted benzyl group, an optionally at least mono-substituted naphthyl group, which may be bonded via a Cι-3-alkylene group, an optionally at least mono-substituted thienyl group, an optionally at least mono-substituted 2,1,3-Benzothiadiazole group, an optionally at least mono-substituted Benzo[b]thiophenyl group, an optionally at least mono- substituted lmidazo[2.1-b]thiazole group, an optionally at least mono-substituted 1H- pyrazole group or a 7,7-Dimethyl-2-oxo-bicyclo-[2.2.1]-hept-1-yl group, most preferably R8 represents a methyl group, an ethyl group, an n-propyl group, an n- butyl group, an optionally at least mono-substituted phenyl group, an optionally at least mono-substituted benzyl group, an optionally at least mono-substituted naphthyl group, which may be bonded via a Cι-3-alkylene group, an optionally at least mono- substituted thienyl group, an optionally at least mono-substituted 2,1 ,3- Benzothiadiazole group, an optionally at least mono-substituted Benzo[b]thiophenyl group, an optionally at least mono-substituted lmidazo[2.1-b]thiazole group, an optionally at least mono-substituted 1 H-pyrazole group or a 7,7-Dimethyl-2-oxo- bicyclo-[2.2.1]-hept-1-yl group, wherein said substituents, if present, are identical or different and selected from the group consisting of a fluorine atom, a chlorine atom, a bromine atom, a methyl group, a formyl group, a phenyl group, a phenoxy group, a phenoxy group substituted with bromine in the 4-position and a methylsulfonyl group, and R1-R7 and R9-R13 have the meaning given above, optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding N-oxide thereof, a corresponding salt thereof, or a corresponding solvate thereof.
Also preferred are compounds of general formula I given above, in which R9 represents an -SO2-R 2-moiety, a -CO-R13-moiety, a linear or branched, saturated or unsaturated, optionally at least mono-substituted d-10 aliphatic group, a saturated or unsaturated, optionally at least mono-substituted, optionally at least heteroatom as ring member containing C3-8 cycloaliphatic group, which may be condensed with a mono- or polycyclic ring-system and/or which may be bonded by a linear or branched C1.6 alkylene group and/or bridged by a linear or branched C1-6 alkylene group, or an optionally at least mono-substituted aryl or heteroaryl group, which may be condensed-with a mono- or-polycyclic ring system and/or which may be bonded via a d.6 alkylene group, preferably R9 represents an -SO2-R12-moiety, a linear or branched C1-10 alkyl group, or an optionally at least mono-substituted phenyl group, which may be bonded via a Cι_2 alkylene group, more preferably R9 represents an - S02-R12-moiety, a linear or branched d_3 alkyl group, or a phenyl group, which may be bonded via a Cι_2 alkylene group and/or substituted with one or more substituents independently selected from the group consisting of a fluorine atom, a chlorine atom and a bromine atom, and R1-R8 and R10-R13 have the meaning given above optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding N-oxide thereof, a corresponding salt thereof, or a corresponding solvate thereof.
Preference is furthermore given to compounds of general formula I given above, wherein R10 represents a linear or branched, saturated or unsaturated, optionally at least mono-substituted Cι.10-aliphatic group, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C3_8-cycloaliphatic group, which may be condensed with a mono- or polycyclic ring- system and/or which may be bonded via a linear or bridged Ci-10-alkylene group and/or which may be bridged by a linear or branched Cι_5-alkylene group, or an optionally at least mono-substituted 5- or 6-membered aryl or heteroaryl group, which may be condensed with a mono- or polycyclic ring system and/or which may be bonded via a linear or branched Ci-10-alkylene group, preferably R10 represents a linear or branched Cι_ι0-alkyl group, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C5.6- cycloaliphatic group, which may be condensed with a mono- or polycyclic ring- system and/or which may be bonded via a linear or bridged Cι-3-alkylene group and/or which may be bridged by a linear or branched Cι-3-alkylene group, or an optionally at least mono-substituted 5- or 6-membered aryl or heteroaryl group, which may be condensed with a mono- or polycyclic ring system and/or which may be bonded via a linear or branched Cι-3-alkylene group, more preferably R10 represents a methyl group, an ethyl group, an n-propyl group, an n-butyl group, an optionally at least mono-substituted phenyl group, an optionally at least mono-substituted benzyl group, an optionally at least mono-substituted naphthyl group, which may be bonded via a Cι_3-alkylene group, an optionally at least mono-substituted thienyl group, an optionally at least mono-substituted 2,1 ,3-Benzothiadiazole group, an optionally at least mono-substituted Benzo[b]thiophenyl group, an optionally at least mono- substituted lmidazo[2.1-b]thiazole group, an optionally at least mono-substituted 1 H- pyrazole group or a 7,7-Dimethyl-2-oxo-bicyclo-[2.2.1]-hept-1-yl group, most preferably R10 represents a methyl group, an ethyl group, an n-propyl group, an n- butyl group, an optionally at least mono-substituted phenyl group, an optionally at least mono-substituted benzyl group, an optionally at least mono-substituted naphthyl group, which may be bonded via a Cι.3-alkylene group, an optionally at least mono- substituted thienyl group, an optionally at least mono-substituted 2,1 ,3- Benzothiadiazole group, an optionally at least mono-substituted Benzo[b]thiophenyl group, an optionally at least mono-substituted lmidazo[2.1-b]thiazole group, an optionally at least mono-substituted 1 H-pyrazole group or a 7,7-Dimethyl-2-oxo- bicyclo-[2.2.1]-hept-1-yl group, wherein said substituents, if present, are identical or different and selected from the group consisting of a fluorine atom, a chlorine atom, a bromine atom, a methyl group, a formyl group, a phenyl group, a phenoxy group, a phenoxy group substituted with bromine in the 4-position and a methylsulfonyl group, and R1-R9 and R11-R13 have the meaning given above, optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding N-oxide thereof, a corresponding salt thereof, or a corresponding solvate thereof.
Furthermore, compounds of general formula I given above are preferred, wherein R11 represents a linear or branched, saturated or unsaturated, optionally at least mono- substituted Cι-ιo-aliphatic group, a saturated or unsaturated, optionally at least mono- substituted, optionally at least one heteroatom as ring member containing C3-8- cycloaliphatic group, which may be condensed with a mono- or polycyclic ring- system and/or which may be bonded via a linear or bridged Cι-ιo-alkylene group and/or which may be bridged by a linear or branched Cι-5-alkylene group, or an optionally at least mono-substituted 5- or 6-membered aryl or heteroaryl group, which may be condensed with a mono- or polycyclic ring system and/or which may be bonded via a linear or branched Cι_ιo-alkylene group, preferably R11 represents a -linear or-branched C^o-alky! group, a-saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C5-6- cycloaliphatic group, which may be condensed with a mono- or polycyclic ring- system and/or which may be bonded via a linear or bridged Cι.3-alkylene group and/or which may be bridged by a linear or branched Cι.3-alkylene group, or an optionally at least mono-substituted 5- or 6-membered aryl or heteroaryl group, which may be condensed with a mono- or polycyclic ring system and/or which may be bonded via a linear or branched Cι.3-alkylene group, more preferably R11 represents a methyl group, an ethyl group, an n-propyl group, an n-butyl group, an optionally at least mono-substituted phenyl group, an optionally at least mono-substituted benzyl group, an optionally at least mono-substituted naphthyl group, which may be bonded via a Cι-3-alkylene group, an optionally at least mono-substituted thienyl group, an optionally at least mono-substituted 2,1 ,3-Benzothiadiazole group, an optionally at least mono-substituted Benzo[b]thiophenyl group, an optionally at least mono- substituted lmidazo[2.1-b]thiazole group, an optionally at least mono-substituted 1 H- pyrazole group or a 7,7-Dimethyl-2-oxo-bicyclo-[2.2.1]-hept-1-yl group, most preferably R11 represents a methyl group, an ethyl group, an n-propyl group, an n- butyl group, an optionally at least mono-substituted phenyl group, an optionally at least mono-substituted benzyl group, an optionally at least mono-substituted naphthyl group, which may be bonded via a Cι.3-alkylene group, an optionally at least mono- substituted thienyl group, an optionally at least mono-substituted 2,1,3- Benzothiadiazole group, an optionally at least mono-substituted Benzo[b]thiophenyl group, an optionally at least mono-substituted lmidazo[2.1-b]thiazole group, an optionally at least mono-substituted 1 H-pyrazole group or a 7,7-Dimethyl-2-oxo- bicyclo-[2.2.1]-hept-1-yl group, wherein said substituents, if present, are identical or different and selected from the group consisting of a fluorine atom, a chlorine atom, a bromine atom, a methyl group, a formyl group, a phenyl group, a phenoxy group, a phenoxy group substituted with bromine in the 4-position and a methylsulfonyl group, and the residues R1-R10, R12 and R13 have the meaning given above optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding N-oxide thereof, a corresponding salt thereof, or a corresponding solvate thereof.
Also preferred-are compounds of general formula I given above, wherein R12 represents a linear or branched, saturated or unsaturated, optionally at least mono- substituted Ci-10-aliphatic group, a saturated or unsaturated, optionally at least mono- substituted, optionally at least one heteroatom as ring member containing C3.8- cycloaliphatic group, which may be condensed with a mono- or polycyclic ring- system and/or which may be bonded via a linear or bridged Cι.ι0-alkylene group and/of which may be bridged by a linear or branched Cι-5-alkylene group, or an optionally at least mono-substituted 5- or 6-membered aryl or heteroaryl group, which may be condensed with a mono- or polycyclic ring system and/or which may be bonded via a linear or branched Cι_ιo-alkylene group, preferably R12 represents a linear or branched Cι_ιo-alkyl group, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C5.6- cycloaliphatic group, which may be condensed with a mono- or polycyclic ring- system and/or which may be bonded via a linear or bridged Cι-3-alkylene group and/or which may be bridged by a linear or branched Cι-3-alkylene group, or an optionally at least mono-substituted 5- or 6-membered aryl or heteroaryl group, which may be condensed with a mono- or polycyclic ring system and/or which may be bonded via a linear or branched d.3-alkylene group, more preferably R12 represents a methyl group, an ethyl group, an n-propyl group, an n-butyl group, an optionally at least mono-substituted phenyl group, an optionally at least mono-substituted benzyl group, an optionally at least mono-substituted naphthyl group, which may be bonded via a d-3-alkylene group, an optionally at least mono-substituted thienyl group, an optionally at least mono-substituted 2,1 ,3-Benzothiadiazole group, an optionally at least mono-substituted Benzo[b]thiophenyl group, an optionally at least mono- substituted lmidazo[2.1-b]thiazole group, an optionally at least mono-substituted 1 H- pyrazole group or a 7,7-Dimethyl-2-oxo-bicyclo-[2.2.1]-hept-1-yl group, most preferably R12 represents a methyl group, an ethyl group, an n-propyl group, an n- butyl group, an optionally at least mono-substituted phenyl group, an optionally at least mono-substituted benzyl group, an optionally at least mono-substituted naphthyl group, which may be bonded via a Cι-3-alkylene group, an optionally at least mono- substituted thienyl group, an optionally at least mono-substituted 2,1 ,3- Benzothiadiazole group, an optionally at least mono-substituted Benzo[b]thiophenyl group, an optionally at least mono-substituted lmidazo[2.1-b]thiazole group, an optionally at least mono-substituted 1 H-pyrazole group or a 7,7-Dimethyl-2~oxo- bicyclo-[2.2.-1]-hept-1-yl group, wherein said substituents, if present, are identical or different and selected from the group consisting of a fluorine atom, a chlorine atom, a bromine atom, a methyl group, a formyl group, a phenyl group, a phenoxy group, a phenoxy group substituted with bromine in the 4-position and a methylsulfonyl group, and residues R1-R11 and R13 have the meaning given above, optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding N-oxide thereof, a corresponding salt thereof, or a corresponding solvate thereof.
Also preferred are compounds of general formula I, wherein R13 represents a linear or branched, saturated or unsaturated, optionally at least mono-substituted C1-10- aliphatic group, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C3-8-cycloaliphatic group, which may be condensed with a mono- or polycyclic ring-system and/or which may be bonded via a linear or bridged Cι_ιo-alkylene group and/or which may be bridged by a linear or branched Cι-5-alkylene group, or an optionally at least mono- substituted 5- or 6-membered aryl or heteroaryl group, which may be condensed with a mono- or polycyclic ring system and/or which may be bonded via a linear or branched C-Mo-alkylene group, preferably R13 represents a linear or branched C-MO- alkyl group, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C5-6-cycloaliphatic group, which may be condensed with a mono- or polycyclic ring-system and/or which may be bonded via a linear or bridged Cι-3-alkylene group and/or which may be bridged by a linear or branched Cι-3-alkylene group, or an optionally at least mono- substituted 5- or 6-membered aryl or heteroaryl group, which may be condensed with a mono- or polycyclic ring system and/or which may be bonded via a linear or branched Cι-3-alkylene group, more preferably R13 represents a methyl group, an ethyl group, an n-propyl group, an n-butyl group, an optionally at least mono- substituted phenyl group, an optionally at least mono-substituted benzyl group, an optionally at least mono-substituted naphthyl group, which may be bonded via a C1.3- alkylene group, an optionally at least mono-substituted thienyl group, an optionally at least mono-substituted 2,1 ,3-Benzothiadiazole group, an optionally at least mono- substituted Benzo[b]thiophenyl group, an optionally at least mono-substituted lmidazo[2.-1-b]thiazole group, an-optionally.at least mono-substituted 1 H-pyrazole group or a 7,7-Dimethyl-2-oxo-bicyclo-[2.2.1]-hept-1-yl group, most preferably R13 represents a methyl group, an ethyl group, an n-propyl group, an n-butyl group, an optionally at least mono-substituted phenyl group, an optionally at least mono- substituted benzyl group, an optionally at least mono-substituted naphthyl group, which may be bonded via a Cι-3-alkylene group, an optionally at least mono- substituted thienyl group, an optionally at least mono-substituted 2,1 ,3- Benzothiadiazole group, an optionally at least mono-substituted Benzo[b]thiophenyl group, an optionally at least mono-substituted lmidazo[2.1-b]thiazole group, an optionally at least mono-substituted 1 H-pyrazole group or a 7,7-Dimethyl-2-oxo- bicyclo-[2.2.1]-hept-1-yl group, wherein said substituents, if present, are identical or different and selected from the group consisting of a fluorine atom, a chlorine atom, a bromine atom, a methyl group, a formyl group, a phenyl group, a phenoxy group, a phenoxy group substituted with bromine in the 4-position and a methylsulfonyl group, and R1-R12 have the meaning given above optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding N-oxide thereof, a corresponding salt thereof, or a corresponding solvate thereof.
Particular preference is also given to compounds of general formula I,
Figure imgf000025_0001
wherein
R1 represents a phenyl group, said phenyl group being unsubstituted or substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, linear or branched C1-6 alkyl, linear or branched .6 alcoxy, -(C=0)-H, -OH, -CF3, -OCF3, -CN and -COOH,
R2 represents a phenyl group, said phenyl group being unsubstituted or substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, linear or branched Cι.6 alkyl, linear or branched Cι.6 alcoxy, -(C=0)-H, -OH, -CF3, -OCF3, -CN and -COOH, R3 represents a linear or branched, unsubstituted Cι.6 alkyl group,
R4 represents a hydrogen atom, -CN, -COOH, a linear or branched, unsubstituted Cι- 6 alkyl group, or a phenyl group, said phenyl group being unsubstituted or substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, linear or branched Cι.6 alkyl, linear or branched Cι-6 alcoxy, -(C=O)-H, -OH, -CF3, -OCF3, -CN and -COOH,
R5 represents an -O-SO2-R6-moiety, an -NH-CO-R7-moiety, an -NH2-moiety, an - NH-SO2-R8 moiety, or an -NR9-SO2-R10-moiety or an -O-C(=O)-R11-moiety,
R6 represents a phenyl group, said phenyl group being unsubstituted or substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, linear or branched C1-6 alkyl, linear or branched C1-6 alcoxy, -(C=O)-H, -OH, -CF3, -OCF3, -CN and -COOH,
R7 represents a linear or branched C1-5 alkyl group, said alkyl group being unsubstituted or substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, -OH, -SH, linear or branched C1.6 alcoxy, -CF3 and -OCF3; a cyclopentyl or cyclohexyl group, said cyclopentyl or cyclohexyl group being unsubstituted or substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, -OH, -SH, linear or branched d-6 alcoxy, -CF3 and -OCF3; or a phenyl group, said phenyl group being unsubstituted or substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, linear or branched Cι-β alkyl, linear or branched C1.6 alcoxy, - (C=0)-H, -OH, -CF3, -OCF3, -CN and -COOH,
-R8 represents a linear or branched C1.5 alkyl group; an aryl or heteroaryl group selected from the group consisting of phenyl, naphthyl, thienyl, furanyl (furyl), 2,1 ,3- benzothiadiazole, benzo[b]thiophenyl, benzo[b]furanyl, imidazo[2.1-b]thiazole and pyrazole, said aryl or heteroaryl group being unsubstituted or substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, linear or branched C1-6 alkyl. linear or branched Cι.6 alcoxy, phenyl (optionally substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, OH, linear or branched Cι_6 alkyl and linear or branched C1-6- alcoxy), phenoxy (optionally substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, OH, linear or branched d-6 alkyl and linear or branched Cι.6-alcoxy), -SO2-CH3, -(C=0)-H, -OH, -CF3, - OCF3, -CN and -COOH and said aryl or heteroaryl group being optionally bonded via a C1.3 alkylene group; or a cyclohexyl group, said cyclohexyl group being optionally bonded via a C1.3 alkylene bridge and/or being optionally bridged by a linear or branched C1-3 alkylene bridge and being unsubstituted or substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, linear or branched Cι.6 alkyl, linear or branched Cι-6 alcoxy, -(C=O)-H, -OH, -CF3, =0, -OCF3, -CN and -COOH;
R9 represents an -S02-R12-moiety; a -(C=O)-R13-moiety; a linear or branched Cι.6 alkyl radical; or a phenyl radical, said phenyl radical being unsubstituted or substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, linear or branched C1-6 alkyl, linear or branched Cι-6 alcoxy, - (C=O)-H, -OH, -CF3, -OCF3, -CN and -COOH and/or said phenyl radical being optionally bonded via a Cι-3-alkylene bridge,
R10 represents a linear or branched C1-5 alkyl group; an aryl or heteroaryl group selected from the group consisting of phenyl, naphthyl, thienyl, furanyl (furyl), 2,1 ,3- benzothiadiazole, benzo[b]thiophenyl, benzo[b]furanyl, imidazo[2.1-b]thiazole and pyrazole, said aryl or heteroaryl group being unsubstituted or substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, linear or branched C1-6 alkyl, linear or branched d-6 alcoxy, phenyl (optionally substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, OH, linear or branched Cι_6 alkyl and linear or branched d.6- alcoxy), phenoxy (optionally substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, OH, linear or branched C1.6 alkyl and linear or branched d_6-alcoxy), -SO2-CH3, -(C=O)-H, -OH, -CF3, - OCF3, -CN and -COOH and said aryl or heteroaryl group being optionally bonded via a C1-3 alkylene group; or a cyclohexyl group, said cyclohexyl group being optionally bonded via a C1.3 alkylene bridge and/or being optionally bridged by a linear or branched C1-3 alkylene bridge and being unsubstituted or substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, linear or branched Cι-6 alkyl, linear or branched Cι_6 alcoxy, -(C=0)-H, -OH, -CF , =O, -OCF3, -CN and -COOH;
R11 represents a linear or branched C1-5 alkyl group; an aryl or heteroaryl group selected from the group consisting of phenyl, naphthyl, thienyl, furanyl (furyl), 2,1 ,3- benzothiadiazole, benzo[b]thiophenyl, benzo[b]furanyl, imidazo[2.1-b]thiazole and pyrazole, said aryl or heteroaryl group being unsubstituted or substituted with 1 , 2, 3,
4 or 5 substituents independently selected from the group consisting of F, Cl, Br, linear or branched C1-6 alkyl, linear or branched d-6 alcoxy, phenyl (optionally substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, OH, linear or branched C1-6 alkyl and linear or branched C1-6- alcoxy), phenoxy (optionally substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, OH, linear or branched C1.6 alkyl and linear or branched d.6-alcoxy), -SO2-CH3, -(C=0)-H, -OH, -CF3, - OCF3, -CN and -COOH and said aryl or heteroaryl group being optionally bonded via a C1.3 alkylene group; or a cyclohexyl group, said cyclohexyl group being optionally bonded via a C1.3 alkylene bridge and/or being optionally bridged by a linear or branched C1.3 alkylene bridge and being unsubstituted or substituted with 1 , 2, 3, 4 or
5 substituents independently selected from the group consisting of F, Cl, Br, linear or branched Cι-6 alkyl, linear or branched Cι-6 alcoxy, -(C=O)-H, -OH, -CF3, =O, -OCF , -CN and -COOH;
R12 represents a linear or branched C1-5 alkyl group, an aryl or heteroaryl group selected from the group consisting of phenyl, naphthyl, thienyl, furanyl (furyl), 2,1 ,3- benzothiadiazole, benzo[b]thiophenyl, benzo[b]furanyl, imidazo[2.1-b]thiazole and pyrazole, said aryl or heteroaryl group being unsubstituted or substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, linear or branched Cι-6 alkyl, linear or branched C1-6 alcoxy, phenyl (optionally substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, OH, linear or branched C1-6 alkyl and linear or branched C1-6- alcoxy), phenoxy (optionally substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, OH, linear or branched Ci-β alkyl and linear or branched Cι-6-alcoxy), -SO2-CH3, -(C=0)-H, -OH, -CF3, - OCF3, -CN and -COOH and said aryl or heteroaryl group being optionally bonded via a C1.3 alkylene group; or a cyclohexyl group, said cyclohexyl group being optionally bonded via a C1-3 alkylene bridge and/or being optionally bridged by a linear or branched Cι_3 alkylene bridge and being unsubstituted or substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, linear or branched d_6 alkyl, linear or branched Ci-β alcoxy, -(C=O)-H, -OH, -CF3, =0, -OCF3, -CN and -COOH;
R13 represents a linear or branched C1.5 alkyl group, an aryl or heteroaryl group selected from the group consisting of phenyl, naphthyl, thienyl, furanyl (furyl), 2,1 ,3- benzothiadiazole, benzo[b]thiophenyl, benzo[b]furanyl, imidazo[2.1-b]thiazole and pyrazole, said aryl or heteroaryl group being unsubstituted or substituted with 1 , 2, 3,
4 or 5 substituents independently selected from the group consisting of F, Cl, Br, linear or branched C1.6 alkyl, linear or branched C1-6 alcoxy, phenyl (optionally substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, OH, linear or branched C1-6 alkyl and linear or branched d.6- alcoxy), phenoxy (optionally substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, OH, linear or branched C1-6 alkyl and linear or branched Ci-β-alcoxy), -SO2-CH3, -(C=O)-H, -OH, -CF3, - OCF3, -CN and -COOH and said aryl or heteroaryl group being optionally bonded via a Cι_3 alkylene group; or a cyclohexyl group, said cyclohexyl group being optionally bonded via a C1.3 alkylene bridge and/or being optionally bridged by a linear or branched C1.3 alkylene bridge and being unsubstituted or substituted with 1 , 2, 3, 4 or
5 substituents independently selected from the group consisting of F, Cl, Br, linear or branched C1.-6 alkyl, linear or branched C1-6 alcoxy, -(C=O)-H, -OHs -CF3, =0, -OCF3, -CN and -COOH;
optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding N-oxide thereof, a corresponding salt thereof, or a corresponding solvate thereof, especially to compounds of the following formula lb,
Figure imgf000030_0001
wherein
wherein X represents a halogen atom, preferably a chlorine atom,
R5 represents an -O-SO2-R6-moiety, an -NH-CO-R7-moiety, an -NH2-moiety, an - NH-SO2-R8 moiety, or an -NR9-SO2-R10-moiety or an -0-C(=O)-R11-moiety,
R6 represents a phenyl group, said phenyl group being unsubstituted or substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, linear or branched C1-6 alkyl, linear or branched C1-6 alcoxy, -(C=0)-H, -OH, -CF3, -OCF3, -CN and -COOH, B7- represents a inear or branched C1.5 alkyl group, said alkyl group being unsubstituted or substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, -OH, -SH, linear or branched C-ι-6 alcoxy, -CF3 and -OCF3; a cyclopentyl or cyclohexyl group, said cyclopentyl or cyclohexyl group being unsubstituted or substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, -OH, -SH, linear or branched C1-6 alcoxy, -CF3 and -OCF3; or a phenyl group, said phenyl group being unsubstituted or substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, linear or branched Cι.6 alkyl, linear or branched Cι.6 alcoxy, - (C=O)-H, -OH, -CF3, -OCF3, -CN and -COOH,
R8 represents a linear or branched C1-5 alkyl group; an aryl or heteroaryl group selected from the group consisting of phenyl, naphthyl, thienyl, furanyl (furyl), 2,1,3- benzothiadiazole, benzo[b]thiophenyl, benzo[b]furanyl, imidazo[2.1-b]thiazole and pyrazole, said aryl or heteroaryl group being unsubstituted or substituted with 1, 2, 3,
4 or 5 substituents independently selected from the group consisting of F, Cl, Br, linear or branched d-6 alkyl, linear or branched d.6 alcoxy, phenyl (optionally substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, OH, linear or branched Cι.6 alkyl and linear or branched Cι.6- alcoxy), phenoxy (optionally substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, OH, linear or branched d-6 alkyl and linear or branched d.6-alcoxy), -SO2-CH3, -(C=O)-H, -OH, -CF3, - OCF3, -CN and -COOH and said aryl or heteroaryl group being optionally bonded via a C1-3 alkylene group; or a cyclohexyl group, said cyclohexyl group being optionally bonded via a C1.3 alkylene bridge and/or being optionally bridged by a linear or branched C1-3 alkylene bridge and being unsubstituted or substituted with 1 , 2, 3, 4 or
5 substituents independently selected from the group consisting of F, Cl, Br, linear or branched Cι_6 alkyl, linear or branched Cι_6 alcoxy, -(C=O)-H, -OH, -CF3, =O, -OCF3, -CN and -COOH;
R9 represents an -SO2-R12-moiety; a -(C=O)-R13-moiety; a linear or branched C-i.6 alkyl radical; or a phenyl radical, said phenyl radical being unsubstituted or substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, linear or branched C1-6 alkyl, linear or branched Cι.6 alcoxy, - (C=O)-H, -OH, -CF3, -OCF3, -CN and -COOH and/or said phenyl radical being optionally bonded via a Cι-3-alkylene bridge,
R10 represents a linear or branched C1.5 alkyl group; an aryl or heteroaryl group selected from the group consisting of phenyl, naphthyl, thienyl, furanyl (furyl), 2,1,3- benzothiadiazole, benzo[b]thiophenyl, benzo[b]furanyl, imidazo[2.1-b]thiazole and pyrazole, said aryl or heteroaryl group being unsubstituted or substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, linear or branched C-i-e alkyl, linear or branched C1-6 alcoxy, phenyl (optionally substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, OH, linear or branched d_6 alkyl and linear or branched d.6- alcoxy), phenoxy (optionally substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, OH, linear or branched d-6 alkyl and linear or branched Cι.6-alcoxy), -SO2-CH3, -(C=O)-H, -OH, -CF3, - OCF3, -CN and -COOH and said aryl or heteroaryl group being optionally bonded via a C1.3 alkylene group; or a cyclohexyl group, said cyclohexyl group being optionally bonded via a Cι_3 alkylene bridge and/or being optionally bridged by a linear or branched C1.3 alkylene bridge and being unsubstituted or substituted with 1 , 2, 3, 4 or
5 substituents independently selected from the group consisting of F, Cl, Br, linear or branched Cι_6 alkyl, linear or branched Cι_6 alcoxy, -(C=O)-H, -OH, -CF3, =O, -OCF3, -CN and -COOH;
R11 represents a linear or branched C1-5 alkyl group; an aryl or heteroaryl group selected from the group consisting of phenyl, naphthyl, thienyl, furanyl (furyl), 2,1 ,3- benzothiadiazole, benzo[b]thiophenyl, benzo[b]furanyl, imidazo[2.1-b]thiazole and pyrazole, said aryl or heteroaryl group being unsubstituted or substituted with 1 , 2, 3,
4 or 5 substituents independently selected from the group consisting of F, Cl, Br, linear or branched Cι-6 alkyl, linear or branched C1-6 alcoxy, phenyl (optionally substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, OH, linear or branched d_6 alkyl and linear or branched C1-6- alcoxy), phenoxy (optionally substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, OH, linear or branched C1-6 alkyl and linear or branched d.6-alcoxy), -SO2-CH3, -(C=0)-H, -OH, -CF3, - OCF3, -CN and -COOH and said aryl or heteroaryl group being optionally bonded via a C1-3 alkylene group; or a cyclohexyl group, said cyclohexyl group being optionally bonded via a C1.3 alkylene bridge and/or being optionally bridged by a linear or branched C1-3 alkylene bridge and being unsubstituted or substituted with 1 , 2, 3, 4 or
5 substituents independently selected from the group consisting of F, Cl, Br, linear or branched C1-6 alkyl, linear or branched Cι_6 alcoxy, -(C=O)-H, -OH, -CF3, =O, -OCF3, -CN and -COOH; R12 represents a linear or branched C1.5 alkyl group, an aryl or heteroaryl group selected from the group consisting of phenyl, naphthyl, thienyl, furanyl (furyl), 2,1 ,3- benzothiadiazole, benzo[b]thiophenyl, benzo[b]furanyl, imidazo[2.1-b]thiazole and pyrazole, said aryl or heteroaryl group being unsubstituted or substituted with 1 , 2, 3,
4 or 5 substituents independently selected from the group consisting of F, Cl, Br, linear or branched Cι.6 alkyl, linear or branched Cι.6 alcoxy, phenyl (optionally substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, OH, linear or branched Cι_6 alkyl and linear or branched Cι-6- alcoxy), phenoxy (optionally substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, OH, linear or branched d-6 alkyl and linear or branched d.6-alcoxy), -SO2-CH3, -(C=O)-H, -OH, -CF3, - OCF3, -CN and -COOH and said aryl or heteroaryl group being optionally bonded via a C1-3 alkylene group; or a cyclohexyl group, said cyclohexyl group being optionally bonded via a C1-3 alkylene bridge and/or being optionally bridged by a linear or branched C1-3 alkylene bridge and being unsubstituted or substituted with 1 , 2, 3, 4 or
5 substituents independently selected from the group consisting of F, Cl, Br, linear or branched C1-6 alkyl, linear or branched C1.6 alcoxy, -(C=O)-H, -OH, -CF3, =0, -OCF3, -CN and -COOH;
R13 represents a linear or branched C1.5 alkyl group, an aryl or heteroaryl group selected from the group consisting of phenyl, naphthyl, thienyl, furanyl (furyl), 2,1 ,3- benzothiadiazole, benzo[b]thiophenyl, benzo[b]furanyl, imidazo[2.1-b]thiazole and pyrazole, said aryl or heteroaryl group being unsubstituted or substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, linear or branched Cι.6 alkyl, linear or branched C1-6 alcoxy, phenyl (optionally substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, OH, linear or branched C1.6 alkyl and linear or branched C1-6- alcoxy), phenoxy (optionally substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, OH, linear or branched C1-6 alkyl and linear or branched Cι.6-alcoxy), -SO2-CH3, -(C=O)-H, -OH, -CF3, - OCF3, -CN and -COOH and said aryl or heteroaryl group being optionally bonded via a C1.3 alkylene group; or a cyclohexyl group, said cyclohexyl group being optionally bonded via a C1-3 alkylene bridge and/or being optionally bridged by a linear or branched C1.3 alkylene bridge and being unsubstituted or substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, linear or branched C1.6 alkyl, linear or branched Cι-β alcoxy, -(C=O)-H, -OH, -CF3, =0, -OCF3, -CN and -COOH;
optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding N-oxide thereof, a corresponding salt thereof, or a corresponding solvate thereof.
Particularly preferred are compounds of general formula I,
Figure imgf000034_0001
wherein
R1 represents a phenyl group, which is mono-substituted with a halogen atom, preferably a chlorine atom, in the 4-position of the phenyl ring,
R2 represents a phenyl group, which is mono-substituted with a halogen atom, preferably a chlorine atom, in the 4-position of the phenyl ring,
R3 represents a linear or branched, unsubstituted Cι_6 alkyl group, preferably a methyl group,
R4 represents a hydrogen atom,
R5 represents an -O-SO2-R6-moiety, an -NH-CO-R7-moiety, an -NH2-moiety, an NH-SO2-R8 moiety, or an -NR9-SO2-R10-moiety R6 represents a phenyl ring, which is optionally substituted with one or more halogen atoms, preferably one or more fluorine and/or one or more chlorine atoms,
R7 represents a linear or branched C1-5 alkyl group, a linear or branched C1-5 alkyl group, which is at least partially fluorinated, a C3.8 cycloalkyl group, or a phenyl group, which is optionally substituted with one or more halogen atoms, preferably one or more fluorine atoms,
R8 represents a linear or branched C1.5 alkyl group,
a phenyl group, which is optionally substituted with one or more substituents independently selected from the group consisting of a fluorine atom, a chlorine atom, an unsubstituted phenyl group, a formyl group, a methylsulfonyl group, a benzyl group and a phenoxy group, which is optionally mono-substituted by a bromine atom in its 4-position,
a naphthyl group, which may be bonded via a methylene or ethylene group,
a Benzo[b]thiophene group, which is optionally substituted with one or more methyl groups and/or one or more chlorine atoms,
a pyrazole group, which is optionally substituted with one or more substituents independently selected from the group consisting of a methyl group, an ethyl group and a phenyl group,
an imidazo[2,1-b]thiazole group, which is optionally substituted with one or more chlorine atoms,
a thienyl group, a furyl group, a.2,1,3-Benzothiadiazole group, a 7,7-Dimethyl-2-oxo- bicyclo-[2.2.1]-hept-1-yl group, or a benzyl group,
R9 represents a C1.5 alkyl group, preferably a methyl group, a phenyl group, which is optionally substituted with one or more fluorine atoms and/or one or more chlorine atoms, a benzyl group, wherein the ring is optionally substituted with one or more fluorine atoms and/or one or more chlorine atoms, or a -S02-R12-moiety,
R10 represents a phenyl group, which is optionally substituted with one or more fluorine atoms and/or one or more chlorine atoms,
R12 represents a C1.5 alkyl group, preferably a methyl group, or a phenyl group, which is optionally substituted with one or more fluorine atoms and/or one or more chlorine atoms,
optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding N-oxide thereof, a corresponding salt thereof, or a corresponding solvate thereof.
Most particularly preferred are substituted azetidine compounds of general formula I given above selected from the group consisting of
[1 ] 4-Fluoro-benzenesulfonic acid 1 -[trans-bis-(4-chloro-phenyl)-methyl]-2- methyl-azetidin-3-yl ester,
[2] N-{(2S,3R)-1-[Bis-(4-chloro-phenyl)-methyl]-2-methyl-azetidin-3-yl}-2,2,2- trifluoro-acetamide,
[3] (2S,3R)-1-[Bis-(4-chloro-phenyl)-methyl]-2-methyl-azetidin-3-ylamine,
[4] Hexanoic acid {1-[bis-(4-chloro-phenyl)-methyl]-2-methyl-azetidin-3-yl}- amide,
[5] N-{(2S,3R)-1-[Bis-(4-chloro-phenyl)-methyl]-2-methyl-azetidin-3-yl}-4-fluoro- benzenesulfonamide, [6] Thiophene-2-sulfonic acid {(2S,3R)-1 -[bis-(4-chloro-phenyl)-methyl]-2- methy l-azetid i n-3-yl}-am ide,
[7] Cyclohexanecarboxylic acid {(2S,3R)-1-[bis-(4-chloro-phenyl)-methyl]-2- methyl-azetidin-3-yl}-amide,
[8] Butane-1-sulfonic acid {(2S,3R)-1-[bis-(4-chloro-phenyl)-methyl]-2-methyl- azetidin-3-yl}-amide,
[9] N-{(2S,3R)-1-[Bis-(4-chloro-phenyl)-methyl]-2-methyl-azetidin-3-yl}-3,5- difluoro-benzamide,
[10] Naphthalene-2-sulfonic acid {trans-1 -[bis-(4-chloro-phenyl)-methyl]-2- methyl-azetidin-3-yl}-amide,
[11 ] Biphenyl-4-sulfonic acid { trans-1 -[bis-(4-chloro-phenyl)-methyl]-2-methyl- azetidin-3-yl}-amide,
[12] 4-Acetyl-N-{trans-1 -[bis-(4-chloro-phenyl)-methyl]-2-methyl-azetidin-3-yl}- benzenesulfonamide,
[13] N-{trans-1 -[Bis-(4-chloro-phenyl)-methyl]-2-methyl-azetidin-3-yl}-4-(4- bromo-phenoxy)-benzenesulfonamide,
[14] N-{trans-1 -[Bis-(4-chloro-phenyl)-methyl]-2-methyl-azetidin-3-yl}-4- methylsulfonyl-benzenesulfonamide,
[15] 2,1 ,3-Benzothiadiazole-4-sulfonic acid {trans-1 -[bis-(4-chloro-phenyl)- -methyl]-2-methyl-azetidin-3-yl}-amide,
[16] 5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonic acid {trans-1 -[bis-(4-chloro- phenyl)-methyl]-2-methyl-azetidin-3-yl}-amide, [17] 6-Chloro-imidazo[2,1-b]thiazole-5-sulfonic acid {trans-1 -[bis-(4-chloro- phenyl)-methyl]-2-methyl-azetidin-3-yl}-amide,
[18] N-{ trans-1 -[Bis-(4-chloro-phenyl)-methyl]-2-methyl-azetidin-3-yl}-3,5- dichloro-benzenesulfonamide,
[19] 2-Naphthalene-1 -yl-ethanesulfonic acid { trans-1 -[bis-(4-chloro-phenyl)- methyl]-2-methyl-azetidin-3-yl}-amide,
[20] N-{trans-1-[Bis-(4-chloro-phenyl)-methyl]-2-methyl-azetidin-3-yl}-phenyl- methylsulfonamide,
[21] N-{ trans-1 -[Bis-(4-chloro-phenyl)-methyl]-2-methyl-azetidin-3-yl}-(7,7- dimethyl-2-oxo-bicyclo[2.2.1]hept-1-yl)-methylsulfonamide,
[22] Naphthalene-1 -sulfonic acid { trans-1 -[bis-(4-chloro-phenyl)-methyl]-2- methyl-azetid in-3-yl}-am ide ,
[23] N-{ trans-1 -[Bis-(4-chloro-phenyl)-methyl]-2-methyl-azetidin-3-yl}-4- phenoxy-benzenesulfonamide,
[24] 1 ,3,5-TrimethyM H-pyrazole-4-sulfonic acid{ trans-1 -[bis-(4-chloro-phenyl)- methyl]-2-methyl-azetidin-3-yl}-amide,
[25] Benzo[b]thiophene-3-sulfonic acid { trans-1 -[bis-(4-chloro-phenyl)-methyl]-2- methyl-azetidin-3-yl}-amide,
[26] 5-Methyl-1 -phenyl-1 H-pyrazole-4-sulfonic acid { trans-1 -[bis-(4-chloro- phenyl)-methyl]-2-methyl-azetidin-3-yl}-amide,
[27] N-{trans-1-[Bis-(4-chloro-phenyl)-methyl]-2-methyl-azetidin-3-yl}-N-methyl- 4-fluoro-benzenesulfonamide, [28] N-{trans-1-[Bis-(4-chloro-phenyl)-methyl]-2-methyl-azetidin-3-yl}-N-(4-fluoro- benzyl)-4-fluoro-benzenesulfonamide,
[29] N-{trans-1-[Bis-(4-chloro-phenyl)-methyl]-2-methyl-azetidin-3-yl}-N-propyl-4- fluoro-benzenesulfonamide,
[30] N-{trans-1-[Bis-(4-chloro-phenyl)-methyl]-2-methyl-azetidin-3-yl}-N- (methylsulphonyl)-4-fluoro-benzenesulfonamide,
[31] N-{trans-1-[Bis-(4-chloro-phenyl)-methyl]-2-methyl-azetidin-3-yl}-N-bis (4- fluoro-benzenesulfonamide),
[32] N-{(trans-1-[Bis-(4-chloro-phenyl)-methyl]-2-methyl-azetidin-3-yl}-4-fluoro- benzenesulfonamide, and
[33] N-{(2R,3S)-1-[Bis-(4-chloro-phenyl)-methyl]-2-methyl-azetidin-3-yl}-4-fluoro- benzenesulfonamide; optionally in form of a corresponding N-oxide, a corresponding salt or a corresponding solvate.
In another aspect the present invention provides a process for the preparation of substituted azetidine compounds of general formula I given above and corresponding stereoisomers thereof, according to which at least one compound of general formula
Figure imgf000039_0001
wherein R1 to R4 have the meaning given above, is reacted with at least one compound of general formula X1-SO2-R6 or X2-CO-R11, wherein R6 and R11 have the meaning given above and X1 and X2 represent suitable leaving groups, in a suitable reaction medium, optionally in the presence of at least one base, to yield at least one compound of general formula I given above, wherein R5 represents an -O-S02-R6- moiety or an -0-CO-R11-moiety, and optionally purifying and/or optionally isolating said compound(s),
and optionally at least one of these afore mentioned compounds, wherein R5 represents an -O-SO2-R6 or an -O-CO-R11 moiety, is reacted with ammonia, to yield a compound of general formula I, wherein R5 represents an -NH2-moiety, and optionally purifying and/or optionally isolating said compound(s),
and optionally at least one of these afore mentioned compounds, wherein R5 represents an -NH2-moiety, is reacted with at least one compound of general formula X3-COR7, X4-SO2-R8 or X5-SO2-R10, wherein R7, R8 and R10 have the meaning given above and X3, X4 and X5 are suitable leaving groups, in a reaction medium, optionally in the presence of at least one base, to yield a compound of general formula I given above, wherein R5 represents an -NH-CO-R7-moiety, an -NH-SO2-R8-moiety or an - NR9-Sθ2-R10-moiety with R9 representing a hydrogen atom, and optionally purifying and/or optionally isolating said compound(s),
and optionally at least one compound of general formula I, wherein R5 represents an -NR9-SO2-R10-moiety with R9 representing a hydrogen atom is reacted with at least one compound of general formula X6-R9, wherein R9 has the meaning given above except for a hydrogen atom and X6 is a leaving group, to yield at least one compound of general formula I given above, wherein R5 represents an -NR9-SO2-R10-moiety, and optionally purifying and/or optionally isolating said compound(s),
or, according to which at least one compound of general formula III,
Figure imgf000041_0001
III
wherein R4 represents a hydrogen atom and R1-R3 have the meaning given above, is oxidized to yield at least one compound of general formula IV,
Figure imgf000041_0002
IV
wherein R1-R3 have the meaning given above, which is optionally purified and/or optionally isolated, and reacted with at least one compound of general formula R5aH, wherein R5a represents an -NH2-moiety or an -NHR9-moiety, wherein R9 has the meaning given above, the resulting compound is optionally purified and/or optionally isolated and optionally reacted with at least one compound of general formula X3-CO-R7, X4-SO2-R8 or X5-SO2-R10, wherein R7, R8 and R10 have the meaning given above and X3, X4 and X5 represent a leaving group, in a reaction medium, optionally in the presence of at least one base, to yield a compound of general formula I given above, wherein R5 represents an -NH2-moiety, an -NH-CO-R7-moiety, an -NH-SO2- R8-moiety, or an -NR9-SO2-R10-moiety, which is optionally purified and/or isolated. Said inventive process is also illustrated in the following scheme 1 : Scheme 1:
Figure imgf000042_0001
with R1 5 = NR9-SO2-R10 R9 ≠H Preferably step (a) according to scheme 1 is carried out in one or more organic solvents as reaction medium. Suitable solvents include but are not limited to halogenated, preferably chlorinated, organic solvents such as dichloromethane or chloroforme and linear or cyclic ethers, such as tetrahydrofurane, 1 ,4-dioxane, or 1,1- dimethoxyethane. Reaction temperature as well as the duration of the reaction may vary over a broad range. The optimum reaction temperature and duration of reaction for a given reaction may be determined by conventional methods known to those skilled in the art.
Preferred reaction temperatures are 0-30 °C, preferably 15-25 °C. Suitable reaction times may vary from approximately 10 minutes to 3 days.
Suitable bases for use in step (a) include organic bases such as triethylamine or pyridine as well as inorganic bases such as sodium hydroxide or potassium hydroxide. Mixtures of one or more organic bases and/or one or more inorganic bases may also be used.
The leaving groups X1 and X2 may be of any type known to those skilled in the art for this type of reaction. Preferably the leaving group is a halogen atom, more preferably a chlorine or bromine atom.
Suitable reaction media for the reaction with ammonia according to step (b) of scheme 1 include, for example, alcohols such as methanol, ethanol, isopropanol or mixtures of at least two of these alcohols. The ammonia is preferably added as a concentrated, preferably aqueous solution.
Reaction temperature, pressure as well as the duration of the reaction may vary over a broad range. The optimum conditions may be determined by conventional methods known to those skilled in the art. Preferred reaction temperatures range from ambient temperature, i.e. approximately 15-25 °C to the boiling point of the reaction medium. Suitable reaction times may vary, for example from approximately 10 minutes to 3 days. Obviously the reaction may also be carried out in a reactor at elevated temperatures and pressure. Preferably compounds of general formula I, wherein R5 represents a -0-S02-R6-moiety with R6 representing a methyl group, are used in step (b). The reaction steps (c) and (d) according to scheme 1 may also be carried out under conventional conditions known to those skilled in the art. A suitable reaction medium used for these reaction steps is preferably comprises one or more organic solvents.
Suitable solvents include but are not limited to halogenated, preferably chlorinated, organic solvents such as dichloromethane or chloroforme and linear or cyclic ethers, such as tetrahydrofurane, 1,4-dioxane, or 1,1-dimethoxyethane. Reaction temperature as well as the duration of the reaction may vary over a broad range. The optimum conditions for a given reaction may be determined by conventional methods known to those skilled in the art. Preferred reaction temperatures are 0-30 °C, preferably 15-25 °C. Suitable reaction times vary, e.g. from approximately 10 minutes to 3 days.
Suitable bases that may be present during reaction steps (c) and (d) include organic bases such as triethylamine or pyridine as well as inorganic bases such as sodium hydroxide or potassium hydroxide. Mixtures of one or more organic bases and/or one or more inorganic bases may also be used.
The leaving groups X3, X4, X5 and X6 may be of any type known to those skilled in the art for this type of reaction. Preferably the leaving group is a halogen atom, more preferably a chlorine or bromine atom.
The preparation of compounds of general formula IV according to step (e) of scheme 1 may preferably be carried out according to the literature publications of Katritzky et al., J. Heterocycl. Chem., 1994, 271-275; P.R. Dave et al., J. Org. Chem., 1996, 61(16), 5453, Synlett. 1991, (11), 783-784 and Axenrod et al., Tetrahedron Lett., 1993, 6677-6680. The respective descriptions are hereby incorporated by reference and form part of the present disclosure.
The respective compounds of general formula R5aH, wherein R5a represents an -NH2-moiety or an -NHR9-moiety, wherein R9 has the meaning given above, are also commercially available or may be prepared by conventional methods known to those skilled in the art. Preferably step (f) according to scheme 1 is carried out in one or more organic solvents as reaction medium such as chlorinated, organic solvents like dichloromethane or chloroforme and preferably in the presence of sodium triacetoxyborohydride and acetic acid, or in the presence of H2 and an alcohol such as methanol and/or ethanol as a reaction medium.
Reaction temperature as well as the duration of the reaction may vary over a broad range. The optimum reaction temperature and duration of reaction for a given reaction may be determined by conventional methods known to those skilled in the art. Preferred reaction temperatures are 0-30 °C, preferably 15-25 °C.
The substituted 3-azetidinol compounds of general formula III may be prepared according to scheme 2 given below:
Scheme 2:
Figure imgf000046_0001
In Scheme 2 the substituents R1-R4 have the same meaning as definied above and X represents a halogen atom, preferably a bromine or chlorine atom. The substituted hydroxy-alkenylene compounds used as a starting material for reaction steps A and A1 according to scheme 2 are commercially available and/or may be prepared according to methods well known to those skilled in the art, e.g. by reduction of the corresponding carbonyl compound with a suitable reducing agent such as aluminium lithium hydride, sodium borohydride or catalysed hydrogenation as described, for example, in Catalysis Letters, 1999, 62(2-4), 175-177; Tetrahedron, 1984, 40(7), 1195-1198; J. Org. Chem., 1999, 64(7), 2582-2589; J. Am. Chem. Soc, 2001, 12168-12175; Synlett. 1763-65 (1999); Bull. Soc. Chim. France, 132(5-6), 522- 30 (1995); Tetrahedron Lett., 43(49), pages 8893-8896 (2002) and J. Natural Products, 65(6), 902-908 (2002). The corresponding descriptions are hereby incorporated by reference and form part of the present disclosure.
The halogenenated alkenylene compounds used as starting material for reaction step B and B1 are commercially available and/or may be prepared from the corresponding hydroxy-alkenylene compounds using a suitable halogenation agent such as thionyl chloride, triphenyl phosphin/carbontetrachloride, bromine, hydrobromic acid, triphenyl phosphin/carbontetrabromide, phosphor tribromide and others described in the literature, for example, in Chem. Ber. 123(12), 2387-94, 1990; J. Am. Chem. Soc, 111(9), 3363-3368, 1989; J. Org. Chem., 63(25), 9565-68, 1998; Heterocycles 32(5), 965-73, 1991 ; Farmaco, 44(12), 1167-91 , 1989; Synthesis, 8, 598-603, 1989; and J. Med. Chem., 33(3), 908-18, 1990. The corresponding descriptions are hereby incorporated by reference and form part of the present disclosure.
The reaction steps A, B and B1 may be carried out as described in Higgins et al., J.
Heterocyclic Chem., 1971, 8, 1059-1062 and in US 5,073,646. The corresponding parts of the descriptions are hereby incorporated by reference and form part of the present disclosure.
Reaction step A is preferably carried out in an organic solvent such as dichloromethane, chlorofom, carbontetrachloride or mixtures thereof as reaction medium.
Reaction temperature as well as the duration of the reaction may vary over a broad range. The optimum conditions for a given reaction may be determined by conventional methods known to those skilled in the art. Preferred reaction temperatures are from -10°C to +30 °C, preferably from 0°C to 25 °C, more preferably from 0 °C to 10°C. Suitable reaction times vary from a few minutes to several hours, preferably from 3 to 8 hours.
Reaction step B is preferably carried out by dissolving the educt in a suitable reaction medium, preferably a linear ether such as diethylether, or a cyclic ether, such as tetrahydrofuran, 1 ,4-dioxane or 1 ,1-dimethoxyethan, and in the presence of an aqueous solution of a base, preferably selected from the group consisting of an alkali metal such as lithium, sodium, or potassium, under vigorous stirring.
Reaction temperature as well as the duration of the reaction may vary over a broad range. The optimum reaction conditions for a given reaction may be determined by conventional methods known to those skilled in the art. Preferred reaction temperatures range from 10°C to the boiling point of the reaction mixture, preferably from 15°C to 25 °C. Suitable reaction times vary from a few minutes to several hours, preferably from 3 to 8 hours
Reaction step B1 is preferably carried out in the presence of an oxidizing agent such as peracetic acid, m-chloro perbenzoic acid, N-Bromsuccinimide or the like.
The 3-azetidinol compound is obtained by carrying out reaction step (c) according to the methods described in the literature publications of M.E. Jung, J. Org. Chem., 1991 , 56(24), 6729-6730; V.R. Gaertner, J. Org. Chem., 1967, 32, 2972, Katrizky et al., J. Heterocycl. Chem. 1994, 271-275, P.R. Dave et al, J. Org. Chem., 1996, 61 (16), 5453 and US 5,073,646. The corresponding descriptions are incorporated by reference and form part of the present disclosure.
The corresponding amines of general formula C(H)(R1)(R2)-NH2 are commercially available and/or may be obtained according to scheme 3 given below: Scheme 3:
Figure imgf000049_0001
The reaction steps A2, B2, C2a and C2b may be carried out according to conventional methods well known to those skilled in the art. Step A2 is for example described in Hajipour et al., Synth. Commun. 1999, 29(10), 1697-1701 , A. Sasse et al., Arch. Pharm., 2001 , 334(2), 45-52. Step B2 is for example described in the publication of Fernandez et al., Synthesis 2001 , (2), 239-242; Baruah et al., Synlett, 1999, (4), 409-410. Steps C2a and C2b are for example disclosed in the publications of M. Grisar et al., J. Med. Chem., 1973, 885 or Dejaegher et al., Synlett. 2002, 113- 115. The respective descriptions are hereby incorporated by reference and form part of the present disclosure. Another aspect the present invention is a process for the preparation of substituted azetidine compounds of general formula I given above and corresponding stereoisomers thereof, according to which at least one compound of general formula
V
Figure imgf000050_0001
V
wherein R and R2 have the meaning given above and Y represents a halogen atom, preferably a chlorine atom or a bromine atom, is reacted with at least one compound of general formula VI,
Figure imgf000050_0002
VI
optionally in form of a salt, wherein R3, R4 and R5 have the meaning given above, in a suitable reaction medium, optionally in the presence of a base, and the resulting azetidine compound(s) is/are optionally purified and/or optionally isolated.
The compounds of general formula V may be obtained according to conventional methods skilled in the art. Some exemplary methods are illustrated in scheme 4 given below: Scheme 4:
Figure imgf000051_0001
The compounds of general formula (Va) may, for example, be obtained according to step A3 of scheme 4 by reduction of a corresponding ketone compound with a suitable reducing agent such as sodium borohydride in a suitable reaction medium such as alcohol, preferably methanol, whereby the reaction temperature is preferably kept in the range of 0°C and the boling point of the reaction medium.
The compounds of general formula (Va) may, for example, also be obtained according to step B3 of scheme 4 by a Grignard reaction in a suitable inert reaction medium such as diethylether or tetrahydrofuran, whereby the reation temperature is preferably kept in the range of 0 °C and the boiling point of the reaction medium.
The corresponding starting materials for the reactions according to steps A3 and B3 of scheme 4 are commercially available and/or may be prepared by methods well known to those skilled in the art.
Reaction step C3 of scheme 4, in which X represents a halogen atom, preferably a chlorine or bromine atom, may be carried out using a suitable halogenating agent such as hydrobromic acid, thionyl bromide, thionyl chloride, acetyl bromide, in a suitable reaction medium such as acetic acid, benzene, toluene, dichloromethane or chloroform, whereby the reaction temperature is preferably kept in the range of 0°C to the boling point of the reaction medium.
The reaction of at least one compound of general formula V given above with at least one compound of general formula VI may preferably be carried out in an inert reaction medium, whereby acetonitrile, tetrahydrofuran or mixtures thereof are preferred. Suitable bases include organic bases such as triethylamine and inorganic bases such as carbonates of alkali metals, preferably potassium carbonate, or potassium iodide. The reaction temperature is preferably in the range of ambient temperature to the boling point of the reaction medium. The reaction times may vary over a broad range.
The compounds of general formula VI may be prepared from the corresponding substituted benzhydrylazetidine compounds of general formula VII,
Figure imgf000052_0001
VII
by hydrogenolysis, preferably in the presence of palladium metal on carbon powder, in a reaction medium such as an alcohol like methanol. Preferably said hydrogenolysis is carried out at ambient temperature, i.e. approximately 15-25 °C. After the hydrogenolysis is completed, compounds of general formula VI are preferably isolated in form of a corresponding salt such as a hydrochloride or hydrobromide salt. The compounds of general formula VII may be prepared according to the methods described, for example, in US 5,073,646 and J. Frigola, J. Med. Chem., 1993, 36, 801-810. The compounds of general formula VI are usually obtained in form of a mixture of diastereoisomers. The respective enantiomers may be obtained by racemic resolution with HPLC using chiral columns or by crystallization with chiral derivatives obtained from the reaction of the corresponding racemate with chiral agents as described in the publication of J. Frigola, J. Med. Chem. 1994, 37, 4195- 4210 and J. Frigola, J. Med. Chem., 1995, 38, 1203-1215. The corresponding enantiomers may also be obtained by asymmetric epoxidation in a corresponding reaction as described in scheme 2, which is carried out according to the method described in the publication of Sharpless et al., J. Am. Chem. Soc, 1980, 102, 5974- 5976; J. A. Marshall et al., Org. Lett., 2000 2(18), 2897-2900 using tert.-Butyl hydroperoxide in the presence of titanium isopropoxide and diethyl or diisopropyl tartrate as oxidant.
The corresponding descriptions of the afore mentioned literature publications are hereby incorporated by reference and are part of the present disclosure.
During the processes described above the protection of sensitive groups or of reagents may be necessary and/or desirable. The introduction of conventional protective groups as well as their removal may be performed by methods well-known to those skilled in the art.
If the substituted azetidine compounds of general formula (I) themselves are obtained in form of a mixture of stereoisomers, particularly enantiomers or diastereomers, said mixtures may be separated by standard procedures known to those skilled in the art, e.g. chromatographic methods or fractunalized crystallization with chiral reagents. It is also possible to obtain pure stereoisomers via stereoselective synthesis. Substituted azetidine compounds of general formula I, which comprise nitrogen-atom containing saturated, unsaturated or aromatic rings may also be obtained in the form of their N-oxides by methods well known to those skilled in the art.
In a further aspect the present invention also provides a process for the preparation of salts of substituted azetidine compounds of general formula (I), stereoisomers thereof or N-oxides thereof, wherein at least one compound of general formula (I) having at least one basic group is reacted with at least one inorganic and/or organic acid, preferably in the presence of a suitable reaction medium. Suitable reaction media include, for example, any of the ones given above. Suitable inorganic acids include hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, nitric acid, suitable organic acids are e.g. citric acid, maleic acid, fumaric acid, tartaric acid, or derivatives thereof, p-toluenesulfonic acid, methanesulfonic acid or camphersulfonic acid.
In yet a further aspect the present invention also provides a process for the preparation of salts of substituted azetidine compounds of general formula (I), stereoisomers thereof or N-oxides thereof, wherein at least one compound of general formula (I) having at least one acidic group is reacted with one or more suitable bases, preferably in the presence of a suitable reaction medium. Suitable bases are e.g. hydroxides, carbonates or alkoxides, which include suitable cations, derived e.g. from alkaline metals, alkaline earth metals or organic cations, e.g. [NHnR4-n]+, wherein n is 0, 1 , 2, 3 or 4 and R represents a branched or unbranched d. -alkyl- radical. Suitable reaction media are, for example, any of the ones given above.
Solvates, preferably hydrates, of the substituted azetidine compounds of general formula (I), of corresponding stereoisomers, corresponding N-oxides thereof, or of corresponding salts thereof may also be obtained by standard procedures known to those skilled in the art. The purification and isolation of the inventive substituted azetidine compounds of general formula (I), of a corresponding stereoisomer, or salt, or solvate or any intermediate thereof may, if required, be carried out by conventional methods known to those skilled in the art, e.g. chromatographic methods or recrystallization.
The substituted azetidine compounds of general formula (I), their N-oxides, their stereoisomers, corresponding salts thereof and corresponding solvates are toxicologically acceptable and are therefore suitable as pharmaceutical active substances for the preparation of medicaments.
It has surprisingly been found that the substituted compounds of general formula I given above, stereoisomers thereof, corresponding N-oxides, corresponding salts and corresponding solvents have a high affinity to cannabinoid receptors, particularly cannabinoid 1 (CB-ι)-receptors, i.e. they act as antagonists on these receptors.
Thus, an other aspect of the present invention is a medicament comprising at least one substituted azetidine compound of general formula I given above including the afore disclaimed compounds, optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding N-oxide thereof, a corresponding salt thereof, or a corresponding solvate thereof, and optionally one or more pharmaceutically acceptable excipients.
Said medicament may comprise any combination of one or more of the substituted azetidine compounds of general formula I given above, stereoisomers thereof, corresponding N-oxides thereof, physiologically acceptable salts thereof or physiologically acceptable solvates thereof. Preferably said medicament is suitable for the modulation (regulation) of cannabinoid-receptors, preferably cannabinoid 1 (CB-i) receptors, for the prophylaxis and/or treatment of disorders of the central nervous system, disorders of the immune system, disorders of the cardiovascular system, disorders of the endocrinous system, disorders of the respiratory system, disorders of the gastrointestinal tract or reproductive disorders.
More preferably said medicament is suitable for the prophylaxis and/or treatment of one or more disorders selected from the group consisting of psychosis, schizophrenia, anxiety, depression, epilepsy, neurodegenerative disorders, cerebellar disorders, spinocerebellar disorders, cognitive disorders, cranial trauma, panic attacks, peripheric neuropathy, inflammation, glaucoma, migraine, Morbus Parkinson, Morbus Huntington, Morbus Alzheimer, Raynaud's disease, tremblement disorders, compulsive disorders, senile dementia, thymic disorders, tardive dyskinesia, bipolar disorders, cancer, medicament-induced movement disorders, dystonia, endotoxemic shock, hemorragic shock, hypotension, insomnia, immunologic disorders, sclerotic plaques, vomiting, diarrhea, asthma, food intake disorders, preferably bulimia, anorexia, cachexia, obesity, type II diabetus mellitus (non-insuline dependent diabetes mellitus), memory disorders, pruritus, alcoholism, drug addiction, medicament addiction, preferably abuse of one or more of medicaments selected from the group consisting of opioids, barbiturates, cannabis, cocaine, amphetamines, phencyclidine, hallucinogens and benzodiazepines, pain, or for potentiation of the analgesic effect of narcotic and non-narcotic analgesics, or for influencing intestinal transit.
Particularly preferably the inventive medicament is suitable for the prophylaxis and/or treatment of pain, of food intake disorders, preferably bulimia, anorexia, cachexia, obesity or type II diabetus mellitus (non-insuline dependent diabetes mellitus), preferably diabetes, psychosis, alcoholism, drug addiction and/or medicament addiction, preferably drug addiction, diarrhea and/or pruritus.
Most preferably the inventive medicament is suitable for the prophylaxis and/or treatment of one or more disorders selected from the group consisting of obesity, psychosis and/or drug addiction. Another aspect of the present invention is the use of at least one substituted azetidine compound of general formula I including the afore disclaimed compounds, optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding N-oxide thereof, a corresponding salt thereof, or a corresponding solvate thereof, and optionally one or more pharmaceutically acceptable excipients, for the preparation of a medicament for the modulation of cannabinoid-receptors, preferably cannabinoid 1 (CBι) receptors, for the prophylaxis and/or treatment of disorders of the central nervous system, disorders of the immune system, disorders of the cardiovascular system, disorders of the endocrinous system, disorders of the respiratory system, disorders of the gastrointestinal tract or reproductive disorders.
The use of at least one substituted azetidine compound of general formula I including the afore disclaimed compounds, optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding N-oxide thereof, a corresponding salt thereof, or a corresponding solvate thereof, and optionally one or more pharmaceutically acceptable excipients, for the preparation of a medicament for the prophylaxis and/or treatment of one or more disorders selected from the group consisting of psychosis, schizophrenia, anxiety, depression, epilepsy, neurodegenerative disorders, cerebellar disorders, spinocerebellar disorders, cognitive disorders, cranial trauma, panic attacks, peripheric neuropathy, glaucoma, migraine, Morbus Parkinson, Morbus Huntington, Morbus Alzheimer, Raynaud's disease, tremblement disorders, compulsive disorders, senile dementia, thymic disorders, tardive dyskinesia, bipolar disorders, cancer, medicament-induced movement disorders, dystonia, endotoxemic shock, hemorragic shock, hypotension, insomnia, immunologic disorders, sclerotic plaques, vomiting, diarrhea, asthma, food intake disorders, preferably for the regulation of appetite, for the maintenance, increase or reduction of body weight, bulimia, anorexia, cachexia, obesity, type II diabetus mellitus (non-insuline dependent diabetes mellitus), memory disorders, alcoholism, pruritus, drug addiction, medicament addiction, preferably abuse of one or more of medicaments selected from the group consisting of opioids, barbiturates, cannabis, cocaine, amphetamines, phencyclidine, hallucinogens and benzodiazepines, paink, or for potentiation of the analgesic effect of narcotic and non-narcotic analgesics, or for influencing intestinal transit is particularly preferred.
The medicament according to the present invention may be in any form suitable for the application to humans and/or animals, preferably humans including infants, children and adults and can be produced by standard procedures known to those skilled in the art. The composition of the medicament may vary depending on the route of administration.
The medicament of the present invention may for example be administered parentally in combination with conventional injectable liquid carriers, such as water or suitable alcohols. Conventional pharmaceutical excipients for injection, such as stabilizing agents, solubilizing agents, and buffers, may be included in such injectable compositions. These medicaments may for example be injected intramuscularly, intraperitoneally, or intravenously.
Medicaments according to the present invention may also be formulated into orally administrable compositions containing one or more physiologically compatible carriers or excipients, in solid or liquid form. These compositions may contain conventional ingredients such as binding agents, fillers, lubricants, and acceptable wetting agents. The compositions may take any convenient form, such as tablets, pellets, capsules, lozenges, aqueous or oily solutions, suspensions, emulsions, or dry powdered forms suitable for reconstitution with water or other suitable liquid medium before use, for immediate or retarded release.
The liquid oral forms for administration may also contain certain additives such as sweeteners, flavoring, preservatives, and emulsifying agents. Non-aqueous liquid compositions for oral administration may also be formulated, containing edible oils. Such liquid compositions may be conveniently encapsulated in e.g., gelatin capsules in a unit dosage amount. The compositions of the present invention may also be administered topically or via a suppository.
The daily dosage for humans and animals may vary depending on factors that have their basis in the respective species or other factors, such as age, sex, weight or degree of illness and so forth. The daily dosage for humans may preferably be in the range froml to 2000, preferably 1 to 1500, more preferably 1 to 1000 milligrams of active substance to be administered during one or several intakes per day.
Pharmacological Methods
I. In-vitro determination of affinity to CB1/CB2-Rezeptors
The in-vitro determination of the affinity of the inventive substituted azetidine compounds to CBι/CB2-Receptors is carried out as described in the publication of Ruth A. Ross, Heather C. Brockie et al., "Agonist-inverse agonist characterization at CBi and CB2 cannabinoid receptors of L-759633, L759656 and AM630", British Journal of Pharmacology, 126, 665-672, (1999). The respective parts of the descriptions are hereby incorporated by reference and form part of the present disclosure. The transfected human CBi and CB2 receptor are obtained from Receptor Biology, Inc. The radioligand used for both receptors is [3H]-CP55940.
II. In-vivo bioassay system for determination of cannabinoid activity
Mouse tetrad model
Substances with affinity for cannabinoid receptors are known to produce a wide range of pharmacological effects. It is also known that intravenous administration of a substance with affinity for cannabinoid receptors in mice produces analgesia , hypothermia, sedation and catalepsy. Individually, none of these effects can be considered as proof that a tested substance has affinity for cannabinoid-receptors, since all of these effects are common for various classes of centrally active agents. However, substances, which show all of these effects, i.e. substances that are active in this so-called tetrad model are considered to have affinity for the cannabinoid receptors. It has further been shown that cannabinoid receptor antagonists are higly effective in blocking the effects of a cannabinoid agonist in the mouse tetrad model.
The tetrad model is described, for example, in the publication of A. C. Howlett et al, International Union of Pharmacology XXVII. Classification of Cannabinoid Receptors, Pharmacol Rev 54, 161-202 , 2002 and David R. Compton et al., „ln-vivo Characterization of a Specific Cannabinoid Receptor Antagonist (SR141716A) inhibition of Tetrahydrocannbinol- induced Responses and Apparent Agonist Activity", J. Pharmacol. Exp. Ther. 277 , 2, 586-594, 1996. The corresponding parts of the description are hereby incorporated by reference.
Material and Methods
Male NMRI mice with a weight of 20-30 g (Harlan, Barcelona, Spain) are used in all of the following experiments.
Before testing in the behavioral procedures given below, mice are acclimatized to the experimental setting. Pre-Treatment control values are determined for analgesia hot plate latency (in seconds), rectal temperature, sedation and catalepsy. In order to determine the agonistic activty of the substance to be tested, the mice are injected intravenously with the substance to be tested or the vehicle alone. 15 minutes after injection, latency in hot plate analgesia is measured. Rectal temperature, sedation and catalepsy are measured 20 minutes after injection.
In order to determine the antagonistic activity the identical procedure is used as for the determination of the agonistic effects, but with the difference that the substance to be evaluated for its antagonistic activity is injectected 5 minutes before the intravenous injection of 1.25 mg/kg Win-55,212 a known cannabinoid-receptor agonist.
Hot plate analgesia
The hot plate analgesia is determined according to the method described in Woolfe D. et al. „The evaluation of analgesic action of pethidine hydrochloride (Demerol)", J. Pharmacol. Exp. Ther. 80, 300-307,1944. The respective description is hereby incorporated by reference and forms part of the present disclosure.
The mice are placed on a hot plate (Harvard Analgesimeter) at 55 ± 0.5 °C until they show a painful sensation by licking their paws or jumping and the time for these sensations to occur is recorded. This reading is considered the basal value (B). The maximum time limit the mice are allowed to remain on the hot plate in absence of any painful response is 40 seconds in order to prevent skin damage. This period is called the cut-off time (PC).
Fifteen minuts after the administration of the substance to be tested, the mice are again placed on the hot plate and the afore described procedure is repeated. This period is called the post-treatment reading (PT).
The degree of analgesia is calculated from the formula :
% MPE of Analgesia = ( PT- B) / (PC-B) x 100
MPE = Maximum possible effect. Determination of sedation and ataxia
Sedation and ataxia is determined according to the method described in Desmet L. K. C. et al. „Anticonvulsive properties of Cinarizine and Flunarizine in Rats and Mice", Arzneim. -Forsch. (Frug Res) 25, 9, 1975. The respective description is hereby incorporated by reference and forms part of the present disclosure.
The chosen scoring system is
0: no ataxia;
1 : doubful;
2: obvious calmness and quiet;
3 pronounced ataxia;
prior to as well as after treatment.
The percentage of sedation is determined according to the formula:
% of sedation = arithmetic mean / 3 X 100
Hypothermia:
Hypothermia is determined according to the method described in David R. Compton et al. „ln-vivo Characterization of a Specific Cannabinoid Receptor Antagonist (SR141716A) Inhibition of Tetrahydrocannbinol- induced Responses and Apparent Agonist Activity", J. Pharmacol Exp Ther. 277 , 2, 586-594, 1996. The respective description is hereby incorporated by reference and forms part of the present disclosure.
The base-line rectal temperatures are determined with a thermometer (Yello Springs Instruments Co., Panlabs) and a thermistor probe inserted to 25mm before the administration of the substance to be tested. Rectal temperature is again measured 20 minutes after the administration of the substances to be tested. The temperature difference is calculated for each animal, whereby differences of >-2 °C are considered to represent activity.
Catalepsy:
Catalepsy is determined according to the method described in Alpermann H. G. et al. -Pharmacological effets of Hoe 249: A new potential antidepressant", Drugs Dev. Res. 25, 267-282. 1992. The respective description is hereby incorporated by reference and forms part of the present disclosure.
The cataleptic effect of the substance to be tested is evaluated according to the duration of catalepsy, whereby the animals are placed head downwards with their kinlegs upon the top of the wooden block.
The chosen scoring system is:
Catalepsy for: more than 60 seconds = 6; 50 -60 seconds = 5, 40-50 seconds = 4, 30-40 seconds = 3, 20-30 seconds = 2, 5-10 seconds = 1, and less than 5 seconds =0.
The percentage of catalepsy is determined according ot the following formula:
% Catalepsy = arithmetic mean / 6 X 100
The present invention is illustrated below with the aid of examples. These illustrations are given solely by way of example and do not limit the general spirit of the present invention. Examples:
The following examples (a)-(i) show the preparation of selected intermediate compounds used in the synthesis of the inventive azetidine compounds.
(a).- threo-3-Bromo-1 ,2-epoxybutane.
Br2 was added dropwise to a solution of 20.4 g (0.284 mol) trans-2-buten-1-ol in 60 ml of chloroform until the solution assumed a slight coloration (theoretical amount of Br2: 45,4 g, 0.284 mol). Crotyl alcohol was then added dropwise until the solution turned transparent again. This reaction mixture was maintained at room temperature (approximately 25 °C) for 15 minutes, the solvent evaporated off and a dark liquid residue was obtained. This crude 2,3-dibromo-1-butanol was dissolved in 140 ml of diethyl ether and 16 g (0.284 mol) of potassium hydroxide in 170 ml of water were added to the resulting solution. The mixture was stirred for 2 hours at room temperature, the two layers separated and the organic layer washed with water. The solvent was evaporated off and the residue distilled under vacuum to yield 24 g (56% of theory) of threo-3-bromo-1 ,2-epoxybutane with a boiling point of 55-60°C at 25 mm Hg.
1H NMR ( CDCI3, δ): 1.68 (d, 3H ,J=7 Hz); 2.69 (dd, 1 H, J=5 y 2,5 Hz); 2.88 (dd, 1 H,J=5 y 4 Hz); 3.18 (ddd.1 H, J=7 , 4 y 2,5 Hz ); 3.86 (q. 1 H, J=7 Hz)
(b).- trans-1 -Diphenylmethyl-3-hydroxy-2- methylazetidine.
A solution of threo-3-bromo-1 ,2-epoxybutane (9.8 g, 64.90 mmol) and aminodiphenylmethane (11.8 g, 64.5 mmol) in 70 ml of methanol was kept stirring for 80 hours at room temperature and 72 hours under reflux. The reaction mixture was then evaporated to dryness and the viscous residue treated with diethyl ether and water. The aqueous layer was alkalinized with potassium carbonate and extracted with diethyl ether to yield 9.4 g (61% of theory) of trans-1 -diphenylmethyl-3-hydroxy- 2-methylazetidine. The corresponding hydrochloride salt was obtained by dissolving a solution of the compound in an ethanol solution saturated with HCl gas and subsequent elimination of the solvent in vacuum.
Melting point of hydrochloride: 100-103°C,
IR ( film, cm'1 ): 3400, 1450, 1156, 749. 702,
1H NMR (CDCIs, δ): 0.75 (d, J=6 Hz); 2.40 (b, 1 H); 2.56 (t, 1 H, J=6 Hz); 3.02 (q.
1 H,J=6 Hz); 3.64 (t, 1 H, J=6 Hz); 3.87 (quint., 1 H, J=6 Hz); 4.34 (s, 1 H); 7.27 (m. 10
H).
(c) trans-1 -Diphenylmethyl-2-methyl-3-methylsulphonyloxyazetidine.
50 g (0.495 mol) of triethylamine were added to a solution of 77.33 g (0.329 mol) trans-1 -diphenylmethyl-3-hydroxy-2-methylazetidine in 600 ml of dichloromethane and the resulting mixture was cooled to 0° C. The temperature was maintained, a solution of 50 g (0.437 mol) of mesyl chloride added dropwise and the resulting mixture was left stirring for 24 hours at room temperature. The resulting solution was washed twice with water (300 ml), dried with anhydrous sodium sulphate and evaporated to yield an oil, which, when crystallized with petroleum ether, gave 104.6 g (96% of theory) of trans-1 -diphenylmethyl-2-methyl-3-methylsulphonyloxyazetidine with a melting point of 68-71° C.
IR ( film, cm"1 ): 1361 , 1339, 1178, 1152, 708,
1H NMR (CDCI3, δ): 0.63 (d, 3H, J=7 Hz); 2.85 (t. 1 H, J=6 Hz); 2.96 (s, 3H); 3,62 (t, 2H, J=6 Hz), 4.39 (s. 1 H); 4.55 (quint., 1 H, J=6 Hz); 7.23 (m, 10H).
(d) trans-3-Amino-1 -diphenylmethyl-2-methylazetidine
31 g (93.65 mmol) of trans-1 -diphenylmethyl-2-methyl-3-methylsulphonyloxyazetidine were dissolved in a mixture of 150 ml isopropanol and 100 ml of 30 % (weight/weight) aqueous ammonia solution. The resulting solution was heated to 70° C for 2-3 hours while the reaction was monitored by thin-layer chromatography. After completion of the reaction, the reaction mixture was evaporated until the isopropanol was removed completely (approximately 1/3 of the volume) and the residue was extracted with diethyl ether and water. The aqueous layer was alkalinized and extracted with dichloromethane to yield 10 g of the desired compound. The etheric layer of the first extraction was acidified with dilute 5 % (volume/volume) acetic acid, the acidic layer alkalinized with sodium hydroxide and extracted wilh dichloromethane, to yield 6.3 g of the compound giving a total of 16.3 g (70% of theory) of trans-3-amino-1-diphenylmethyl-2-methylazetidine having a melting point of 68-69° C.
M.p. of corresponding dihydrochloride : 150-153° C,
IR ( film, cm"1 ): 3270, 1450. 702,
1H NMR (CDC.3, δ): 0.64 (d, 3H, J=7 Hz), 2.20 (q, 1H, J=7 Hz); 2.63 (t, 1H, J=7 Hz);
2.90 (quinl., 1 H, J=7 Hz), 3.50 (t, 1 H, J=7 Hz), 4.20 (s, 1 H); 7.20 (m, 10H).
(e).- (2S,3R)-1-Diphenylmethyl-2-methyl-3-methylsulphonyloxyazetidine
The enantiomer (2S, 3R)-1-diphenylmethyl-2-methyl-3-methylsulphonyloxyazetidine was obtained by the same procedure as described above for the preparation of the trans-racemate but using (2S, 3R)-1-diphenylmethyl-3-hydroxy-2-methylazetidine. The compound (2S, 3R)-1-diphenylmethyl-3-hydroxy-2-methylazetidine was obtained via the optical resolution of trans-1 -diphenylmethyl-3-hydroxy-2-methylazetidine with (+)-(1S)-camphersulfonic acid, as described in the literature publication of J. Frigola et al., J. Med. Chem., 1995, 38, 1203-1215.
(f).- (2S, 3R)-3-amino-1-diphenylmethyl-2-methylazetidine
The compound (2S, 3R)-3-amino-1-diphenylmethyl-2-methylazetidine was obtained as described above under (d) using (2S, 3R)-1-diphenylmethyl-2-methyl-3- methylsulphonyloxyazetidine.
(g).- (2S, 3R)-N-(1 -Benzhydryl-2-methyl-azetidin-3-yl)-2,2,2-trifluoro-acetamide
A solution of trifluoracetic anhydride (18,3 ml, 131 ,7 mmoles) in 25 ml of dichloromethane is added dropwise under stirring and cooling to approximately 0°C to a solution of (2S, 3R)-3-amino-1-diphenylmethyl-2-methylazetidine (16,6 g, 65,9 mmoles) in dichloromethane (90 ml).
After the addition has been completed, the reaction mixture was stirred at room temperature for two hours, ice-cooled water was added, and the different phases were separated. The organic phase was washed with a solution of sodium bicarbonate 10 % (weight/weight), followed by a saturated solution of sodium chloride, dried and evaporated to dryness under reduced pressure to give 23.35 g (yield 92% of theory) of (2S, 3R)-N-(1-Benzhydryl-2-methyl-azetidin-3-yl)-2,2,2- trifluoro-acetamide in form of an oil.
IR (film, cm'1) : 3260, 1710, 1660, 1230.
Said product was dissolved in dried ethanol and a solution of hydrochloride gas in diethylether was added, and the resulting solution was evaporated to dryness. The corresponding hydrochloride was obtained in form of a white solid with a melting point of 208 - 212 °C.
IR of hydrochloride (KBr, cm'1) : 3319, 1700, 1562, 1213, 1187, 700.
(h).- (2S, 3R)-2,2,2-Trifluoro-N-(2-methyl-azetidin-3-yl)-acetamide, hydrochloride
(21 ,9 g, 57 mmoles) of (2S, 3R)-N-(1-Benzhydryl-2-methyl-azetidin-3-yl)-2,2,2- trifluoro-acetamide hydrochloride was dissolved in 300 ml methanol, Pd(OH)2/C (20%, 4,4 g, humidity 50%) were added, and the resulting mixture was treated with H2 at room temperature under a pressure of 150 psi for 15 minutes. The reaction mixture was filtered, the solvent evaporated off, and the residue was washed with toluene to give 12.3 g (yield 99%) of (2S, 3R)-2,2,2-Trifluoro-N-(2-methyl-azetidin-3- yl)-acetamide with a melting point of 219 - 221 °C.
IR (KBr, cm'1) : 3244, 2895, 1727, 1563, 1213, 1177 (i). - Bis-(4-clorophenyl)methyl bromide
A solution of 4,4'-dichlorobenzhydrol (5g, 19,8 mmoles) and acetyl bromide (6 ml, 80 mmoles) in benzene (40 ml) is heated to reflux for three hours. The reaction mixture is evaporated to dryness, and the resulting solid (6.2 g, yield 100%) is used directly for further synthesis without purification.
1H NMR (CDCI3, δ) : 6,2 (s, 1 H), 7,3 (d, J=8,7Hz, 4H), 7,36 (d, J=8,7Hz, 4H).
Example 1 :
4-Fluoro-benzenesulfonic acid-trans-1-[bis-(4-chloro-phenyl)-methyl]-2-methyl- azetidin-3-yl ester
(1a)
2,2-dimethyl-propionic acid-trans-1-benzhydryl-2-methyl-azetidin-3-yl-ester
To a solution of the hydrochloride salt of trans-1 -benzhydryl-2-methyl-azetidin-3-ol (3,73 g, 12,8 mmoles) prepared according to example (b) given above in 80 ml pyridine, 4,4 ml of triethylamine were added and the mixture was cooled to approximately 0 °C. Afterwards, a solution of (2,4 ml, 19,2 mmoles) trimethylacetylchloride (pivaloylchloride) was added, and the reaction mixture was heated to approximately 70 °C under an inert gas atmosphere for eight hours. The solvent was evaporated off, and the residue was dissolved in diethylether, washed with water, and the ether evaporated to yield the free base.
1H NMR (CDCI3, δ) : 0,8 (d, J=6,3 Hz, 3H), 1 ,2 (s, 9H), 2,6 (m, 1 H), 3,15 (m, 1 H), 3,7 (dd, J=7,0 y 7,5 Hz, 1 H), 4,3 (s, 1H); 4,6 (dd, J=6,0, 6,6 y 12,6 Hz), 7,25 (m, 6H), 7,4 (m, 4H). The crude material is dissolved in 15 ml of ethanol, and an ethanolic solution saturated with hydrochloride gas is added to precipitate the corresponding hydrochloride salt, which is filtered off and washed with diethylether to yield 3.95 g (yield 85% of theory) of the hydrochloride salt having a melting point of 163 - 166 °C.
1H NMR (de-DMSO, δ) : 1 ,15 (s+d, 12H), 3,8 (m, 1 H), 4,2 (m,1 H), 4,6 (m,1 H), 4,9 (m,1 H), 5,8 (d, J=10 Hz, 1 H), 7,4 (m, 6H), 7,75 (m,4H), 12,2 (s, 1 H).
(1b)
2,2-dimethyl-propionic acid (trans-2-methyl-azetidin-3-yl) ester hydrochloride
2,2-dimethyl-propionic acid 2-methyl-azetidin-3-yl ester hydrochloride was obtained from the compound obtained according to step (1a) following treatment described in example (h) given above (yield 94% of theory).
1H NMR (CDCI3, δ) : 1 ,2 (s, 9H), 1 ,7 (d, J=6,9 Hz, 3H), 3,9 (m, 1 H), 4,2 (m, 1 H), 4,4 (m, 1H), 4,9 (m, 1H), 9,8-10,1 (b, 2H).
(1c) trans-1 -[Bis-(4-chloro-phenyl)-methyl]-2-methyl-azetidin-3-yl-2,2-dimethyl- propionic acid
Said compound was obtained according to the method described in example 2 given below using bis-(4-chlorophenyl)methyl bromide which was prepared according to example (i) given above (yield 95% of theory).
1H NMR (CDCI3, δ) : 0,8 (d, J=6,5 Hz, 3H), 1 ,2 (s, 9H), 2,6 (m, 1 H), 3,15 (m, 1H), 3,7 (m, 1 H), 4,3 (s, 1 H), 4,6 (m, 1 H), 7,2-7,35 (m, 8H) (1d)
1 -[Bis-(4-chloro-phenyl)-methyl]-2-methyl-azetidin-3-ol
This compound was obtained via the hydrolysis of the ester prepared according to step (1c) given above, which was dissolved in ethanol comprising 10 % by weight of sodium hydroxide. The reaction mixture was kept at room temperature (approximately 25 °C) overnight. 1-[Bis-(4-chloro-phenyi)-methyl]-2-methyl-azetidin- 3-ol was obtained in a yield of 89%.
1H NMR(CDCI3, δ) : 0,8 (d, J=6,2 Hz, 3H), 2,5 (m, 1 H), 3,0 (m, 1 H), 3,6 (m, 1 H), 3,9 (m, 1 H), 4,3 (s, 1 H), 7,2-7,3 (m, 8H)
(1e) trans-4-Fluoro-benzenesulfonic acid 1 -[bis-(4-chloro-phenyl)-methyl]-2-methyl- azetidin-3-yl ester
Said compound was obtained according to the method described in example 5 given below.
Melting poing = 105-107°C,
IR (KBr, cm'1) : 1494, 1370, 1187, 1159, 1089, 1015,
1H RMN (CDC.3, δ) : 0,7 (d, J=6,2 Hz, 3H), 2,7 (m, 1 H), 3,3 (m, 1 H), 3,5 (m, 1 H), 4,3
(s, 1 H), 4,4 (m, 1 H), 7,2 (m, 10H), 7,9 (m, 2H).
Example 2
(2R, 3S)-N-{1-[Bis-(4-chloro-phenyl)-methyl]-2-methyl-azetidin-3-yl}-2,2,2-trifluoro- acetamide
A mixture of bis-(4-chlorophenyl)methyl bromide (4 g, 12,6 mmoles), the hydrochloride of (2R, 3S)-2-methyl-3-trifluoroacetylamino azetidine ( 2,3 g, 10,5 mmoles) and potassium carbonate (16,5 g, 120 mmoles) in 400 ml of acetonitrile was heated to reflux for 24 hours. The reaction mixture was filtered and the resulting clear solution evaporated to dryness. The crude material is cristallized from ethylacetate to yield 2.9 g of the product. Another 0,4 g of the product were obtained by working up the mother liquors. The overall yield of the comound (2R, 3S)-N-{1-[bis-(4-chloro-phenyl)-methyl]-2-methyl-azetidin-3- yl}-2,2,2-trifluoro-acetamide was 3.3 g (yield 67% of theory).
IR (KBr, cm'1) : 3262, 3080, 1678, 1495, 1200, 1080, 799,
1H RMN (de-DMSO + TFA, δ) : 1 ,0 (d, J=5,6Hz, 3H). 3,95, dd, J=6,8 y 17,9Hz, 1 H), 4,3 (2dd, 2H), 4,6 (dd, J=6,8 y 13,2Hz, 1 H), 5,7 (s, 1 H), 7,4-7,5 (m, 8H), 9,8 (d, J=5,3Hz, 1H).
Example 3
(2R, 3S)-1-[Bis-(4-chlorophenyl)methyl]-2-methyl-azetidin-3-yl amine
(2R, 3S)-N-{1-[bis-(4-chloro-phenyl)-methyl]-2-methyl-azetidin-3-yl}-2,2,2-trifluoro- acetamide ( 2,8 g, 6,7 mmoles ) was suspended in a solution of sodium hydroxide (25 ml, ~ 60 mmoles) and 60 ml ethanol and stirred at room temperature (approximately 25 °C), whereby the gradual dissolution was observed until a transparent solution was obtained. After three hours, the solvent was evaporated under reduced pressure and the resulting basic solution was extracted with ethylacetate, washed with water, dried over sodium sulfate and evaporated to dryness. (2R, 3S)-1-[Bis-(4-chlorophenyl)methyl]-2-methyl-azetidin-3-yl amine was obtained in form of an oil (1.95 g, yield 91% of theory).
IR (KBr, cm'1) : 3369, 1495, 1110, 1030, 790,
1H RMN (CDCI3, δ) : 0,75 (d, J=5,8Hz, 3H), 2,3 (m, 1H), 2,7 (m, 1 H), 3,0 (m, 1H), 3,6 (m,
1H), 4,2, (s, 1H ), 9, 7,2-7,3 (m, 8H).
The product was dissolved in an ethanolic solution saturated with hydrochloride gas and afterwards, the solvent was evaporated to yield the corresponding dihydrochloride salt.
IR (KBr, cm'1) : 3380, 1488, 1094, 1014 [ α ]D -35,5 (c 1 ,0, MeOH ) Example 5
(2S, 3R)-N-{1-[Bis-(4-chlorophenyl)methyl]-2-methylazetidin-3-yl}-4-fluoro- benzene sulfonamide
(2R, 3S)-1-[bis-(4-chlorophenyl)methyl]-2-methyl-azetidin-3-yl amine ( 0,15 g, 0,47 mmoles) and triethylamine (84 μl, 0,59 mmoles) was dissolved in anhydrous tetrahydrofuran (6ml). The mixture was cooled with an ice-bath to 0 °C and a solution of 4-benzene-sulphonylchloride (0,11 g, 0,54 mmoles) in THF (4 ml) was added dropwise. The cooling bath was removed, and the reaction mixture was allowed to warm up to room temperature (approximately 25 °C) and stirred overnight. The solvent was removed under reduced pressure, and the residue was re-dissolved in ethylacetate and water. The organic solution was washed with a saturated solution of sodium bicarbonate, water and dried over sodium sulfate and evaporated to dryness. 0.16 g of (2R, 3S)-1-N-{1-[bis-(4-chlorophenyl) methyl]-2-methylazetidin-3-yl}-4-fluorobenzenesulfonamide were obtained (yield 75% of theory) with a melting point of 154-157 °C.
IR (KBr, cm'1) : 3255, 1592, 1492, 1155, 1090, 802.
1H RMN (CDCI3, δ) : 0,6 (d, J=5,8Hz, 3H), 2,3 (m, 1 H), 2,9 (m, 1H), 3,4 (m, 2H), 4,2
(s, 1H), 4,8 (d, J=8,4Hz, 1H), 7,1-7,25 (m, 10H), 7,8 (m, 2H).
[ α ]D -61,5 (c 1,0, MeOH ).
The compounds prepared according to examples 1 , 2, 3 and 5 given above are given in the following table 1. Also included are example compounds 4 and 6-31 , which were prepared by analogous methods.
Table 1:
Figure imgf000073_0001
Figure imgf000074_0001
Figure imgf000075_0001
Figure imgf000076_0001
Pharmacological Data:
I. In-vitro determination of affinity to CB1/CB2-Rezeptors
The affinity of the inventive substituted azetidine compounds to CB1/CB2 receptors is determined as described above. Some of the values obtained are given in the following table II:
Table II:
Figure imgf000077_0001
II. In-vivo bioassay system for determination of cannabinoid activity
The determinination of cannabinoid activity in-vivo was determined as described above. Some of the values obtained are given in the following table III:
Table
Figure imgf000078_0001
i.v. intravenous A: Hot-Plate test B: Hypothermia C: Catalepsy D: Sedation
As can be seen from the values given in table III the inventive azetidine compounds act as cannabinoid receptor antagonists, particularly for the CB-i-receptors.

Claims

Claims:
1. Substituted Azetidine compounds of general formula
Figure imgf000079_0001
wherein
R1 represents an optionally at least mono-substituted phenyl group,
R2 represents a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic group, which may be condensed with an optionally at least mono-substituted mono- or polycyclic ring system, or an optionally at least mono-substituted aryl or heteroaryl group, which may be condensed with an optionally at least mono- substituted mono- or polycyclic ring system,
R3 represents a linear or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic group, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic group, which may be condensed with a mono- or polycyclic ring- system and/or which may be bonded via a linear or branched alkylene group, or an optionally at least mono-substituted aryl or heteroaryl group, which may be condensed with a mono- or polycyclic ring system and/or which may be bonded via a linear or branched alkylene group, with the proviso that R3 is bonded to the azetidine ring via a carbon atom, R4 represents a hydrogen atom, a cyano group, a carboxy group, a linear or branched alkyl group, or an optionally at least mono-substituted aryl group,
R5 represents an -0-SO2-R6-moiety, an -NH-CO-R7-moiety, an -NH2-moiety, an -NH-SO2-R8 moiety, an -NR9-SO2-R10-moiety or an O-CO-R11-moiety,
R6 represents a linear or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic group, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic group, which may be condensed with a mono- or polycyclic ring- system and/or which may be bonded via a linear or branched alkylene group, or an optionally at least mono-substituted aryl or heteroaryl group, which may be condensed with a mono- or polycyclic ring system and/or which may be bonded via a linear or branched alkylene group,
R7 represents a linear or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic group, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic group, which may be condensed with a mono- or polycyclic ring- system and/or which may be bonded via a linear or branched alkylene group, or an optionally at least mono-substituted aryl or heteroaryl group, which may be condensed with a mono- or polycyclic ring system and/or which may be bonded via a linear or branched alkylene group,
R8 represents a linear or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic group, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic group, which may be condensed with a mono- or polycyclic ring- system and/or which may be bonded via a linear or bridged alkylene group, and/or which may be bridged by a linear or branched alkylene group, or an optionally at least mono-substituted aryl or heteroaryl group, which may be condensed with a mono- or polycyclic ring system and/or which may be bonded via a linear or branched alkylene group, R9 represents an -SO2-R12-moiety, a -CO-R13-moiety, a linear or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic group, a saturated or unsaturated, optionally at least mono-substituted, optionally at least heteroatom as ring member containing cycloaliphatic group, which may be condensed with a mono- or polycyclic ring-system and/or which may be bonded by a linear or branched alkylene group and/or bridged by a linear or branched alkylene group, or an optionally at least mono-substituted aryl or heteroaryl group, which may be condensed with a mono- or polycyclic ring system and/or which may be bonded via an alkylene group,
R10 represents a linear or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic group, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic group, which may be condensed with a mono- or polycyclic ring- system and/or which may be bonded via a linear or bridged alkylene group, and/or which may be bridged by a linear or branched alkylene group, or an optionally at least mono-substituted aryl or heteroaryl group, which may be condensed with a mono- or polycyclic ring system and/or which may be bonded via a linear or branched alkylene group,
R11 represents a linear or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic group, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic group, which may be condensed with a mono- or polycyclic ring- system and/or which may be bonded via a linear or bridged alkylene group, and/or which may be bridged by a linear or branched alkylene group, or an optionally at least mono-substituted aryl or heteroaryl group, which may be condensed with a mono- or polycyclic ring system and/or which may be bonded via a linear or branched alkylene group,
R12 represents a linear or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic group, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic group, which may be condensed with a mono- or polycyclic ring- system and/or which may be bonded via a linear or bridged alkylene group, and/or which may be bridged by a linear or branched alkylene group, or an optionally at least mono-substituted aryl or heteroaryl group, which may be condensed with a mono- or polycyclic ring system and/or which may be bonded via a linear or branched alkylene group,
R13 represents a linear or branched, saturated or unsaturated, optionally at least mono-substituted aliphatic group, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing cycloaliphatic group, which may be condensed with a mono- or polycyclic ring- system and/or which may be bonded via a linear or bridged alkylene group, and/or which may be bridged by a linear or branched alkylene group, or an optionally at least mono-substituted aryl or heteroaryl group, which may be condensed with a mono- or polycyclic ring system and/or which may be bonded via a linear or branched alkylene group, optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding N-oxide thereof, a corresponding salt thereof, or a corresponding solvate thereof, with the proviso that compounds of general formula I, in which R1 and R2 each represent an unsubstituted phenyl group, R5 represents an -O-SO2-R6-moiety and R6 represents a methyl group are excluded.
2. Compounds according to claim 1 , characterized in that R1 represents a phenyl group, which is optionally substituted by one or more substituents independently selected from the group consisting of a halogen atom, a linear or branched Cι-6- alkyl group, a linear or branched Cι-6 alcoxy group, a formyl group, a hydroxy group, a trifluoromethyl group, a trifluoromethoxy group, a -CO-Cι.6-alkyl group, a cyano group, a carboxy group, a -CO-O-Cι.6-alkyl group, a -CO-NRARB- moiety, a -CO-NH-NRcRD-moiety, an -S-Cι.6-alkyl group, an -SO-Cι.6-alkyl group, an - SO2-Cι-6-alkyl group, a -Cι-6-alkylene-S-Cι_6-alkyl group, a -Cι.6-alkylene-SO-Cι.6- alkyl group, a -Cι.6-alkylene-S02-Cι-6-alkyl group, a Cι.6-alkyl group substituted by one or more hydroxy groups and a -C1.6-alkylene-NRERF group,
whereby RA, RB, identical or different, represent hydrogen or a Cι.6-alkyl group, or RA and RB together with the bridging nitrogen atom form a saturated, mono- or bicyclic, 3-10 membered heterocyclic ring system, which may be at least mono- substituted by one or more, identical or different, C-i.6 alkyl groups and/or which may contain at least one further heteroatom selected from the group consisting of nitrogen, oxygen and sulphur as a ring member,
Rc, RD, identical or different, represent a hydrogen atom, a Cι-6-alkyl group, a -CO-O-Cι-6-alkyl group, a C3.8-cycloalkyl group, a Cι_6-alkylene-C3.8-cycloalkyl group, Cι-6-alkylene-O-Cι-6-alkyl group or a Ci-6-alkyl group substituted with one or more hydroxy groups, or Rc, RD together with the bridging nitrogen atom form a saturated, mono- or bicyclic, 3-10 membered heterocyclic ring system, which may be at least mono-substituted by one or more substituents independently selected from the group consisting of Cι_6 alkyl group, a -CO-C-ι-6-alkyl group, a -CO-O- Cι-6-alkyl group, a -CO-NH- Cι_6-alkyl group, a -CS-NH- C-ue-alkyl group, an oxo group, a C-ι-6-alkyl group substituted with one or more hydroxy groups, a Cι-6-alkylene-O-Cι.6-alkyl group and a -CO-NH2 group and/or which may contain at least one further heteroatom selected from the group consisting of nitrogen, oxygen and sulphur as a ring member, and
wherein RE, RF, identical or different, represent hydrogen or a C-ι-6-alkyl group, or RE and RF together with the bridging nitrogen atom form a saturated, mono- or bicyclic, 3-10 membered heterocyclic ring system, which may be at least mono- substituted by one or more, identical or different Cι_6 alkyl groups and/or which may contain at least one further heteroatom selected from the group consisting of nitrogen, oxygen and sulphur as a ring member,
preferably R1 represents a phenyl group, which is optionally substituted by one or more substituents independently selected from the group consisting of a fluorine atom, a chlorine atom, a bromine atom, a linear or branched Cι.6-alkyl group, a linear or branched Ci-β alcoxy group, a formyl group, a hydroxy group, a trifluoromethyl group, a trifluoromethoxy group, a cyano group and a carboxy group, more preferably R1 represents a phenyl group, which is optionally substituted by one or more substituents independently selected from the group consisting of a fluorine atom, a chlorine atom, a bromine atom, a methyl group, a methoxy group, a trifluoromethyl group and a trifluoromethoxy group, most preferably R1 represents a phenyl group, which is substituted by a chlorine atom in the 4-position.
3. Compounds according to claim 1 or 2, characterized in that R2 represents a saturated or unsaturated, optionally at least mono-substituted, optionally at least heteroatom as ring member containing C3-8 cycloaliphatic group, which may be condensed with an optionally at least mono-substituted mono- or polycyclic ring system, or an optionally at least mono-substituted, 5- or 6-membered aryl or heteroaryl group, which may be condensed with an optionally at least mono- substituted mono- or polycyclic ring system, preferably R2 represents a phenyl group, which is optionally substituted by one or more substituents independently selected from the group consisting of a halogen atom, a linear or branched Chalky! group, a linear or branched C-i_6 alcoxy group, a formyl group, a hydroxy group, a trifluoromethyl group, a trifluoromethoxy group, a -CO-C-|.6-alkyl group, a cyano group, a carboxy group, a -CO-O-Cι_6-alkyl group, a -CO-NRARB- moiety, a -CO-NH-NRcRD-moiety, an -S-Cι.6-alkyl group, an -SO-Cι-6-alkyl group, an - Sθ2-C-ι_6-alkyl group, a -C-ι-6-alkylene-S-C-|.6-alkyl group, a -Cι-6-alkylene-SO-Cι_6- alkyl group, a -Cι.6-alkylene-SO2-Cι.6-alkyl group, a Cι-6-alkyl group substituted by one or more hydroxy groups and a -Cι-6-alkylene-NRERF group, whereby RA, RB, identical or different, represent hydrogen or a Cι.6-alkyl group, or RA and RB together with the bridging nitrogen atom form a saturated, mono- or bicyclic, 3-10 membered heterocyclic ring system, which may be at least mono- substituted by one or more, identical or different, Cι.6 alkyl groups and/or which may contain at least one further heteroatom selected from the group consisting of nitrogen, oxygen and sulphur as a ring member,
Rc, RD, identical or different, represent a hydrogen atom, a Cι-6-alkyl group, a -CO-0-Cι.6-alkyl group, a C3-8-cycloalkyl group, a Cι.6-alkylene-C3.8-cycloalkyl group, Cι-6-alkylene-O-Cι.6-alkyl group or a Cι.6-alkyl group substituted with one or more hydroxy groups, or Rc, RD together with the bridging nitrogen atom form a saturated, mono- or bicyclic, 3-10 membered heterocyclic ring system, which may be at least mono-substituted by one or more substituents independently selected from the group consisting of Cι-6 alkyl group, a -CO-Cι.6-alkyl group, a -CO-O- Cι-6-alkyl group, a -CO-NH- Cι-6-alkyl group, a -CS-NH- C^-alkyl group, an oxo group, a Cι.6-alkyl group substituted with one or more hydroxy groups, a Ci-e-alkylene-O-C-i-β-alkyl group and a -CO-NH2 group and/or which may contain at least one further heteroatom selected from the group consisting of nitrogen, oxygen and sulphur as a ring member, and wherein RE, RF, identical or different, represent hydrogen or a Cι-6-alkyl group, or RE and RF together with the bridging nitrogen atom form a saturated, mono- or bicyclic, 3-10 membered heterocyclic ring system, which may be at least mono- substituted by one or more, identical or different C-i-β alkyl groups and/or which may contain at least one further heteroatom selected from the group consisting of nitrogen, oxygen and sulphur as a ring member, more preferably R2 represents a phenyl group, which is optionally substituted by one or more substituents independently selected from the group consisting of a fluorine atom, a chlorine atom, a bromine atom, a methyl group, a methoxy group, a trifluoromethyl group and a trifluoromethoxy group, most preferably R2 represents a phenyl group, which is substituted by a chlorine atom in the 4- position.
4. Compounds according to one or more of claims 1-3, characterized in that R3 represents a linear or branched, saturated or unsaturated, optionally at least mono-substituted Cι-ιn-aliphatic group, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C3-8-cycloaliphatic group, which may be condensed with a mono- or polycyclic ring-system and/or which may be bonded via a linear or branched C-ι-6- alkylene group, or an optionally at least mono-substituted, 5- or 6- membered aryl or heteroaryl group, which may be condensed with a mono- or polycyclic ring system and/or which may be bonded via a linear or branched Cι.6-alkylene group, preferably R3 represents a linear or branched, optionally at least mono-substituted Cι-ιo-alkyl group, or an optionally at least mono-substituted, 5- or 6- membered aryl or heteroaryl group, which may be condensed with a mono- or polycyclic ring system and/or which may be bonded via a linear or branched Cι.6-alkylene group, more preferably R3 represents a linear or branched, unsubstituted Cι-ι0-alkyl group, most preferably R3 represents a methyl group.
5. Compounds according to one or more of claims 1-4, characterized in that R4 represents a hydrogen atom, a cyano group, a carboxy group, a linear or branched Cι-ι0-alkyl group, or an optionally at least mono-substituted, 5- or 6- membered aryl group, preferably R4 represents a hydrogen atom, a linear or branched C-|.3-alkyl group, or an optionally at least mono-substituted phenyl group, more preferably preferably R4 represents a hydrogen atom or a linear or branched Cι-3-alkyl group, most preferably R4 represents a hydrogen atom.
6. Compounds according to one or more of claims 1-5, characterized in that R5 represents an -O-Sθ2-R6-moiety, an -NH-CO-R7-moiety, an -NH2-moiety, an - NH-SO2-R8 moiety or an -NR9-SO2-R10-moiety, preferably R5 represents an -O-SO2-R6-moiety, an -NH-SO2-R8 moiety or an -NR9-SO2-R10-moiety.
7. Compounds according to one or more of claims 1-6, characterized in that R6 represents a linear or branched, saturated or unsaturated, optionally at least mono-substituted C1-10 aliphatic group, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C3-8-cycloaliphatic group, which may be condensed with a mono- or polycyclic ring-system and/or which may be bonded via a linear or branched Cι_6- alkylene group, or an optionally at least mono-substituted, 5- or 6-membered aryl or heteroaryl group, which may be condensed with a mono- or polycyclic ring system and/or which may be bonded via a linear or branched Cι.6-alkylene group, preferably R6 represents an optionally at least mono-substituted C3-8- cycloaliphatic group or an optionally at least mono-substituted phenyl group, wherein the respective substituents are independently selected from the group consisting of a fluorine atom, a chlorine atom, a bromine atom, a linear or branched Cι.6-alkyl group, a linear or branched C-i-β alcoxy group, a formyl group, a hydroxy group, a trifluoromethyl group, a trifluoromethoxy group, a cyano group and a carboxy group, more preferably R6 represents a phenyl group, which is optionally substituted by one or more substituents independently selected from the group consisting of a fluorine atom, a chlorine atom, a bromine atom, a methyl group, a methoxy group, a trifluoromethyl group and a trifluoromethoxy group.
8. Compounds according to one or more of claims 1-7, characterized in that R7 represents a linear or branched, saturated or unsaturated, optionally at least mono-substituted Cι_ι0-aliphatic group, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C3-8-cyc!oaliphatic group, which may be condensed with a mono- or polycyclic ring-system and/or which may be bonded via a linear or branched Cι_6- alkylene group, or an optionally at least mono-substituted aryl or heteroaryl group, which may be condensed with a mono- or polycyclic ring system and/or which may be bonded via a linear or branched Cι.6-alkylene group, preferably R7 represents a linear or branched, optionally at least mono-substituted C-ι-5-alkyl group, a saturated, optionally at least mono-substituted Cs-β-cycloaliphatic group, or an optionally at least mono-substituted phenyl group, more preferably R7 represents a linear or branched, optionally at least mono-substituted Cι-5-alkyl group, a saturated, optionally at least mono-substituted Cs-δ-cycloaliphatic group, or an optionally at least mono-substituted phenyl group, wherein in each case the substituents are independently from one another selected from the group consisting of group consisting of a fluorine atom, a chlorine atom, a bromine atom, a methyl group, a methoxy group, a trifluoromethyl group and a trifluoromethoxy group.
9. Compounds according to one or more of claims 1-8, characterized in that R8 represents a linear or branched, saturated or unsaturated, optionally at least mono-substituted Cι-10-aliphatic group, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C3-8-cycloaliphatic group, which may be condensed with a mono- or polycyclic ring-system and/or which may be bonded via a linear or bridged Cι_ 0- alkylene group and/or which may be bridged by a linear or branched Cι.5-alkylene group, or an optionally at least mono-substituted 5- or 6-membered aryl or heteroaryl group, which may be condensed with a mono- or polycyclic ring system and/or which may be bonded via a linear or branched Cι.10-alkylene group, preferably R8 represents a linear or branched Cι-ι0-alkyl group, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C5.6-cycloaliphatic group, which may be condensed with a mono- or polycyclic ring-system and/or which may be bonded via a linear or bridged Ci-3-alkylene group and/or which may be bridged by a linear or branched Cι.3-alkylene group, or an optionally at least mono-substituted 5- or 6-membered aryl or heteroaryl group, which may be condensed with a mono- or polycyclic ring system and/or which may be bonded via a linear or branched C-ι-3-alkylene group, more preferably R8 represents a methyl group, an ethyl group, an n-propyl group, an n-butyl group, an optionally at least mono- substituted phenyl group, an optionally at least mono-substituted benzyl group, an optionally at least mono-substituted naphthyl group, which may be bonded via a C-ι-3-alkylene group, an optionally at least mono-substituted thienyl group, an optionally at least mono-substituted 2,1 ,3-Benzothiadiazole group, an optionally at least mono-substituted Benzo[b]thiophenyl group, an optionally at least mono- substituted lmidazo[2.1-b]thiazole group, an optionally at least mono-substituted 1 H-pyrazole group or a 7,7-Dimethyl-2-oxo-bicyclo-[2.2.1]-hept-1-yl group, most preferably R8 represents a methyl group, an ethyl group, an n-propyl group, an n- butyl group, an optionally at least mono-substituted phenyl group, an optionally at least mono-substituted benzyl group, an optionally at least mono-substituted naphthyl group, which may be bonded via a C-ι-3-alkylene group, an optionally at least mono-substituted thienyl group, an optionally at least mono-substituted 2,1 ,3-Benzothiadiazole group, an optionally at least mono-substituted Benzo[b]thiophenyl group, an optionally at least mono-substituted lmidazo[2.1- b]thiazole group, an optionally at least mono-substituted 1 H-pyrazole group or a 7,7-Dimethyl-2-oxo-bicyclo-[2.2.1]-hept-1-yl group, wherein said substituents, if present, are identical or different and selected from the group consisting of a fluorine atom, a chlorine atom, a bromine atom, a methyl group, a formyl group, a phenyl group, a phenoxy.group.-a phenoxy group substituted with bromine in the 4-position and a methylsulfonyl group.
10. Compounds according to one or more of claims 1-9, characterized in that R9 represents an -S02-R12-moiety, a -CO-R13-moiety, a linear or branched, saturated or unsaturated, optionally at least mono-substituted CMO aliphatic group, a saturated or unsaturated, optionally at least mono-substituted, optionally at least heteroatom as ring member containing C3-s cycloaliphatic group, which may be condensed with a mono- or polycyclic ring-system and/or which may be bonded by a linear or branched Cι_6 alkylene group and/or bridged by a linear or branched Cι_6 alkylene group, or an optionally at least mono-substituted aryl or heteroaryl group, which may be condensed with a mono- or polycyclic ring system and/or which may be bonded via a Cι-6 alkylene group, preferably R9 represents an - SO2-R12-moiety, a linear or branched C-MO alkyl group, or an optionally at least mono-substituted phenyl group, which may be bonded via a Cι_2 alkylene group, more preferably R9 represents an -SO2-R12-moiety, a linear or branched C1-3 alkyl group, or a phenyl group, which may be bonded via a C1-2 alkylene group and/or substituted with one or more substituents independently selected from the group consisting of a fluorine atom, a chlorine atom and a bromine atom.
11.Compounds according to one or more of claims 1-10, characterized in that R10 represents a linear or branched, saturated or unsaturated, optionally at least mono-substituted Cι-10-aliphatic group, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C3.8-cycloaliphatic group, which may be condensed with a mono- or polycyclic ring-system and/or which may be bonded via a linear or bridged C1-10- alkylene group and/or which may be bridged by a linear or branched Cι-5-alkylene group, or an optionally at least mono-substituted 5- or 6-membered aryl or heteroaryl group, which may be condensed with a mono- or polycyclic ring system and/or which may be bonded via a linear or branched Cι-10-alkylene group, preferably R10 represents a linear or branched Cι-ι0-alkyl group, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C -6-cycloaliphatic group, which may be condensed with a mono- or polycyclic ring-system and/or which may be bonded via a linear or bridged Cι.3-alkylene group and/or which may be bridged by a linear or branched Cι-3-alkylene group, or an optionally at least mono-substituted 5- or 6-membered aryl or heteroaryl group, which may be condensed with a mono- or polycyclic ring system and/or which may be bonded via a linear or branched Cι-3-alkylene group, more preferably R10 represents a methyl group, an ethyl group, an n-propyl group, an n-butyl group, an optionally at least mono- substituted phenyl group, an optionally at least mono-substituted benzyl group, an optionally at least mono-substituted naphthyl group, which may be bonded via a C-ι-3-alkylene group, an optionally at least mono-substituted thienyl group, an optionally at least mono-substituted 2,1 ,3-Benzothiadiazole group, an optionally at least mono-substituted Benzo[b]thiophenyl group, an optionally at least mono- substituted lmidazo[2.1-b]thiazole group, an optionally at least mono-substituted 1 H-pyrazole group or a 7,7-Dimethyl-2-oxo-bicyclo-[2.2.1]-hept-1-yl group, most preferably R10 represents a methyl group, an ethyl group, an n-propyl group, an n- butyl group, an optionally at least mono-substituted phenyl group, an optionally at least mono-substituted benzyl group, an optionally at least mono-substituted naphthyl group, which may be bonded via a C-ι-3-alkylene group, an optionally at least mono-substituted thienyl group, an optionally at least mono-substituted 2,1 ,3-Benzothiadiazole group, an optionally at least mono-substituted Benzo[b]thiophenyl group, an optionally at least mono-substituted imidazo[2.1- b]thiazole group, an optionally at least mono-substituted 1 H-pyrazole group or a 7,7-Dimethyl-2-oxo-bicyclo-[2.2.1]-hept-1-yl group, wherein said substituents, if present, are identical or different and selected from the group consisting of a fluorine atom, a chlorine atom, a bromine atom, a methyl group, a formyl group, a phenyl group, a phenoxy group, a phenoxy group substituted with bromine in the 4-position and a methylsulfonyl group.
12. Compounds according to one or more of claims 1-11 , characterized in that R11 represents a linear or branched, saturated or unsaturated, optionally at least mono-substituted Ci.io-aliphatic group, a saturated or unsaturated, optionally at least mono-substituted,-optionally at least one heteroatom as ring member containing C3_8-cycloaliphatic group, which may be condensed with a mono- or polycyclic ring-system and/or which may be bonded via a linear or bridged Cι_ιo- alkylene group and/or which may be bridged by a linear or branched C-t-s-alkylene group, or an optionally at least mono-substituted 5- or 6-membered aryl or heteroaryl group, which may be condensed with a mono- or polycyclic ring system and/or which may be bonded via a linear or branched Cι-ιn-alkylene group, preferably R11 represents a linear or branched Cι-ι0-alkyl group, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C5.6-cycloaliphatic group, which may be condensed with a mono- or polycyclic ring-system and/or which may be bonded via a linear or bridged Cι_3-alkylene group and/or which may be bridged by a linear or branched Cι-3-alkylene group, or an optionally at least mono-substituted 5- or 6-membered aryl or heteroaryl group, which may be condensed with a mono- or polycyclic ring system and/or which may be bonded via a linear or branched Cι-3-alkylene group, more preferably R11 represents a methyl group, an ethyl group, an n-propyl group, an n-butyl group, an optionally at least mono- substituted phenyl group, an optionally at least mono-substituted benzyl group, an optionally at least mono-substituted naphthyl group, which may be bonded via a C-ι-3-alkylene group, an optionally at least mono-substituted thienyl group, an optionally at least mono-substituted 2,1 ,3-Benzothiadiazole group, an optionally at least mono-substituted Benzo[b]thiophenyl group, an optionally at least mono- substituted lmidazo[2.1-b]thiazole group, an optionally at least mono-substituted 1 H-pyrazole group or a 7,7-Dimethyl-2-oxo-bicyclo-[2.2.1]-hept-1-yl group, most preferably R11 represents a methyl group, an ethyl group, an n-propyl group, an n- butyl group, an optionally at least mono-substituted phenyl group, an optionally at least mono-substituted benzyl group, an optionally at least mono-substituted naphthyl group, which may be bonded via a C-|.3-alkylene group, an optionally at least mono-substituted thienyl group, an optionally at least mono-substituted 2,1 ,3-Benzothiadiazole group, an optionally at least mono-substituted Benzo[b]thiophenyl group, an optionally at least mono-substituted lmidazo[2.1- b]thiazole group, an optionally at least mono-substituted 1 H-pyrazole group or a 7,7-Dimethyl-2-oxo-bicyclo-[2.2.1]-hept-1-yl group, wherein said substituents, if present, are identical or different and selected from the group consisting of a fluorine atom, a chlorine atom, a bromine atom, a methyl group, a formyl group, a phenyl group, a phenoxy group, a phenoxy group substituted with bromine in the 4-position and a methylsulfonyl group.
3. Compounds according to one or more of claims 1-12, characterized in that R12 represents a linear or branched, saturated or unsaturated, optionally at least mono-substituted Cι-10-aliphatic group, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C3-8-cycloaliphatic group, which may be condensed with a mono- or polycyclic ring-system and/or which may be bonded via a linear or bridged C1-10- alkylene group and/or which may be bridged by a linear or branched C-i-s-alkylene group, or an optionally at least mono-substituted 5- or 6-membered aryl or heteroaryl group, which may be condensed with a mono- or polycyclic ring system and/or which may be bonded via a linear or branched Cι-ιn-alkylene group, preferably R12 represents a linear or branched C-ι.ιo-alkyl group, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C5-6-cycloaliphatic group, which may be condensed with a mono- or polycyclic ring-system and/or which may be bonded via a linear or bridged C-ι-3-alkylene group and/or which may be bridged by a linear or branched Cι-3-alkylene group, or an optionally at least mono-substituted 5- or 6-membered aryl or heteroaryl group, which may be condensed with a mono- or polycyclic ring system and/or which may be bonded via a linear or branched Cι-3-alkylene group, more preferably R12 represents a methyl group, an ethyl group, an n-propyl group, an n-butyl group, an optionally at least mono- substituted phenyl group, an optionally at least mono-substituted benzyl group, an optionally at least mono-substituted naphthyl group, which may be bonded via a C-ι-3-alkylene group, an optionally at least mono-substituted thienyl group, an optionally at least mono-substituted 2,1 ,3-Benzothiadiazole group, an optionally at least mono-substituted Benzo[b]thiophenyl group, an optionally at least mono- substituted lmidazo[2.1-b]thiazole group, an optionally at least mono-substituted 1 H-pyrazole group or a 7,7-Dimethyl-2-oxo-bicyclo-[2.2.1]-hept-1-yl group, most preferably R12 represents a methyl group, an ethyl group, an n-propyl group, an n- butyl group, an optionally at least mono-substituted phenyl group, an optionally at least mono-substituted benzyl group, an optionally at least mono-substituted naphthyl group, which may be bonded via a Ci-3-alkylene group, an optionally at least mono-substituted thienyl group, an optionally at least mono-substituted 2,1 ,3-Benzothiadiazole group, an optionally at least mono-substituted Benzo[b]thiophenyl group, an optionally at least mono-substituted lmidazo[2.1- b]thiazole group, an optionally at least mono-substituted 1 H-pyrazole group or a 7,7-Dimethyl-2-oxo-bicyclo-[2.2.1]-hept-1-yl group, wherein said substituents, if present, are identical or different and selected from the group consisting of a fluorine atom, a chlorine atom, a bromine atom, a methyl group, a formyl group, a phenyl group, a phenoxy group, a phenoxy group substituted with bromine in the 4-position and a methylsulfonyl group.
14. Compounds according to one or more of claims 1-13, characterized in that R13 represents a linear or branched, saturated or unsaturated, optionally at least mono-substituted C-i-io-aliphatic group, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C3-8-cycloaliphatic group, which may be condensed with a mono- or polycyclic ring-system and/or which may be bonded via a linear or bridged C1-10- alkylene group and/or which may be bridged by a linear or branched Ci-s-alkylene group, or an optionally at least mono-substituted 5- or 6-membered aryl or heteroaryl group, which may be condensed with a mono- or polycyclic ring system and/or which may be bonded via a linear or branched Ci.io-alkylene group, preferably R13 represents a linear or branched Cι_ιo-alkyl group, a saturated or unsaturated, optionally at least mono-substituted, optionally at least one heteroatom as ring member containing C5_6-cycloaliphatic group, which may be condensed with a mono- or polycyclic ring-system and/or which may be bonded via a linear or bridged Ci-3-alkylene group and/or which may be bridged by a linear or branched Cι_3-alkylene group, or an optionally at least mono-substituted 5- or 6-membered aryl or heteroaryl group, which may be condensed with a mono- or polycyclic ring system and/or which may be bonded via a linear or branched Cι_3-alkylene group, more preferably R13 represents a methyl group, an ethyl group, an n-propyl group, an n-butyl group, an optionally at least mono- substituted phenyl group, an optionally at least mono-substituted benzyl group, an —optionally at least mono-substituted naphthyl group, which may be bonded via a Cι.3-alkylene group, an optionally at least mono-substituted thienyl group, an optionally at least mono-substituted 2,1 ,3-Benzothiadiazole group, an optionally at least mono-substituted Benzo[b]thiophenyl group, an optionally at least mono- substituted lmidazo[2.1-b]thiazole group, an optionally at least mono-substituted 1 H-pyrazole group or a 7,7-Dimethyl-2-oxo-bicyclo-[2.2.1]-hept-1-yl group, most preferably R13 represents a methyl group, an ethyl group, an n-propyl group, an n- butyl group, an optionally at least mono-substituted phenyl group, an optionally at least mono-substituted benzyl group, an optionally at least mono-substituted naphthyl group, which may be bonded via a Cι.3-alkylene group, an optionally at least mono-substituted thienyl group, an optionally at least mono-substituted 2,1,3-Benzothiadiazole group, an optionally at least mono-substituted Benzo[b]thiophenyl group, an optionally at least mono-substituted lmidazo[2.1- b]thiazole group, an optionally at least mono-substituted 1 H-pyrazole group or a 7,7-Dimethyl-2-oxo-bicyclo-[2.2.1]-hept-1-yl group, wherein said substituents, if present, are identical or different and selected from the group consisting of a fluorine atom, a chlorine atom, a bromine atom, a methyl group, a formyl group, a phenyl group, a phenoxy group, a phenoxy group substituted with bromine in the 4-position and a methylsulfonyl group.
5. Compounds according, to one or more of claims 1-14 of general formula
Figure imgf000095_0001
wherein
R1 represents a phenyl group, said phenyl group being unsubstituted or substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, linear or branched C1-6 alkyl, linear or branched Cι_6 alcoxy, -(C=0)-H, -OH, -CF3, -OCF3, -CN and -COOH,
R2 represents a phenyl group, said phenyl group being unsubstituted or substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, linear or branched C-ι-6 alkyl, linear or branched Ci-β alcoxy, -(C=O)-H, -OH, -CF3, -OCF3, -CN and -COOH,
R3 represents a linear or branched, unsubstituted d.6 alkyl group,
R4 represents a hydrogen atom, -CN, -COOH, a linear or branched, unsubstituted C-ι-6 alkyl group, or a phenyl group, said phenyl group being unsubstituted or substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, linear or branched Cι.6 alkyl, Jinear on branched C^ alcoxy, -(C=0)-H, -OH, -CF3, -OCF3, -CN and -COOH,
R5 represents an -O-S02-R6-moiety, an -NH-CO-R7-moiety, an -NH2-moiety, an -NH-SO2-R8 moiety, or an -NR9-SO2-R10-moiety or an -O-C(=O)-R11 -moiety, R6 represents a phenyl group, said phenyl group being unsubstituted or substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, linear or branched C-i_6 alkyl, linear or branched Cι-β alcoxy, -(C=0)-H, -OH, -CF3, -OCF3l -CN and -COOH,
R7 represents a linear or branched C1.5 alkyl group, said alkyl group being unsubstituted or substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, -OH, -SH, linear or branched C-i-β alcoxy, -CF3 and -OCF3; a cyclopentyl or cyclohexyl group, said cyclopentyl or cyclohexyl group being unsubstituted or substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, -OH, - SH, linear or branched C-ι„6 alcoxy, -CF3 and -OCF3; or a phenyl group, said phenyl group being unsubstituted or substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, linear or branched C1-6 alkyl, linear or branched Ci.6 alcoxy, -(C=O)-H, -OH, -CF3, -OCF3, -CN and - COOH,
R8 represents a linear or branched Cι_5 alkyl group; an aryl or heteroaryl group selected from the group consisting of phenyl, naphthyl, thienyl, furanyl (furyl), 2,1 ,3-benzothiadiazole, benzo[b]thiophenyl, benzo[b]furanyl, imidazo[2.1- b]thiazole and pyrazole, said aryl or heteroaryl group being unsubstituted or substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, linear or branched Cι_6 alkyl, linear or branched Cι-6 alcoxy, phenyl (optionally substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, OH, linear or branched C1.6 alkyl and linear or branched Cι.6-alcoxy), phenoxy (optionally substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, OH, linear or branched C1-6 alkyl and linear or branched d-e-alcoxy), -SO2-CH3, -(C=O)-H, -OH, -CF3, -OCF3, -CN and -COOH and said aryl or heteroaryl group being optionally bonded via a C1.3 alkylene group; or a cyclohexyl group, said cyclohexyl group being optionally bonded via a C1-3 alkylene bridge and/or being optionally bridged by a linear or branched C1.3 alkylene bridge and being unsubstituted or substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, linear or branched Cι_6 alkyl, linear or branched Cι_6 alcoxy, -(C=O)-H, -OH, -CF3, =0, - OCF3, -CN and -COOH;
R9 represents an -SO2-R12-moiety; a -(C=O)-R13-moiety; a linear or branched C-ι-6 alkyl radical; or a phenyl radical, said phenyl radical being unsubstituted or substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, linear or branched C1-6 alkyl, linear or branched C1.6 alcoxy, -(C=O)-H, -OH, -CF3, -OCF3, -CN and -COOH and/or said phenyl radical being optionally bonded via a Cι-3-alkylene bridge,
R10 represents a linear or branched C1.5 alkyl group; an aryl or heteroaryl group selected from the group consisting of phenyl, naphthyl, thienyl, furanyl (furyl), 2,1 ,3-benzothiadiazole, benzo[b]thiophenyl, benzo[b]furanyl, imidazo[2.1- b]thiazole and pyrazole, said aryl or heteroaryl group being unsubstituted or substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, linear or branched C1-6 alkyl, linear or branched C1.6 alcoxy, phenyl (optionally substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, OH, linear or branched C1-6 alkyl and linear or branched C-ι-6-alcoxy), phenoxy (optionally substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, OH, linear or branched C1.6 alkyl and linear or branched Cι.6-alcoxy), -SO2-CH3, -(C=O)-H, -OH, -CF3, -OCF3, -CN and -COOH and said aryl or heteroaryl group being optionally bonded via a C1.3 alkylene group; or a cyclohexyl group, said cyclohexyl group being optionally bonded via a C1.3 alkylene bridge and/or being optionally bridged by a linear or branched C1.3 alkylene bridge and being unsubstituted or substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, linear or branched C-i.6 alkyl, linear or branched Cι-6 alcoxy, -(C=O)-H, -OH, -CF3, =0, -
Figure imgf000097_0001
R11 represents a linear or branched C1-5 alkyl group; an aryl or heteroaryl group selected from the group consisting of phenyl, naphthyl, thienyl, furanyl (furyl), 2,1 ,3-benzothiadiazole, benzo[b]thiophenyl, benzo[b]furanyl, imidazo[2.1- b]thiazole and pyrazole, said aryl or heteroaryl group being unsubstituted or substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, linear or branched Cι.6 alkyl, linear or branched Cι-6 alcoxy, phenyl (optionally substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, OH, linear or branched C-|.6 alkyl and linear or branched d-6-alcoxy), phenoxy (optionally substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, OH, linear or branched Cι-6 alkyl and linear or branched d-e-alcoxy), -SO2-CH3, -(C=0)-H, -OH, -CF3, -OCF3, -CN and -COOH and said aryl or heteroaryl group being optionally bonded via a C1.3 alkylene group; or a cyclohexyl group, said cyclohexyl group being optionally bonded via a C1.3 alkylene bridge and/or being optionally bridged by a linear or branched C1-3 alkylene bridge and being unsubstituted or substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, linear or branched Cι.6 alkyl, linear or branched Cι-6 alcoxy, -(C=O)-H, -OH, -CF3, =O, - OCF3, -CN and -COOH;
R12 represents a linear or branched C1.5 alkyl group, an aryl or heteroaryl group selected from the group consisting of phenyl, naphthyl, thienyl, furanyl (furyl), 2,1 ,3-benzothiadiazole, benzo[b]thiophenyl, benzo[b]furanyl, imidazo[2.1- b]thiazole and pyrazole, said aryl or heteroaryl group being unsubstituted or substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, linear or branched C1-6 alkyl, linear or branched C1-6 alcoxy, phenyl (optionally substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, OH, linear or branched C1-6 alkyl and linear or branched C-ι-6-alcoxy), phenoxy (optionally substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, OH, linear or branched Cι.6 alkyl and linear or branched Ci-e-alcoxy), -SO2-CH3, -(C=O)-H, -OH, -CF3, -OCF3, -CN and -COOH and said aryl or heteroaryl group being optionally bonded via a C1-3 alkylene group; or a cyclohexyl group, said cyclohexyl group being optionally bonded via a C1-3 alkylene bridge and/or being optionally bridged by a linear or branched C1.3 alkylene bridge and being unsubstituted or substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, linear or branched Cι-6 alkyl, linear or branched Cι-6 alcoxy, -(C=0)-H, -OH, -CF3, =0, - OCF3, -CN and -COOH;
R13 represents a linear or branched d-s alkyl group, an aryl or heteroaryl group selected from the group consisting of phenyl, naphthyl, thienyl, furanyl (furyl), 2,1 ,3-benzothiadiazole, benzo[b]thiophenyl, benzo[b]furanyl, imidazo[2.1- b]thiazole and pyrazole, said aryl or heteroaryl group being unsubstituted or substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, linear or branched d-6 alkyl, linear or branched C1-6 alcoxy, phenyl (optionally substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, OH, linear or branched C1-6 alkyl and linear or branched Cι.6-alcoxy), phenoxy (optionally substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, OH, linear or branched d.6 alkyl and linear or branched d_6-alcoxy), -SO2-CH3, -(C=0)-H, -OH, -CF3, -OCF3, -CN and -COOH and said aryl or heteroaryl group being optionally bonded via a C1-3 alkylene group; or a cyclohexyl group, said cyclohexyl group being optionally bonded via a C1.3 alkylene bridge and/or being optionally bridged by a linear or branched C-1.3 alkylene bridge and being unsubstituted or substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, linear or branched Cι.6 alkyl, linear or branched Cι-6 alcoxy, -(C=O)-H, -OH, -CF3, =0, - OCF3, -CN and -COOH;
optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding N-oxide thereof, a corresponding salt thereof, or a corresponding solvate thereof.
16. Compounds according to claim 15
Figure imgf000100_0001
wherein X represents a halogen atom, preferably a chlorine atom,
R5 represents an -O-SO2-R6-moiety, an -NH-CO-R7-moiety, an -NH2-moiety, an -NH-S02-R8 moiety, or an -NR9-SO2-R10-moiety or an -O-C(=O)-R11-moiety,
R6 represents a phenyl group, said phenyl group being unsubstituted or substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, linear or branched C1-6 alkyl, linear or branched C1.6 alcoxy, -(C=O)-H, -OH, -CF3, -OCF3, -CN and -COOH,
R7 represents a linear or branched C1-5 alkyl group, said alkyl group being unsubstituted or substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, -OH, -SH, linear or branched C1-6 alcoxy, -CF3 and -OCF3; a cyclopentyl or cyclohexyl group, said cyclopentyl or cyclohexyl group being unsubstituted or substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, -OH, - SH, linear or branched C1-6 alcoxy, -CF3 and -OCF3; or a phenyl group, said phenyl group being unsubstituted or substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, linear or branched d.6 alkyl, linear or branched d.6 alcoxy, -(C=0)-H, -OH, -CF3, -OCF3, -CN and - COOH,
R8 represents a linear or branched C1-5 alkyl group; an aryl or heteroaryl group selected from the group consisting of phenyl, naphthyl, thienyl, furanyl (furyl), 2,1 ,3-benzothiadiazole, benzo[b]thiophenyl, benzo[b]furanyl, imidazo[2.1- b]thiazole and pyrazole, said aryl or heteroaryl group being unsubstituted or substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, linear or branched Cι.6 alkyl, linear or branched C1-6 alcoxy, phenyl (optionally substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, OH, linear or branched d_6 alkyl and linear or branched
Figure imgf000101_0001
phenoxy (optionally substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, OH, linear or branched Ci-β alkyl and linear or branched d_6-alcoxy), -S02-CH3, -(C=0)-H, -OH, -CF3, -OCF3, -CN and -COOH and said aryl or heteroaryl group being optionally bonded via a Cι_3 alkylene group; or a cyclohexyl group, said cyclohexyl group being optionally bonded via a C1.3 alkylene bridge and/or being optionally bridged by a linear or branched C1.3 alkylene bridge and being unsubstituted or substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, linear or branched Cι-6 alkyl, linear or branched Cι.6 alcoxy, -(C=O)-H, -OH, -CF3, =O, - OCF3, -CN and -COOH;
R9 represents an -SO2-R 2-moiety; a -(C=O)-R13-moiety; a linear or branched C1.6 alkyl radical; or a phenyl radical, said phenyl radical being unsubstituted or substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, linear or branched d_6 alkyl, linear or branched C1-6 alcoxy, -(C=0)-H, -OH, -CF3, -OCF3, -CN and -COOH and/or said phenyl radical being optionally bonded via a Cι_3-alkylene bridge,
R10 represents a linear or branched C1.5 alkyl group; an aryl or heteroaryl group selected from the group consisting of phenyl, naphthyl, thienyl, furanyl (furyl), 2,1 ,3-benzothiadiazole, benzo[b]thiophenyl, benzo[b]furanyl, imidazo[2.1- b]thiazole and pyrazole, said aryl or heteroaryl group being unsubstituted or substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, linear or branched Cι-6 alkyl, linear or branched Cι.6 alcoxy, phenyl (optionally substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, OH, linear or branched Cι.6 alkyl and linear or branched Cι.6-alcoxy), phenoxy (optionally substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, OH, linear or branched Cι.6 alkyl and linear or branched d_6-alcoxy), -S02-CH3, -(C=O)-H, -OH, -CF3, -OCF3, -CN and -COOH and said aryl or heteroaryl group being optionally bonded via a C1-3 alkylene group; or a cyclohexyl group, said cyclohexyl group being optionally bonded via a C1.3 alkylene bridge and/or being optionally bridged by a linear or branched Cι_3 alkylene bridge and being unsubstituted or substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, linear or branched Cι_6 alkyl, linear or branched C-ι_6 alcoxy, -(C=O)-H, -OH, -CF3, =O, - OCF3, -CN and -COOH;
R11 represents a linear or branched C1-5 alkyl group; an aryl or heteroaryl group selected from the group consisting of phenyl, naphthyl, thienyl, furanyl (furyl), 2,1 ,3-benzothiadiazole, benzo[b]thiophenyl, benzo[b]furanyl, imidazo[2.1- b]thiazole and pyrazole, said aryl or heteroaryl group being unsubstituted or substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, linear or branched d.6 alkyl, linear or branched d-6 alcoxy, phenyl (optionally substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, OH, linear or branched C1.6 alkyl and linear or branched Cι-6-alcoxy), phenoxy (optionally substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, OH, linear or branched Cι.6 alkyl and linear or branched d-e-alcoxy), -SO2-CH3, -(C=0)-H, -OH, -CF3, -OCF3, -CN and -COOH and said aryl or heteroaryl group being optionally bonded via a C1-3 alkylene group; or a cyclohexyl group, said cyclohexyl group being optionally bonded via a C1-3 alkylene bridge and/or being optionally bridged by a linear or branched C1-3 alkylene bridge and being unsubstituted or substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, linear or branched Cι-6 alkyl, linear or branched Ci-β alcoxy, -(C=0)-H, -OH, -CF3, =0, - OCF3, -CN and -COOH;
R12 represents a linear or branched C1.5 alkyl group, an aryl or heteroaryl group selected from the group consisting of phenyl, naphthyl, thienyl, furanyl (furyl), 2,1,3-benzothiadiazole, benzo[b]thiophenyl, benzo[b]furanyl, imidazo[2.1- b]thiazole and pyrazole, said aryl or heteroaryl group being unsubstituted or substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, linear or branched Cι.6 alkyl, linear or branched C1-6 alcoxy, phenyl (optionally substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, OH, linear or branched C1-6 alkyl and linear or branched Ci-β-alcoxy), phenoxy (optionally substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, OH, linear or branched Cι.6 alkyl and linear or branched d-β-alcoxy), -SO2-CH3, -(C=0)-H, -OH, -CF3, -OCF3, -CN and -COOH and said aryl or heteroaryl group being optionally bonded via a C1-3 alkylene group; or a cyclohexyl group, said cyclohexyl group being optionally bonded via a C1.3 alkylene bridge and/or being optionally bridged by a linear or branched C1-3 alkylene bridge and being unsubstituted or substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, linear or branched C1-6 alkyl, linear or branched C1-6 alcoxy, -(C=0)-H, -OH, -CF3, =O, - OCF3, -CN and -COOH;
R13 represents a linear or branched C1.5 alkyl group, an aryl or heteroaryl group selected from the group consisting of phenyl, naphthyl, thienyl, furanyl (furyl), 2,1 ,3-benzothiadiazole, benzo[b]thiophenyl, benzo[b]furanyl, imidazo[2.1- b]thiazole and pyrazole, said aryl or heteroaryl group being unsubstituted or substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, linear or branched C1-6 alkyl, linear or branched C1-6 alcoxy, phenyl (optionally substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, OH, linear or branched C1.6 alkyl and linear or branched Ci-6-alcoxy), phenoxy (optionally substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, OH, linear or branched C1.6 alkyl and linear or branched Ci-e-alcoxy), -SO2-CH3, -(C=0)-H, -OH, -CF3, -OCF3, -CN and -COOH and said aryl or heteroaryl group being optionally bonded via a C1.3 alkylene group; or a cyclohexyl group, said cyclohexyl group being optionally bonded via a C1-3 alkylene bridge and/or being optionally bridged by a linear or branched C1.3 alkylene bridge and being unsubstituted or substituted with 1 , 2, 3, 4 or 5 substituents independently selected from the group consisting of F, Cl, Br, linear or branched Cι.6 alkyl, linear or branched Cι-6 alcoxy, -(C=0)-H, -OH, -CF3, =0, - OCF3, -CN and -COOH; optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding N-oxide thereof, a corresponding salt thereof, or a corresponding solvate thereof.
17. Compounds according to one or more of claims 1-16 of general formula I,
Figure imgf000104_0001
wherein
R1 represents a phenyl group, which is mono-substituted with a halogen atom, preferably a chlorine atom, in the 4-position of the phenyl ring,
R2 represents a phenyl group, which is mono-substituted with a halogen atom, preferably a chlorine atom, in the 4-position of the phenyl ring,
R3 represents a linear or branched, unsubstituted Cι.6 alkyl group, preferably a methyl group, R4 represents a hydrogen atom,
R5 represents an -0-SO2-R6-moiety, an -NH-CO-R7-moiety, an -NH2-moiety, an -NH-SO2-R8 moiety, or an -NR9-SO2-R10-moiety
R6 represents a phenyl ring, which is optionally substituted with one or more halogen atoms, preferably one or more fluorine and/or one or more chlorine atoms,
R7 represents a linear or branched C1-5 alkyl group, a linear or branched C1.5 alkyl group, which is at least partially fluorinated, a C3-8 cycloalkyl group, or a phenyl group, which is optionally substituted with one or more halogen atoms, preferably one or more fluorine atoms,
R8 represents a linear or branched C1.5 alkyl group,
a phenyl group, which is optionally substituted with one or more substituents independently selected from the group consisting of a fluorine atom, a chlorine atom, an unsubstituted phenyl group, a formyl group, a methylsulfonyl group, a benzyl group and a phenoxy group, which is optionally mono-substituted by a bromine atom in its 4-position,
a naphthyl group, which may be bonded via a methylene or ethylene group,
a Benzo[b]thiophene group, which is optionally substituted with one or more methyl groups and/or one or more chlorine atoms,
a pyrazole group, which is optionally substituted with one or more substituents independently selected from the group consisting of a methyl group, an ethyl group and a phenyl group,
an imidazo[2,1-b]thiazole group, which is optionally substituted with one or more chlorine atoms, a thienyl group, a furyl group, a 2,1,3-Benzothiadiazole group, a 7,7-Dimethyl-2- oxo-bicyclo-[2.2.1]-hept-1-yl group, or a benzyl group,
R9 represents a C1-5 alkyl group, preferably a methyl group, a phenyl group, which is optionally substituted with one or more fluorine atoms and/or one or more chlorine atoms, a benzyl group, wherein the ring is optionally substituted with one or more fluorine atoms and/or one or more chlorine atoms, or a -S02- R12-moiety,
R10 represents a phenyl group, which is optionally substituted with one or more fluorine atoms and/or one or more chlorine atoms,
R12 represents a C1-5 alkyl group, preferably a methyl group, or a phenyl group, which is optionally substituted with one or more fluorine atoms and/or one or more chlorine atoms, optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding N-oxide thereof, a corresponding salt thereof, or a corresponding solvate thereof.
18. Compounds according to one or more of claims 1-17 selected from the group consisting of
[1] 4-Fluoro-benzenesulfonic acid 1-[trans-bis-(4-chloro-phenyl)-methyl]-2- methyl-azetidin-3-yl ester,
[2] N-{(2S,3R)-1-[Bis-(4-chloro-phenyl)-methyl]-2-methyl-azetidin-3-yl}-2,2,2- trifluoro-acetamide,
[3] (2S,3R)-1-[Bis-(4-chloro-phenyl)-methyl]-2-methyl-azetidin-3-ylamine, [4] Hexanoic acid {1-[bis-(4-chloro-phenyl)-methyl]-2-methyl-azetidin-3-yl}~ amide,
[5] N-{(2S,3R)-1-[Bis-(4-chloro-phenyl)-methyl]-2-methyl-azetidin-3-yl}-4- fluoro-benzenesulfonamide,
[6] Thiophene-2-sulfonic acid {(2S,3R)-1 -[bis-(4-chloro-phenyl)-methyl]-2- methy l-azetidi n-3-yl}-am ide ,
[7] Cyclohexanecarboxylic acid {(2S,3R)-1-[bis-(4-chloro-phenyl)-methyl]-2- methyl-azetidin-3-yl}-amide,
[8] Butane-1 -sulfonic acid {(2S,3R)-1 -[bis-(4-chloro-phenyl)-methyl]-2-methyl- azetidin-3-yl}-amide,
[9] N-{(2S,3R)-1-[Bis-(4-chloro-phenyl)-methyl]-2-methyl-azetidin-3-yl}-3,5- difluoro-benzamide,
[10] Naphthalene-2-sulfonic acid {trans-1 -[bis-(4-chloro-phenyl)-methyl]-2- methyl-azetidin-3-yl}-amide,
[11 ] Biphenyl-4-sulfonic acid { trans-1 -[bis-(4-chloro-phenyl)-methyl]-2-methyl- azetidin-3-yl}-amide,
[12] 4-Acetyl-N-{trans-1 -[bis-(4-chloro-phenyl)-methyl]-2-methyl-azetidin-3-yl}- benzenesulfonamide,
[13] N-{trans-1 -[Bis-(4-chloro-phenyl)-methyl]-2-methyl-azetidin-3-yl}-4-(4- bromo-phenoxy)-benzenesulfonamide,
[14] N-{trans-1 -[Bis-(4-chloro-phenyl)-methyl]-2-methyl-azetidin-3-yl}-4- methylsulfonyl-benzenesulfonamide,
[15] 2,1 ,3-Benzothiadiazole-4-sulfonic acid {trans-1 -[bis-(4-chloro-phenyl)- methyl]-2-methyl-azetidin-3-yl}-amide,
[16] 5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonic acid {trans-1 -[bis-(4- chloro-phenyl)-methyl]-2-methyl-azetidin-3-yl}-amide,
[17] 6-Chloro-imidazo[2, 1 -b]thiazole-5-sulfonic acid {trans-1 -[bis-(4-chloro- phenyl)-methyl]-2-methyl-azetidin-3-yl}-amide,
[18] N-{ trans-1 -[Bis-(4-chloro-phenyl)-methyl]-2-methyi-azetidin-3-yl}-3,5- dichloro-benzenesulfonamide,
[19] 2-Naphthalene-1 -yl-ethanesulfonic acid { trans-1 -[bis-(4-chloro-phenyl)- methyl]-2-methyl-azetidin-3-yl}-amide,
[20] N-{trans-1-[Bis-(4-chloro-phenyl)-methyl]-2-methyl-azetidin-3-yl}-phenyl- methylsulfonamide,
[21 ] N-{ trans-1 -[Bis-(4-chloro-phenyl)-methyl]-2-methyl-azetidin-3-yl}-(7,7- dimethyl-2-oxo-bicyclo[2.2.1]hept-1-yl)-methylsulfonamide,
[22] Naphthalene-1 -sulfonic acid { trans-1 -[bis-(4-chloro-phenyl)-methyl]-2- methyl-azetidin-3-yl}-amide,
[23] N-{ trans-1 -[Bis-(4-chloro-phenyl)-methyl]-2-methyl-azetidin-3-yl}-4- phenoxy-benzenesulfonamide,
[24] 1 ,3,5-Trimethyl-1 H-pyrazole-4-sulfonic acid{ trans-1 ~[bis-(4-chloro-phenyl)- methyl]-2-methyl-azetidin-3-yl}-amide,
[25] Benzo[b]thiophene-3-sulfonic acid { trans-1 -[bis-(4-chloro-phenyl)-methyl]- 2-methyl-azetidin-3-yl}-amide,
[26] 5-Methyl-1 -phenyl-1 H-pyrazole-4-sulfonic acid { trans-1 -[bis-(4-chloro- phenyl)-methyl]-2-methyl-azetidin-3-yl}-amide,
[27] N-{trans-1-[Bis-(4-chloro-phenyl)-methyl]-2-methyl-azetidin-3-yl}-N-methyl- 4-fluoro-benzenesulfonamide,
[28] N-{trans-1 -[Bis-(4-chloro-phenyl)-methyl]-2-methyl-azetidin-3-yl}-N-(4- fluoro-benzyl)-4-fluoro-benzenesulfonamide,
[29] N-{trans-1-[Bis-(4-chloro-phenyl)-methyl]-2-methyl-azetidin-3-yl}-N-propyl- 4-fluoro-benzenesulfonamide,
[30] N-{trans-1 -[Bis-(4-chloro-phenyl)-methyl]-2-methyl-azetidin-3-yl}-N- (methylsulphonyl)-4-fluoro-benzenesulfonamide,
[31] N-{trans-1-[Bis-(4-chloro-phenyl)-methyl]-2-methyl-azetidin-3-yl}-N-bis(4- fluoro-benzenesulfonamide),
[32] N-{(trans-1-[Bis-(4-chloro-phenyl)-methyl]-2-methyl-azetidin-3-yl}-4-fluoro- benzenesulfonamide, and
[33] N-{(2R,3S)-1-[Bis-(4-chloro-phenyl)-methyl]-2-methyl-azetidin-3-yl}-4- fluoro-benzenesulfonamide;
optionally in form of a corresponding N-oxide, a corresponding salt or a corresponding solvate.
9. Process for the preparation of substituted azetidine compounds according to one or more of claims 1-18, characterized in that at least one compound of general formula II
Figure imgf000110_0001
wherein R1 to R4 have the meaning according to one or more of claims 1-18, is reacted with at least one compound of general formula X1-SO2-R6 or X2-CO-R11, wherein R6 and R11 have the meaning according to one or more of claims 1-18 and X1 and X2 are leaving groups, in a reaction medium, optionally in the presence of at least one base, to yield at least one compound of general formula I according to claim 1, wherein R5 represents an -O-SO -R6 or a -O-CO-R11 moiety, and optionally purifying and/or optionally isolating said compound(s), and optionally at least one of these afore mentioned compounds, wherein R5 represents a -O-SO2-R6 or an -O-CO-R11 moiety is reacted with ammonia, to yield a compound of general formula I according to claim 1 , wherein R5 represents an -NH2-moiety, and optionally purifying and/or optionally isolating said compound(s), and optionally at least one of these afore mentioned compounds, wherein R5 represents an -NH2-moiety, is reacted with at least one compound of general formula X3 COR7, X4-SO2-R8 or X5-SO2-R10, wherein R7, R8 and R10 have the meaning according to one or more of claims 1-15 and X3, X4 and X5 represent leaving groups, in a reaction medium, optionally in the presence of at least one base, to yield a compound of general formula I according to claim 1 , wherein R5 represents an -NH-CO-R7-moiety, an -NH-SO2-R8-moiety, or an -NR9-S02-R1°- moiety with R9 representing a hydrogen atom, and optionally purifying and/or optionally isolating said compound(s),
and optionally at least one compound of general formula I, wherein R5 represents an -NR9-SO -R10-moiety with R9 representing a hydrogen atom is reacted with at least one compound of general formula X6-R9, wherein R9 has the meaning according to one or more of claims 1-18 with the exception of a hydrogen atom, and X6 represents a leaving group, to yield at least one compound of general formula I according to claim 1 , wherein R5 represents an -NR9-SO2-R10-moiety, and optionally purifying and/or optionally isolating said compound(s),
or, that at least one compound of general formula III,
Figure imgf000111_0001
III
wherein R1-R3 have the meaning according to one or more of claims 1-18, is oxidized to yield at least one compound of general formula IV,
Figure imgf000111_0002
IV wherein R1-R3 have the meaning according to one or more of claims 1-18, which is optionally purified and/or optionally isolated, and reacted with at least one compound of general formula R5aH, wherein R5a represents an -NH2-moiety or an -NHR9-moiety, wherein R9 has the meaning given above, the resulting compound is optionally purified and/or optionally isolated and optionally reacted with at least one compound of general formula X3-CO-R7, X4-S02-R8 or X5-S02- R10, wherein R7, R8 and R10 have the meaning given above and X3, X4 and X5 represent leaving groups, in a reaction medium, optionally in the presence of at least one base, to yield a compound of general formula I according to one or more of claims 1-18, wherein R5 represents an -NH2-moiety, an -NH-CO-R7- moiety, an -NH-SO2-R8-moiety, or an -NR9-SO2-R10-moiety, which is optionally purified and/or isolated.
20. Process for the preparation of substituted azetidine compounds according to one or more of claims 1-18, characterized in that at least one compound of general formula II,
Figure imgf000112_0001
R'
V wherein Y represents a halogen atom, preferably a chlorine atom or a bromine atom, and R1 and R2 have the meaning according to one or more of claims 1-18, is reacted with at least one compound of general formula VI,
Figure imgf000112_0002
VI optionally in form of a salt, wherein R3, R4 and R5 have the meaning according to one or more of claims 1-18, in a suitable reaction medium, optionally in the presence of a base, and the resulting azetidine compound(s) is/are optionally purified and/or optionally isolated.
21. Medicament comprising at least one substituted azetidine compound according to one or more of claims 1-18 inclusive of the disclaimed compounds and optionally one or more pharmaceutically acceptable excipients.
22. Medicament according to claim 21 for the modulation of cannabinoid-receptors, preferably cannabinoid 1 (CB-i) receptors, for the prophylaxis and/or treatment of disorders of the central nervous system, disorders of the immune system, disorders of the cardiovascular system, disorders of the endocrinous system,, disorders of the respiratory system, disorders of the gastrointestinal tract or reproductive disorders.
23. Medicament according to claim 21 or 22 for the prophylaxis and/or treatment of food intake disorders, preferably selected from the group consisting of bulimia, anorexia, cachexia, obesity and type II diabetus mellitus (non-insuline dependent diabetes mellitus), more preferably obesity.
24. Medicament according to claim 21 or 22 for the prophylaxis and/or treatment of psychosis.
25. Medicament according to claim 21 or 22 for the prophylaxis and/or treatment of alcohol abuse and/or alcohol addiction, nicotine abuse and/or nicotine addiction, drug abuse and/or drug addiction and/or medicament abuse and/or medicament addiction, preferably drug abuse and/or drug addiction.
26. Medicament according to claim 21 or 22 for the prophylaxis and/or treatment of one or more disorders selected from the group consisting of schizophrenia, anxiety, depression, epilepsy, neurodegenerative disorders, cerebellar disorders, spinocerebellar disorders, cognitive disorders, cranial trauma, panic attacks, peripheric neuropathy, glaucoma, migraine, Morbus Parkinson, Morbus Huntington, Morbus Alzheimer, Raynaud's disease, tremblement disorders, compulsive disorders, senile dementia, thymic disorders, tardive dyskinesia, bipolar disorders, cancer, medicament-induced movement disorders, dystonia, endotoxemic shock, hemorragic shock, hypotension, insomnia, immunologic disorders, sclerotic plaques, vomiting, diarrhea, asthma, memory disorders, pruritus, pain or for potentiation of the analgesic effect of narcotic and non- narcotic analgesics, or for influencing intestinal transit
27. Use of at least one substituted azetidine compound according to one or more of claims 1-18 inclusive of the disclaimed compounds and optionally one or more pharmaceutically acceptable excipients, for the preparation of a medicament for the modulation of cannabinoid-receptors, preferably cannabinoid 1 (CB-i) receptors, for the prophylaxis and/or treatment of disorders of the central nervous system, disorders of the immune system, disorders of the cardiovascular system, disorders of the endocrinous system, disorders of the respiratory system, disorders of the gastrointestinal tract or reproductive disorders.
28. Use of at least one substituted azetidine compound according to one or more of claims 1-18 inclusive of the disclaimed compounds and optionally one or more pharmaceutically acceptable excipients, for the preparation of a medicament for the prophylaxis and/or treatment of food intake disorders, preferably selected from the group consisting of bulimia, anorexia, cachexia, obesity and type II diabetus mellitus (non-insuline dependent diabetes mellitus), more preferably obesity.
29. Use of at least one substituted azetidine compound according to one or more of claims 1-18 inclusive of the disclaimed compounds and optionally one or more pharmaceutically acceptable excipients, for the preparation of a medicament for the prophylaxis and/or treatment of psychosis.
30. Use of at least one substituted azetidine compound according to one or more of claims 1-18 inclusive of the disclaimed compounds and optionally one or more pharmaceutically acceptable excipients, for the preparation of a medicament for the prophylaxis and/or treatment of alcohol abuse and/or alcohol addiction, nicotine abuse and/or nicotine addiction, drug abuse and/or drug addiction and/or medicament abuse and/or medicament addiction, preferably drug abuse and/or drug addiction.
31. Use of at least one substituted azetidine compound according to one or more of claims 1-18 inclusive of the disclaimed compounds and optionally one or more pharmaceutically acceptable excipients, for the preparation of a medicament for the prophylaxis and/or treatment of one or more disorders selected from the group consisting of schizophrenia, anxiety, depression, epilepsy, neurodegenerative disorders, cerebellar disorders, spinocerebellar disorders, cognitive disorders, cranial trauma, panic attacks, peripheric neuropathy, glaucoma, migraine, Morbus Parkinson, Morbus Huntington, Morbus Alzheimer, Raynaud's disease, tremblement disorders, compulsive disorders, senile dementia, thymic disorders, tardive dyskinesia, bipolar disorders, cancer, medicament-induced movement disorders, dystonia, endotoxemic shock, hemorragic shock, hypotension, insomnia, immunologic disorders, sclerotic plaques, vomiting, diarrhea, asthma, memory disorders, pruritus, pain, or for potentiation of the analgesic effect of narcotic and non-narcotic analgesics, or for influencing intestinal transit.
PCT/EP2005/001658 2004-02-17 2005-02-16 Substituted azetidine compounds, their preparation and use as medicaments WO2005077897A1 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
RU2006133258/04A RU2006133258A (en) 2004-02-17 2005-02-16 SUBSTITUTED AZETIDINE DERIVATIVES, THEIR PRODUCTION AND APPLICATION AS MEDICINES
AU2005212835A AU2005212835A1 (en) 2004-02-17 2005-02-16 Substituted Azetidine compounds, their preparation and use as medicaments
BRPI0507801-6A BRPI0507801A (en) 2004-02-17 2005-02-16 substituted azetidine compounds, process for preparing substituted azetidine compounds, medicament and use of at least one substituted azetidine compound
CA002556565A CA2556565A1 (en) 2004-02-17 2005-02-16 Substituted azetidine compounds, their preparation and use as medicaments
JP2006553539A JP2007522255A (en) 2004-02-17 2005-02-16 Substituted azetidine compounds, their manufacture and use as pharmaceuticals
EP05715383A EP1718609A1 (en) 2004-02-17 2005-02-16 Substituted azetidine compounds, their preparation and use as medicaments
IL177456A IL177456A0 (en) 2004-02-17 2006-08-10 Substituted azetidine compounds, their preparation and use as medicaments
US11/505,463 US20070066587A1 (en) 2004-02-17 2006-08-17 Substituted azetidine compounds, their preparation and use as medicaments
NO20064078A NO20064078L (en) 2004-02-17 2006-09-11 Substituted azetidine compositions, their preparation and use as drugs

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
ES200400379 2004-02-17
ES200400379A ES2244314B1 (en) 2004-02-17 2004-02-17 SUBSTITUTED AZETIDINIC COMPOUNDS, THEIR PREPARATION AND THEIR APPLICATION AS MEDICATIONS.
US10/804,558 2004-03-19
US10/804,558 US20050187208A1 (en) 2004-02-17 2004-03-19 Substituted Azetidine compounds, their preparation and use as medicaments

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/505,463 Continuation-In-Part US20070066587A1 (en) 2004-02-17 2006-08-17 Substituted azetidine compounds, their preparation and use as medicaments

Publications (1)

Publication Number Publication Date
WO2005077897A1 true WO2005077897A1 (en) 2005-08-25

Family

ID=34863169

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/001658 WO2005077897A1 (en) 2004-02-17 2005-02-16 Substituted azetidine compounds, their preparation and use as medicaments

Country Status (9)

Country Link
EP (1) EP1718609A1 (en)
JP (1) JP2007522255A (en)
KR (1) KR20060124756A (en)
AU (1) AU2005212835A1 (en)
BR (1) BRPI0507801A (en)
CA (1) CA2556565A1 (en)
NO (1) NO20064078L (en)
RU (1) RU2006133258A (en)
WO (1) WO2005077897A1 (en)

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007169270A (en) * 2005-11-25 2007-07-05 Tanabe Seiyaku Co Ltd Medicinal composition
WO2008017381A1 (en) 2006-08-08 2008-02-14 Sanofi-Aventis Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use
US7485732B2 (en) 2003-06-11 2009-02-03 Merck & Co., Inc. Substituted 3-alkyl and 3-alkenyl azetidine derivatives
WO2009021740A2 (en) 2007-08-15 2009-02-19 Sanofis-Aventis Substituted tetrahydronaphthalenes, process for the preparation thereof and the use thereof as medicaments
FR2928149A1 (en) * 2008-02-29 2009-09-04 Sanofi Aventis Sa AZETIDINE-DERIVED COMPOUNDS, THEIR PREPARATION AND THEIR THERAPEUTIC USE
WO2010003624A2 (en) 2008-07-09 2010-01-14 Sanofi-Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
FR2946650A1 (en) * 2009-06-16 2010-12-17 Sanofi Aventis ESTERS DERIVED FROM AZETIDINES, THEIR PREPARATION AND THEIR USE IN THERAPEUTICS.
WO2011023754A1 (en) 2009-08-26 2011-03-03 Sanofi-Aventis Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
US7906652B2 (en) 2005-11-28 2011-03-15 Merck Sharp & Dohme Corp. Heterocycle-substituted 3-alkyl azetidine derivatives
WO2011157827A1 (en) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
WO2012120051A1 (en) 2011-03-08 2012-09-13 Sanofi Benzyl-oxathiazine derivates substituted with adamantane or noradamantane, medicaments containing said compounds and use thereof
WO2012120050A1 (en) 2011-03-08 2012-09-13 Sanofi Novel substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
WO2012120057A1 (en) 2011-03-08 2012-09-13 Sanofi Novel substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
WO2012120052A1 (en) 2011-03-08 2012-09-13 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
WO2012120054A1 (en) 2011-03-08 2012-09-13 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120055A1 (en) 2011-03-08 2012-09-13 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120056A1 (en) 2011-03-08 2012-09-13 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120053A1 (en) 2011-03-08 2012-09-13 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120058A1 (en) 2011-03-08 2012-09-13 Sanofi Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2013001505A3 (en) * 2011-06-29 2013-03-07 Adamed Sp. Z O.O. Sulphonamide derivatives of alicyclic amines for the treatment of central nervous system diseases
EP2754653A2 (en) * 2011-09-05 2014-07-16 Korea Institute of Science and Technology Azetidine derivative and antidepressant composition containing same
US9440948B2 (en) 2010-09-03 2016-09-13 University Of Florida Research Foundation, Inc. Nicotine compounds and analogs thereof, synthetic methods of making compounds, and methods of use

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0406112A1 (en) * 1989-06-29 1991-01-02 Laboratorios Del Dr. Esteve, S.A. 1-Benzhydrylazetidines, their preparation and their use as intermediates for the preparation of compounds with antimicrobial activity
WO2001064633A1 (en) * 2000-03-03 2001-09-07 Aventis Pharma S.A. Pharmaceutical compositions containing 3-amino-azetidine derivatives, novel derivatives and preparation thereof
WO2003020314A1 (en) * 2001-08-29 2003-03-13 Aventis Pharma S.A. Compositions for the treatment of parkinson's disease containing a cb1 receptor antagonist and a product that activates dopaminergic neurotransmission in the brain
WO2003053431A2 (en) 2001-12-21 2003-07-03 Aventis Pharma S.A. Pharmaceutical compositions based on azetidine derivatives

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0406112A1 (en) * 1989-06-29 1991-01-02 Laboratorios Del Dr. Esteve, S.A. 1-Benzhydrylazetidines, their preparation and their use as intermediates for the preparation of compounds with antimicrobial activity
US5073646A (en) 1989-06-29 1991-12-17 Laboratorios Del Dr. Esteve, S.A. Substituted 1-diphenylmethyl azetidines
WO2001064633A1 (en) * 2000-03-03 2001-09-07 Aventis Pharma S.A. Pharmaceutical compositions containing 3-amino-azetidine derivatives, novel derivatives and preparation thereof
WO2003020314A1 (en) * 2001-08-29 2003-03-13 Aventis Pharma S.A. Compositions for the treatment of parkinson's disease containing a cb1 receptor antagonist and a product that activates dopaminergic neurotransmission in the brain
WO2003053431A2 (en) 2001-12-21 2003-07-03 Aventis Pharma S.A. Pharmaceutical compositions based on azetidine derivatives

Non-Patent Citations (47)

* Cited by examiner, † Cited by third party
Title
A. C. HOWLETT ET AL.: "International Union of Pharmacology XXVII. Classification of Cannabinoid Receptors", PHARMACOL REV, vol. 54, 2002, pages 161 - 202
A. SASSE ET AL., ARCH. PHARM., vol. 334, no. 2, 2001, pages 45 - 52
ALPERMANN H. G. ET AL.: "Pharmacological effets of Hoe 249: A new potential antidepressant", DRUGS DEV. RES., vol. 25, 1992, pages 267 - 282
AXENROD ET AL., TETRAHEDRON LETT., 1993, pages 6677 - 6680
BARUAH ET AL., SYNLETT, no. 4, 1999, pages 409 - 410
BULL. SOC. CHIM. FRANCE, vol. 132, no. 5-6, 1995, pages 522 - 30
CATALYSIS LETTERS, vol. 62, no. 2-4, 1999, pages 175 - 177
CHEM. BER., vol. 123, no. 12, 1990, pages 2387 - 94
CONSROE; SANDYK: "Neurobiology and Neurophysiology", vol. 459, 1992, CRC PRESS, article "Marijuana/Cannabinoids"
DAVID R. COMPTON ET AL.: "In-vivo Characterization of a Specific Cannabinoid Receptor Antagonist (SR141716A) :Inhibition of Tetrahvdrocannbinol- induced Responses and Apparent Aaonist Activity", J. PHARMACOL. EXP. THER., vol. 277, no. 2, 1996, pages 586 - 594
DAVID R. COMPTON ET AL.: "In-vivo Characterization of a Specific Cannabinoid Receptor Antagonist (SR141716A) Inhibition of Tetrahydrocannbinol- induced Responses and Apparent Agonist Activity", J. PHARMACOL EXP THER., vol. 277, no. 2, 1996, pages 586 - 594
DEJAEGHER ET AL., SYNLETT., 2002, pages 113 - 115
DESMET L. K. C. ET AL.: "Anticonvulsive properties of Cinarizine and Flunarizine in Rats and Mice", ARZNEIM. -FORSCH. (FRUG RES), vol. 25, 1975, pages 9
FARMACO, vol. 44, no. 12, 1989, pages 1167 - 91
FERNANDEZ ET AL., SYNTHESIS, no. 2, 2001, pages 239 - 242
FRIGOLA J ET AL: "7-Azetidinylquinolones as Antibacterial Agents. 2. Synthesis and Biological Activity of 7-(2,3-Disubstituted-1-azetidinyl)-4-oxoquino line- and -1,8-naphthyridine-3-carboxylic Acids. Properties and Structure-Activity Relationships of Quinolones with an Azetidine Moiety", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 37, no. 24, 1994, pages 4195 - 4210, XP002115349, ISSN: 0022-2623 *
FRIGOLA J ET AL: "7-Azetidinylquinolones as Antibacterial Agents. 3. Synthesis, Properties and Structure-Activity Relationships of the Stereoisomers Containing a 7-(3-Amino-2-methyl-1-azetidinyl) Moiety", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 38, no. 7, 1995, pages 1203 - 1215, XP002115345, ISSN: 0022-2623 *
HAJIPOUR ET AL., SYNTH. COMMUN., vol. 29, no. 10, 1999, pages 1697 - 1701
HETEROCYCLES, vol. 32, no. 5, 1991, pages 965 - 73
HIGGINS ET AL., J. HETEROCYCLIC CHEM., vol. 8, 1971, pages 1059 - 1062
HOLLISTER, PHARM. REV., vol. 38, 1986, pages 1 - 20
J. A. MARSHALL ET AL., ORG. LETT., vol. 2, no. 18, 2000, pages 2897 - 2900
J. AM. CHEM. SOC., 2001, pages 12168 - 12175
J. AM. CHEM. SOC., vol. 111, no. 9, 1989, pages 3363 - 3368
J. FRIGOLA ET AL., J. MED. CHEM., vol. 38, 1995, pages 1203 - 1215
J. FRIGOLA, J. MED. CHEM., vol. 36, 1993, pages 801 - 810
J. FRIGOLA, J. MED. CHEM., vol. 37, 1994, pages 4195 - 4210
J. FRIGOLA, J. MED. CHEM., vol. 38, 1995, pages 1203 - 1215
J. MED. CHEM., vol. 33, no. 3, 1990, pages 908 - 18
J. NATURAL PRODUCTS, vol. 65, no. 6, 2002, pages 902 - 908
J. ORG. CHEM., vol. 63, no. 25, 1998, pages 9565 - 68
J. ORG. CHEM., vol. 64, no. 7, 1999, pages 2582 - 2589
KATRITZKY ET AL., J. HETEROCYCL. CHEM., 1994, pages 271 - 275
KATRIZKY ET AL., J. HETEROCYCL. CHEM., 1994, pages 271 - 275
M. GRISAR ET AL., J. MED. CHEM., 1973, pages 885
M.E. JUNG, J. ORG. CHEM., vol. 56, no. 24, 1991, pages 6729 - 6730
P.R. DAVE ET AL., J. ORG. CHEM., vol. 61, no. 16, 1996, pages 5453
RENY; SINGHA, PROG. DRUG. RES., vol. 36, 1991, pages 71 - 114
RUTH A. ROSS; HEATHER C. BROCKIE ET AL.: "Agonist-inverse agonist characterization at CB and CB2 cannabinoid receptors of L-759633, L759656 and AM630", BRITISH JOURNAL OF PHARMACOLOGY, vol. 126, 1999, pages 665 - 672
SHARPLESS ET AL., J. AM. CHEM. SOC., vol. 102, 1980, pages 5974 - 5976
SYNLETT., 1991, pages 783 - 784
SYNLETT., 1999, pages 1763 - 65
SYNTHESIS, vol. 8, 1989, pages 598 - 603
TETRAHEDRON LETT., vol. 43, no. 49, 2002, pages 8893 - 8896
TETRAHEDRON, vol. 40, no. 7, 1984, pages 1195 - 1198
V.R. GAERTNER, J. ORG. CHEM., vol. 32, 1967, pages 2972
WOOLFE D. ET AL.: "The evaluation of analgesic action of pethidine hydrochloride (Demerol)", J. PHARMACOL. EXP. THER., vol. 80, 1944, pages 300 - 307

Cited By (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7485732B2 (en) 2003-06-11 2009-02-03 Merck & Co., Inc. Substituted 3-alkyl and 3-alkenyl azetidine derivatives
US7906503B2 (en) 2003-06-11 2011-03-15 Merck Sharp & Dohme Corp. Substituted 3-alkyl and 3-alkenyl azetidine derivatives
JP2007169270A (en) * 2005-11-25 2007-07-05 Tanabe Seiyaku Co Ltd Medicinal composition
US7906652B2 (en) 2005-11-28 2011-03-15 Merck Sharp & Dohme Corp. Heterocycle-substituted 3-alkyl azetidine derivatives
WO2008017381A1 (en) 2006-08-08 2008-02-14 Sanofi-Aventis Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use
WO2009021740A2 (en) 2007-08-15 2009-02-19 Sanofis-Aventis Substituted tetrahydronaphthalenes, process for the preparation thereof and the use thereof as medicaments
WO2009118473A3 (en) * 2008-02-29 2009-11-19 Sanofi-Aventis Azetidine-derived compounds, preparation method therefor and therapeutic use of same
WO2009118473A2 (en) 2008-02-29 2009-10-01 Sanofi-Aventis Azetidine-derived compounds, preparation method therefor and therapeutic use of same
FR2928149A1 (en) * 2008-02-29 2009-09-04 Sanofi Aventis Sa AZETIDINE-DERIVED COMPOUNDS, THEIR PREPARATION AND THEIR THERAPEUTIC USE
WO2010003624A2 (en) 2008-07-09 2010-01-14 Sanofi-Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
FR2946650A1 (en) * 2009-06-16 2010-12-17 Sanofi Aventis ESTERS DERIVED FROM AZETIDINES, THEIR PREPARATION AND THEIR USE IN THERAPEUTICS.
WO2010146299A1 (en) * 2009-06-16 2010-12-23 Sanofi-Aventis Azetidine-derived esters, preparation thereof, and therapeutic use thereof as cannabinoid receptor modulators
WO2011023754A1 (en) 2009-08-26 2011-03-03 Sanofi-Aventis Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
WO2011157827A1 (en) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US9440948B2 (en) 2010-09-03 2016-09-13 University Of Florida Research Foundation, Inc. Nicotine compounds and analogs thereof, synthetic methods of making compounds, and methods of use
WO2012120056A1 (en) 2011-03-08 2012-09-13 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120057A1 (en) 2011-03-08 2012-09-13 Sanofi Novel substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
WO2012120052A1 (en) 2011-03-08 2012-09-13 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
WO2012120054A1 (en) 2011-03-08 2012-09-13 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120055A1 (en) 2011-03-08 2012-09-13 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120051A1 (en) 2011-03-08 2012-09-13 Sanofi Benzyl-oxathiazine derivates substituted with adamantane or noradamantane, medicaments containing said compounds and use thereof
WO2012120053A1 (en) 2011-03-08 2012-09-13 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120058A1 (en) 2011-03-08 2012-09-13 Sanofi Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120050A1 (en) 2011-03-08 2012-09-13 Sanofi Novel substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
WO2013001505A3 (en) * 2011-06-29 2013-03-07 Adamed Sp. Z O.O. Sulphonamide derivatives of alicyclic amines for the treatment of central nervous system diseases
EP2754653A2 (en) * 2011-09-05 2014-07-16 Korea Institute of Science and Technology Azetidine derivative and antidepressant composition containing same
EP2754653A4 (en) * 2011-09-05 2015-02-18 Korea Inst Sci & Tech Azetidine derivative and antidepressant composition containing same
US9120771B2 (en) 2011-09-05 2015-09-01 Korea Institute Of Science And Technology Azetidine derivative and antidepressant composition including the same

Also Published As

Publication number Publication date
JP2007522255A (en) 2007-08-09
CA2556565A1 (en) 2005-08-25
EP1718609A1 (en) 2006-11-08
BRPI0507801A (en) 2007-07-10
KR20060124756A (en) 2006-12-05
NO20064078L (en) 2006-09-11
AU2005212835A1 (en) 2005-08-25
RU2006133258A (en) 2008-04-10

Similar Documents

Publication Publication Date Title
WO2005077897A1 (en) Substituted azetidine compounds, their preparation and use as medicaments
US7524868B2 (en) Substituted pyrazoline compounds, their preparation and use as medicaments
UA73554C2 (en) A pharmaceutical composition containing azetidine derivatives, azetidine derivatives and preparation thereof
US20070066587A1 (en) Substituted azetidine compounds, their preparation and use as medicaments
EP1757587A1 (en) Substituted pyrazoline compounds, their preparation and use as medicaments
EP1743890A1 (en) 4,5-Dihydro-1H-pyrazole derivatives, their preparation and use as medicaments
WO2006069807A1 (en) Substituted phenyl-piperazine compounds, their preparation and use in medicaments
JP2008525388A (en) N-[(4,5-diphenyl-3-alkyl-2-thienyl) methyl] amine (amide, sulfonamide, carbamic acid and urea) derivatives as cannabinoid CB1 receptor antagonists
WO2007017124A1 (en) Amorphous phase of a substituted pyrazoline, its preparation and use as medicament
WO2007009705A1 (en) (rac)-n-piperidinyl-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4,5-dihydr0-1h-pyrazole-3-carboxamide hydrates
WO2007017126A2 (en) POLYMORPH OF N-PIPERIDINYL-5- (4-CHLOROPHENYL) -1- (2, 4-DICHLOROPHENYL) -4, 5-DIHYDRO-lH-PYRAZOLE- 3 -CARBOXAMIDE AND ITS USE AS A CAMNABINOID RECEPTOR MODULATOR
EP1743892A1 (en) Substituted pyrazoline compounds, their preparation and use as medicaments
EP1743888A1 (en) Carbonyl substituted pyrazoline compounds, their preparation and use as CB1 receptor modulators
US7790727B2 (en) Benzenesulfonanilide compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor
JP2008088057A (en) N-substituted-n-(4-piperidinyl)amide derivative
EP1743894A1 (en) Heterocyclyl-substituted pyrazoline compounds, their preparation and use as medicaments
MXPA06009336A (en) Substituted azetidine compounds, their preparation and use as medicaments
US20090149472A1 (en) Salts of substitutted pyrazoline compounds, their preparation and use and medicaments
MX2011001669A (en) Azetidine polysubstituted compounds, preparation thereof, and therapeutic application thereof.
EP1749821A1 (en) Quaternary ammonium salts of substituted pyrazoline compounds, their preparation and use as medicaments
MXPA06009334A (en) Substituted pyrazoline compounds, their preparation and use as medicaments
EP1743887A1 (en) Thiocarbonyl-substituted pyrazoline compounds, their preparation and use as CB1 modulators

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 177456

Country of ref document: IL

Ref document number: 4609/DELNP/2006

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2006/06732

Country of ref document: ZA

Ref document number: 200606732

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2556565

Country of ref document: CA

Ref document number: PA/a/2006/009336

Country of ref document: MX

Ref document number: 549201

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2006553539

Country of ref document: JP

Ref document number: 11505463

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 2005212835

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2005715383

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2005212835

Country of ref document: AU

Date of ref document: 20050216

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005212835

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1020067018702

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2006133258

Country of ref document: RU

WWE Wipo information: entry into national phase

Ref document number: 200580011514.6

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2005715383

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020067018702

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 11505463

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0507801

Country of ref document: BR